Source Name	Provider	Material Type	Term Source REF	Characteristics[Organism]	Term Source REF	Characteristics[Sex]	Term Source REF	Characteristics[DiseaseState]	Term Source REF	Sample Name	Material Type	Term Source REF	Characteristics[OrganismPart]	Term Source REF	Description	Protocol REF	Performer	Extract Name	Material Type	Term Source REF	Comment[SRA_SAMPLE]	Protocol REF	Performer	Extract Name	Comment[LIBRARY_LAYOUT]	Comment[LIBRARY_SOURCE]	Comment[LIBRARY_STRATEGY]	Comment[LIBRARY_SELECTION]	Comment[NOMINAL_LENGTH]	Comment[LIBRARY_NAME]	Comment[SRA_EXPERIMENT]	Description	Protocol REF	Performer	Date	Assay Name	Technology Type	Term Source REF	Comment[SPOT_LENGTH]	Protocol REF	Parameter Value[Software Versions]	Scan Name	Comment[SRA_RUN]	Comment[SRA_FILE_URI]	Comment[OCG Data Level]	Protocol REF	Derived Array Data File	Comment[SRA_RUN]	Comment[SRA_FILE_URI]	Comment[OCG Data Level]	Comment[ASSEMBLY_NAME]	Protocol REF	Derived Array Data File	Comment[OCG Data Level]
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR316306	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR316306/SRR316306.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR316306	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR316306/SRR316306.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR316306	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR316306/SRR316306.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR316306	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR316306/SRR316306.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	119	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_8_lanes_dupsFlagged.bam	SRR554509	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR554509/SRR554509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	119	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_8_lanes_dupsFlagged.bam	SRR554509	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR554509/SRR554509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	119	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_8_lanes_dupsFlagged.bam	SRR554509	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR554509/SRR554509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	119	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_8_lanes_dupsFlagged.bam	SRR554509	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR554509/SRR554509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..fastq	SRR1302925	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302925/SRR1302925.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..fastq	SRR1302925	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302925/SRR1302925.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..fastq	SRR1302925	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302925/SRR1302925.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..fastq	SRR1302925	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302925/SRR1302925.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..1.fastq	SRR1302926	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302926/SRR1302926.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..1.fastq	SRR1302926	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302926/SRR1302926.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..1.fastq	SRR1302926	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302926/SRR1302926.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..1.fastq	SRR1302926	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302926/SRR1302926.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR1302927	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302927/SRR1302927.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR1302927	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302927/SRR1302927.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR1302927	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302927/SRR1302927.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..2.fastq	SRR1302927	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302927/SRR1302927.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..3.fastq	SRR1302928	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302928/SRR1302928.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..3.fastq	SRR1302928	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302928/SRR1302928.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..3.fastq	SRR1302928	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302928/SRR1302928.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..3.fastq	SRR1302928	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302928/SRR1302928.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..4.fastq	SRR1302929	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302929/SRR1302929.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..4.fastq	SRR1302929	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302929/SRR1302929.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..4.fastq	SRR1302929	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302929/SRR1302929.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS0637 HS0637 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0637-1..4.fastq	SRR1302929	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302929/SRR1302929.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..6.fastq	SRR1302930	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302930/SRR1302930.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..6.fastq	SRR1302930	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302930/SRR1302930.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..6.fastq	SRR1302930	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302930/SRR1302930.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..6.fastq	SRR1302930	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302930/SRR1302930.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..7.fastq	SRR1302931	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302931/SRR1302931.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..7.fastq	SRR1302931	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302931/SRR1302931.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..7.fastq	SRR1302931	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302931/SRR1302931.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS0637 HS0637 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0637-1..7.fastq	SRR1302931	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302931/SRR1302931.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0637 HS0637 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0637-1..8.fastq	SRR1302932	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302932/SRR1302932.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0637 HS0637 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0637-1..8.fastq	SRR1302932	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302932/SRR1302932.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0637 HS0637 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0637-1..8.fastq	SRR1302932	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302932/SRR1302932.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0637 HS0637 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0637-1..8.fastq	SRR1302932	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1302932/SRR1302932.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	126	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_4_lanes_dupsFlagged.bam	SRR1303112	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1303112/SRR1303112.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.exon.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	126	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_4_lanes_dupsFlagged.bam	SRR1303112	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1303112/SRR1303112.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.gene.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	126	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_4_lanes_dupsFlagged.bam	SRR1303112	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1303112/SRR1303112.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0637_8_lanes.spljxn.quantification.txt	3
05-25439	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0637	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637	RNA	EFO	SRS405390	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0637 HS0637 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	198	HS0637	SRX085009	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0637 HS0637 run	sequencing assay	EFO	126	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0637_4_lanes_dupsFlagged.bam	SRR1303112	@dbgap@:reads/SRP020237/SRS405390/SRX085009/SRR1303112/SRR1303112.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0637_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
02-30647	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0639	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639	RNA	EFO	SRS405578	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639 HS0639 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0639	SRX016902	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0639 HS0639 run	sequencing assay	EFO	90	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0639_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390820	@dbgap@:reads/SRP020237/SRS405578/SRX016902/SRR390820/SRR390820.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0639.exon.quantification.txt	3
02-30647	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0639	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639	RNA	EFO	SRS405578	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639 HS0639 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0639	SRX016902	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0639 HS0639 run	sequencing assay	EFO	90	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0639_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390820	@dbgap@:reads/SRP020237/SRS405578/SRX016902/SRR390820/SRR390820.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0639.gene.quantification.txt	3
02-30647	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0639	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639	RNA	EFO	SRS405578	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639 HS0639 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0639	SRX016902	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0639 HS0639 run	sequencing assay	EFO	90	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0639_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390820	@dbgap@:reads/SRP020237/SRS405578/SRX016902/SRR390820/SRR390820.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0639.spljxn.quantification.txt	3
02-30647	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0639	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639	RNA	EFO	SRS405578	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0639 HS0639 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0639	SRX016902	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0639 HS0639 run	sequencing assay	EFO	90	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0639_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390820	@dbgap@:reads/SRP020237/SRS405578/SRX016902/SRR390820/SRR390820.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0639_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-11156	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0640	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640	RNA	EFO	SRS405579	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640 HS0640 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0640	SRX016905	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0640 HS0640 run	sequencing assay	EFO	97	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0640_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390821	@dbgap@:reads/SRP020237/SRS405579/SRX016905/SRR390821/SRR390821.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0640.exon.quantification.txt	3
04-11156	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0640	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640	RNA	EFO	SRS405579	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640 HS0640 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0640	SRX016905	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0640 HS0640 run	sequencing assay	EFO	97	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0640_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390821	@dbgap@:reads/SRP020237/SRS405579/SRX016905/SRR390821/SRR390821.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0640.gene.quantification.txt	3
04-11156	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0640	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640	RNA	EFO	SRS405579	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640 HS0640 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0640	SRX016905	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0640 HS0640 run	sequencing assay	EFO	97	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0640_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390821	@dbgap@:reads/SRP020237/SRS405579/SRX016905/SRR390821/SRR390821.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0640.spljxn.quantification.txt	3
04-11156	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0640	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640	RNA	EFO	SRS405579	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0640 HS0640 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0640	SRX016905	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0640 HS0640 run	sequencing assay	EFO	97	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0640_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390821	@dbgap@:reads/SRP020237/SRS405579/SRX016905/SRR390821/SRR390821.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0640_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR316312	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR316312/SRR316312.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.exon.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR316312	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR316312/SRR316312.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.gene.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR316312	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR316312/SRR316312.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.spljxn.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR316312	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR316312/SRR316312.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR1302933	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302933/SRR1302933.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.exon.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR1302933	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302933/SRR1302933.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.gene.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR1302933	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302933/SRR1302933.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.spljxn.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..fastq	SRR1302933	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302933/SRR1302933.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..1.fastq	SRR1302934	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302934/SRR1302934.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.exon.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..1.fastq	SRR1302934	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302934/SRR1302934.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.gene.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..1.fastq	SRR1302934	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302934/SRR1302934.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.spljxn.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..1.fastq	SRR1302934	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302934/SRR1302934.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..2.fastq	SRR1302935	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302935/SRR1302935.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.exon.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..2.fastq	SRR1302935	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302935/SRR1302935.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.gene.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..2.fastq	SRR1302935	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302935/SRR1302935.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0641_3_lanes.spljxn.quantification.txt	3
03-31713	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0641	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641	RNA	EFO	SRS405391	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0641 HS0641 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS0641	SRX085010	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS0641 HS0641 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS0641-1..2.fastq	SRR1302935	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR1302935/SRR1302935.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391486	@dbgap@:reads/SRP020237/SRS405391/SRX085010/SRR391486/SRR391486.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0641_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-33266	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0644	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644	RNA	EFO	SRS405580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644 HS0644 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	211	HS0644	SRX016907	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0644 HS0644 run	sequencing assay	EFO	61	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0644_19_lanes_dupsFlagged.bam	SRR554510	@dbgap@:reads/SRP020237/SRS405580/SRX016907/SRR554510/SRR554510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0644.exon.quantification.txt	3
03-33266	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0644	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644	RNA	EFO	SRS405580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644 HS0644 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	211	HS0644	SRX016907	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0644 HS0644 run	sequencing assay	EFO	61	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0644_19_lanes_dupsFlagged.bam	SRR554510	@dbgap@:reads/SRP020237/SRS405580/SRX016907/SRR554510/SRR554510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0644.gene.quantification.txt	3
03-33266	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0644	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644	RNA	EFO	SRS405580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644 HS0644 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	211	HS0644	SRX016907	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0644 HS0644 run	sequencing assay	EFO	61	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0644_19_lanes_dupsFlagged.bam	SRR554510	@dbgap@:reads/SRP020237/SRS405580/SRX016907/SRR554510/SRR554510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0644.spljxn.quantification.txt	3
03-33266	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0644	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644	RNA	EFO	SRS405580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0644 HS0644 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	211	HS0644	SRX016907	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS0644 HS0644 run	sequencing assay	EFO	61	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0644_19_lanes_dupsFlagged.bam	SRR554510	@dbgap@:reads/SRP020237/SRS405580/SRX016907/SRR554510/SRR554510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0644_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0645 HS0645 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..fastq	SRR036426	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036426/SRR036426.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0645 HS0645 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..fastq	SRR036426	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036426/SRR036426.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0645 HS0645 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..fastq	SRR036426	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036426/SRR036426.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0645 HS0645 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..fastq	SRR036426	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036426/SRR036426.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..1.fastq	SRR036427	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036427/SRR036427.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..1.fastq	SRR036427	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036427/SRR036427.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..1.fastq	SRR036427	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036427/SRR036427.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..1.fastq	SRR036427	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036427/SRR036427.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..2.fastq	SRR036428	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036428/SRR036428.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..2.fastq	SRR036428	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036428/SRR036428.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..2.fastq	SRR036428	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036428/SRR036428.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..2.fastq	SRR036428	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036428/SRR036428.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..3.fastq	SRR036429	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036429/SRR036429.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..3.fastq	SRR036429	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036429/SRR036429.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..3.fastq	SRR036429	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036429/SRR036429.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..3.fastq	SRR036429	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036429/SRR036429.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..4.fastq	SRR036430	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036430/SRR036430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..4.fastq	SRR036430	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036430/SRR036430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..4.fastq	SRR036430	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036430/SRR036430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..4.fastq	SRR036430	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036430/SRR036430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..5.fastq	SRR036431	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036431/SRR036431.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..5.fastq	SRR036431	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036431/SRR036431.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..5.fastq	SRR036431	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036431/SRR036431.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..5.fastq	SRR036431	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036431/SRR036431.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..6.fastq	SRR036432	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036432/SRR036432.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.exon.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..6.fastq	SRR036432	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036432/SRR036432.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.gene.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..6.fastq	SRR036432	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036432/SRR036432.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0645.spljxn.quantification.txt	3
02-30519	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0645	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645	RNA	EFO	SRS405581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0645 HS0645 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0645	SRX016911	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-02	HS0645 HS0645 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06451..6.fastq	SRR036432	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR036432/SRR036432.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390823	@dbgap@:reads/SRP020237/SRS405581/SRX016911/SRR390823/SRR390823.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0645_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR316321	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR316321/SRR316321.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR316321	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR316321/SRR316321.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR316321	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR316321/SRR316321.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR316321	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR316321/SRR316321.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..1.fastq	SRR1302936	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302936/SRR1302936.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..1.fastq	SRR1302936	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302936/SRR1302936.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..1.fastq	SRR1302936	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302936/SRR1302936.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..1.fastq	SRR1302936	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302936/SRR1302936.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..2.fastq	SRR1302937	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302937/SRR1302937.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..2.fastq	SRR1302937	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302937/SRR1302937.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..2.fastq	SRR1302937	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302937/SRR1302937.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..2.fastq	SRR1302937	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302937/SRR1302937.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..3.fastq	SRR1302938	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302938/SRR1302938.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..3.fastq	SRR1302938	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302938/SRR1302938.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..3.fastq	SRR1302938	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302938/SRR1302938.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..3.fastq	SRR1302938	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302938/SRR1302938.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..4.fastq	SRR1302939	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302939/SRR1302939.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..4.fastq	SRR1302939	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302939/SRR1302939.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..4.fastq	SRR1302939	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302939/SRR1302939.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..4.fastq	SRR1302939	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302939/SRR1302939.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..5.fastq	SRR1302940	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302940/SRR1302940.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..5.fastq	SRR1302940	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302940/SRR1302940.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..5.fastq	SRR1302940	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302940/SRR1302940.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..5.fastq	SRR1302940	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302940/SRR1302940.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..6.fastq	SRR1302941	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302941/SRR1302941.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..6.fastq	SRR1302941	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302941/SRR1302941.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..6.fastq	SRR1302941	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302941/SRR1302941.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..6.fastq	SRR1302941	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302941/SRR1302941.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR1302942	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302942/SRR1302942.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.exon.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR1302942	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302942/SRR1302942.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.gene.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR1302942	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302942/SRR1302942.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0646_7_lanes.spljxn.quantification.txt	3
04-23426	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0646	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646	RNA	EFO	SRS405393	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0646 HS0646 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	190	HS0646	SRX085011	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-10	HS0646 HS0646 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0646-1..7.fastq	SRR1302942	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR1302942/SRR1302942.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391487	@dbgap@:reads/SRP020237/SRS405393/SRX085011/SRR391487/SRR391487.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0646_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0647 HS0647 run	sequencing assay	EFO	50	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.fastq	SRR036433	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036433/SRR036433.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0647 HS0647 run	sequencing assay	EFO	50	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.fastq	SRR036433	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036433/SRR036433.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0647 HS0647 run	sequencing assay	EFO	50	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.fastq	SRR036433	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036433/SRR036433.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0647 HS0647 run	sequencing assay	EFO	50	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.fastq	SRR036433	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036433/SRR036433.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.2.fastq	SRR036434	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036434/SRR036434.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.2.fastq	SRR036434	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036434/SRR036434.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.2.fastq	SRR036434	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036434/SRR036434.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.2.fastq	SRR036434	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036434/SRR036434.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.3.fastq	SRR036435	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036435/SRR036435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.3.fastq	SRR036435	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036435/SRR036435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.3.fastq	SRR036435	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036435/SRR036435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.3.fastq	SRR036435	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036435/SRR036435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.4.fastq	SRR036436	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036436/SRR036436.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.4.fastq	SRR036436	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036436/SRR036436.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.4.fastq	SRR036436	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036436/SRR036436.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.4.fastq	SRR036436	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036436/SRR036436.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.5.fastq	SRR036437	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036437/SRR036437.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.5.fastq	SRR036437	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036437/SRR036437.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.5.fastq	SRR036437	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036437/SRR036437.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.5.fastq	SRR036437	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036437/SRR036437.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.6.fastq	SRR036438	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036438/SRR036438.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.6.fastq	SRR036438	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036438/SRR036438.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.6.fastq	SRR036438	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036438/SRR036438.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.6.fastq	SRR036438	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036438/SRR036438.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0647 HS0647 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.7.fastq	SRR036439	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036439/SRR036439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0647 HS0647 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.7.fastq	SRR036439	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036439/SRR036439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0647 HS0647 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.7.fastq	SRR036439	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036439/SRR036439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0647 HS0647 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06471.PET.7.fastq	SRR036439	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR036439/SRR036439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06471.PET.1.fastq	SRR363976	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR363976/SRR363976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.exon.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06471.PET.1.fastq	SRR363976	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR363976/SRR363976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.gene.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06471.PET.1.fastq	SRR363976	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR363976/SRR363976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0647.spljxn.quantification.txt	3
98-22532	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0647	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647	RNA	EFO	SRS405582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0647 HS0647 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS0647	SRX016913	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0647 HS0647 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06471.PET.1.fastq	SRR363976	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR363976/SRR363976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0647_8_lanes_dupsFlagged.bam	SRR390849	@dbgap@:reads/SRP020237/SRS405582/SRX016913/SRR390849/SRR390849.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0647_8_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.fastq	SRR036440	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036440/SRR036440.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.fastq	SRR036440	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036440/SRR036440.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.fastq	SRR036440	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036440/SRR036440.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.fastq	SRR036440	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036440/SRR036440.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.1.fastq	SRR036441	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036441/SRR036441.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.1.fastq	SRR036441	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036441/SRR036441.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.1.fastq	SRR036441	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036441/SRR036441.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.1.fastq	SRR036441	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036441/SRR036441.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.2.fastq	SRR036442	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036442/SRR036442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.2.fastq	SRR036442	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036442/SRR036442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.2.fastq	SRR036442	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036442/SRR036442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.2.fastq	SRR036442	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036442/SRR036442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.3.fastq	SRR036443	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036443/SRR036443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.3.fastq	SRR036443	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036443/SRR036443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.3.fastq	SRR036443	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036443/SRR036443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.3.fastq	SRR036443	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036443/SRR036443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.4.fastq	SRR036444	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036444/SRR036444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.4.fastq	SRR036444	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036444/SRR036444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.4.fastq	SRR036444	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036444/SRR036444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.4.fastq	SRR036444	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036444/SRR036444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.5.fastq	SRR036445	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036445/SRR036445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.5.fastq	SRR036445	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036445/SRR036445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.5.fastq	SRR036445	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036445/SRR036445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.5.fastq	SRR036445	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036445/SRR036445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.6.fastq	SRR036446	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036446/SRR036446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.exon.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.6.fastq	SRR036446	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036446/SRR036446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.gene.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.6.fastq	SRR036446	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036446/SRR036446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0648.spljxn.quantification.txt	3
05-32947	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0648	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648	RNA	EFO	SRS405583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0648 HS0648 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0648	SRX016916	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-20	HS0648 HS0648 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06481.PET.6.fastq	SRR036446	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR036446/SRR036446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390824	@dbgap@:reads/SRP020237/SRS405583/SRX016916/SRR390824/SRR390824.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0648_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR316322	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR316322/SRR316322.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR316322	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR316322/SRR316322.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR316322	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR316322/SRR316322.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR316322	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR316322/SRR316322.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR1302943	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302943/SRR1302943.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR1302943	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302943/SRR1302943.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR1302943	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302943/SRR1302943.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-30	HS0649 HS0649 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.fastq	SRR1302943	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302943/SRR1302943.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.1.fastq	SRR1302944	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302944/SRR1302944.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.1.fastq	SRR1302944	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302944/SRR1302944.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.1.fastq	SRR1302944	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302944/SRR1302944.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.1.fastq	SRR1302944	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302944/SRR1302944.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.2.fastq	SRR1302945	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302945/SRR1302945.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.2.fastq	SRR1302945	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302945/SRR1302945.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.2.fastq	SRR1302945	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302945/SRR1302945.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.2.fastq	SRR1302945	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302945/SRR1302945.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.3.fastq	SRR1302946	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302946/SRR1302946.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.3.fastq	SRR1302946	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302946/SRR1302946.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.3.fastq	SRR1302946	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302946/SRR1302946.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.3.fastq	SRR1302946	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302946/SRR1302946.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.4.fastq	SRR1302947	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302947/SRR1302947.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.4.fastq	SRR1302947	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302947/SRR1302947.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.4.fastq	SRR1302947	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302947/SRR1302947.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.4.fastq	SRR1302947	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302947/SRR1302947.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.5.fastq	SRR1302948	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302948/SRR1302948.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.5.fastq	SRR1302948	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302948/SRR1302948.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.5.fastq	SRR1302948	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302948/SRR1302948.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.5.fastq	SRR1302948	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302948/SRR1302948.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.6.fastq	SRR1302949	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302949/SRR1302949.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.exon.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.6.fastq	SRR1302949	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302949/SRR1302949.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.gene.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.6.fastq	SRR1302949	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302949/SRR1302949.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0649_7_lanes.spljxn.quantification.txt	3
04-39108	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0649	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649	RNA	EFO	SRS405392	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0649 HS0649 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS0649	SRX085012	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-02	HS0649 HS0649 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS0649-1.PET.6.fastq	SRR1302949	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR1302949/SRR1302949.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391488	@dbgap@:reads/SRP020237/SRS405392/SRX085012/SRR391488/SRR391488.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0649_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0650 HS0650 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.fastq	SRR036447	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036447/SRR036447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0650 HS0650 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.fastq	SRR036447	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036447/SRR036447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0650 HS0650 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.fastq	SRR036447	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036447/SRR036447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0650 HS0650 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.fastq	SRR036447	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036447/SRR036447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.1.fastq	SRR036448	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036448/SRR036448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.1.fastq	SRR036448	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036448/SRR036448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.1.fastq	SRR036448	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036448/SRR036448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.1.fastq	SRR036448	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036448/SRR036448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.2.fastq	SRR036449	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036449/SRR036449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.2.fastq	SRR036449	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036449/SRR036449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.2.fastq	SRR036449	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036449/SRR036449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-23	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.2.fastq	SRR036449	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036449/SRR036449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.3.fastq	SRR036450	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036450/SRR036450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.3.fastq	SRR036450	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036450/SRR036450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.3.fastq	SRR036450	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036450/SRR036450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.3.fastq	SRR036450	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036450/SRR036450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.4.fastq	SRR036451	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036451/SRR036451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.4.fastq	SRR036451	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036451/SRR036451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.4.fastq	SRR036451	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036451/SRR036451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.4.fastq	SRR036451	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036451/SRR036451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.5.fastq	SRR036452	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036452/SRR036452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.5.fastq	SRR036452	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036452/SRR036452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.5.fastq	SRR036452	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036452/SRR036452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.5.fastq	SRR036452	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036452/SRR036452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.6.fastq	SRR036453	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036453/SRR036453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.exon.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.6.fastq	SRR036453	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036453/SRR036453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.gene.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.6.fastq	SRR036453	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036453/SRR036453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0650.spljxn.quantification.txt	3
05-26084	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0650	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650	RNA	EFO	SRS405584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0650 HS0650 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS0650	SRX016918	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-20	HS0650 HS0650 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06501.PET.6.fastq	SRR036453	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR036453/SRR036453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390825	@dbgap@:reads/SRP020237/SRS405584/SRX016918/SRR390825/SRR390825.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0650_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-02	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..fastq	SRR036454	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036454/SRR036454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-02	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..fastq	SRR036454	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036454/SRR036454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-02	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..fastq	SRR036454	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036454/SRR036454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-02	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..fastq	SRR036454	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036454/SRR036454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..1.fastq	SRR036455	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036455/SRR036455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..1.fastq	SRR036455	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036455/SRR036455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..1.fastq	SRR036455	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036455/SRR036455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..1.fastq	SRR036455	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036455/SRR036455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..3.fastq	SRR036456	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036456/SRR036456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..3.fastq	SRR036456	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036456/SRR036456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..3.fastq	SRR036456	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036456/SRR036456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..3.fastq	SRR036456	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036456/SRR036456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..4.fastq	SRR036457	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036457/SRR036457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..4.fastq	SRR036457	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036457/SRR036457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..4.fastq	SRR036457	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036457/SRR036457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..4.fastq	SRR036457	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036457/SRR036457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..5.fastq	SRR036458	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036458/SRR036458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..5.fastq	SRR036458	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036458/SRR036458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..5.fastq	SRR036458	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036458/SRR036458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..5.fastq	SRR036458	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036458/SRR036458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..6.fastq	SRR036459	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036459/SRR036459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..6.fastq	SRR036459	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036459/SRR036459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..6.fastq	SRR036459	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036459/SRR036459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..6.fastq	SRR036459	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR036459/SRR036459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..2.fastq	SRR354107	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR354107/SRR354107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.exon.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..2.fastq	SRR354107	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR354107/SRR354107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.gene.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..2.fastq	SRR354107	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR354107/SRR354107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0651.spljxn.quantification.txt	3
06-25470	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0651	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651	RNA	EFO	SRS405585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0651 HS0651 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	206	HS0651	SRX016921	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-19	HS0651 HS0651 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06511..2.fastq	SRR354107	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR354107/SRR354107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390826	@dbgap@:reads/SRP020237/SRS405585/SRX016921/SRR390826/SRR390826.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0651_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-08	HS0652 HS0652 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.fastq	SRR036460	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036460/SRR036460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-08	HS0652 HS0652 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.fastq	SRR036460	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036460/SRR036460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-08	HS0652 HS0652 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.fastq	SRR036460	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036460/SRR036460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-08	HS0652 HS0652 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.fastq	SRR036460	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036460/SRR036460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.1.fastq	SRR036461	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036461/SRR036461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.1.fastq	SRR036461	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036461/SRR036461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.1.fastq	SRR036461	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036461/SRR036461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.1.fastq	SRR036461	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036461/SRR036461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.3.fastq	SRR036462	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036462/SRR036462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.3.fastq	SRR036462	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036462/SRR036462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.3.fastq	SRR036462	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036462/SRR036462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.3.fastq	SRR036462	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036462/SRR036462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.4.fastq	SRR036463	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036463/SRR036463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.4.fastq	SRR036463	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036463/SRR036463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.4.fastq	SRR036463	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036463/SRR036463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.4.fastq	SRR036463	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036463/SRR036463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.5.fastq	SRR036464	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036464/SRR036464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.5.fastq	SRR036464	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036464/SRR036464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.5.fastq	SRR036464	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036464/SRR036464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.5.fastq	SRR036464	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036464/SRR036464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.6.fastq	SRR036465	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036465/SRR036465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.6.fastq	SRR036465	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036465/SRR036465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.6.fastq	SRR036465	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036465/SRR036465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.6.fastq	SRR036465	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR036465/SRR036465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.2.fastq	SRR354108	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR354108/SRR354108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.exon.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.2.fastq	SRR354108	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR354108/SRR354108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.gene.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.2.fastq	SRR354108	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR354108/SRR354108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0652.spljxn.quantification.txt	3
06-27347	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0652	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652	RNA	EFO	SRS405586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0652 HS0652 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0652	SRX016923	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0652 HS0652 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06521.PET.2.fastq	SRR354108	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR354108/SRR354108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390827	@dbgap@:reads/SRP020237/SRS405586/SRX016923/SRR390827/SRR390827.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0652_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..fastq	SRR036466	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036466/SRR036466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..fastq	SRR036466	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036466/SRR036466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..fastq	SRR036466	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036466/SRR036466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-10	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..fastq	SRR036466	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036466/SRR036466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..1.fastq	SRR036467	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036467/SRR036467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..1.fastq	SRR036467	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036467/SRR036467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..1.fastq	SRR036467	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036467/SRR036467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..1.fastq	SRR036467	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036467/SRR036467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..2.fastq	SRR036468	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036468/SRR036468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..2.fastq	SRR036468	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036468/SRR036468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..2.fastq	SRR036468	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036468/SRR036468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..2.fastq	SRR036468	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036468/SRR036468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..3.fastq	SRR036469	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036469/SRR036469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..3.fastq	SRR036469	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036469/SRR036469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..3.fastq	SRR036469	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036469/SRR036469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..3.fastq	SRR036469	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036469/SRR036469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..4.fastq	SRR036470	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036470/SRR036470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..4.fastq	SRR036470	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036470/SRR036470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..4.fastq	SRR036470	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036470/SRR036470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..4.fastq	SRR036470	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036470/SRR036470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..5.fastq	SRR036471	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036471/SRR036471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..5.fastq	SRR036471	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036471/SRR036471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..5.fastq	SRR036471	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036471/SRR036471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..5.fastq	SRR036471	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036471/SRR036471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..6.fastq	SRR036472	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036472/SRR036472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.exon.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..6.fastq	SRR036472	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036472/SRR036472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.gene.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..6.fastq	SRR036472	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036472/SRR036472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0653.spljxn.quantification.txt	3
06-30025	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0653	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653	RNA	EFO	SRS405587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0653 HS0653 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0653	SRX016925	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0653 HS0653 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06531..6.fastq	SRR036472	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR036472/SRR036472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390828	@dbgap@:reads/SRP020237/SRS405587/SRX016925/SRR390828/SRR390828.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0653_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR316331	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR316331/SRR316331.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR316331	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR316331/SRR316331.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR316331	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR316331/SRR316331.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR316331	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR316331/SRR316331.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0654-2.PET.fastq	SRR1302950	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302950/SRR1302950.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0654-2.PET.fastq	SRR1302950	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302950/SRR1302950.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0654-2.PET.fastq	SRR1302950	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302950/SRR1302950.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0654-2.PET.fastq	SRR1302950	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302950/SRR1302950.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.1.fastq	SRR1302951	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302951/SRR1302951.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.1.fastq	SRR1302951	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302951/SRR1302951.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.1.fastq	SRR1302951	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302951/SRR1302951.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.1.fastq	SRR1302951	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302951/SRR1302951.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR1302952	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302952/SRR1302952.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR1302952	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302952/SRR1302952.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR1302952	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302952/SRR1302952.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.2.fastq	SRR1302952	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302952/SRR1302952.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.3.fastq	SRR1302953	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302953/SRR1302953.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.3.fastq	SRR1302953	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302953/SRR1302953.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.3.fastq	SRR1302953	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302953/SRR1302953.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.3.fastq	SRR1302953	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302953/SRR1302953.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.4.fastq	SRR1302954	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302954/SRR1302954.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.4.fastq	SRR1302954	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302954/SRR1302954.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.4.fastq	SRR1302954	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302954/SRR1302954.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.4.fastq	SRR1302954	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302954/SRR1302954.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.5.fastq	SRR1302955	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302955/SRR1302955.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.5.fastq	SRR1302955	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302955/SRR1302955.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.5.fastq	SRR1302955	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302955/SRR1302955.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.5.fastq	SRR1302955	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302955/SRR1302955.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.6.fastq	SRR1302956	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302956/SRR1302956.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.exon.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.6.fastq	SRR1302956	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302956/SRR1302956.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.gene.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.6.fastq	SRR1302956	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302956/SRR1302956.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0654_7_lanes.spljxn.quantification.txt	3
06-31353	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0654	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654	RNA	EFO	SRS405394	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0654 HS0654 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS0654	SRX085013	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0654 HS0654 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0654-2.PET.6.fastq	SRR1302956	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR1302956/SRR1302956.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391489	@dbgap@:reads/SRP020237/SRS405394/SRX085013/SRR391489/SRR391489.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0654_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-06	HS0656 HS0656 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..fastq	SRR036473	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036473/SRR036473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-06	HS0656 HS0656 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..fastq	SRR036473	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036473/SRR036473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-06	HS0656 HS0656 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..fastq	SRR036473	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036473/SRR036473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-06	HS0656 HS0656 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..fastq	SRR036473	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036473/SRR036473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..1.fastq	SRR036474	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036474/SRR036474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..1.fastq	SRR036474	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036474/SRR036474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..1.fastq	SRR036474	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036474/SRR036474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..1.fastq	SRR036474	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036474/SRR036474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..2.fastq	SRR036475	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036475/SRR036475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..2.fastq	SRR036475	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036475/SRR036475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..2.fastq	SRR036475	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036475/SRR036475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..2.fastq	SRR036475	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036475/SRR036475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..3.fastq	SRR036476	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036476/SRR036476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..3.fastq	SRR036476	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036476/SRR036476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..3.fastq	SRR036476	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036476/SRR036476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..3.fastq	SRR036476	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036476/SRR036476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..4.fastq	SRR036477	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036477/SRR036477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..4.fastq	SRR036477	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036477/SRR036477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..4.fastq	SRR036477	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036477/SRR036477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..4.fastq	SRR036477	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036477/SRR036477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..5.fastq	SRR036478	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036478/SRR036478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..5.fastq	SRR036478	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036478/SRR036478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..5.fastq	SRR036478	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036478/SRR036478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..5.fastq	SRR036478	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036478/SRR036478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..6.fastq	SRR036479	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036479/SRR036479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.exon.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..6.fastq	SRR036479	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036479/SRR036479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.gene.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..6.fastq	SRR036479	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036479/SRR036479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0656.spljxn.quantification.txt	3
07-35482	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0656	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656	RNA	EFO	SRS405588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0656 HS0656 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS0656	SRX016927	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-14	HS0656 HS0656 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS06561..6.fastq	SRR036479	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR036479/SRR036479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390829	@dbgap@:reads/SRP020237/SRS405588/SRX016927/SRR390829/SRR390829.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0656_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0685	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685	RNA	EFO	SRS212580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685 HS0685 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0685	SRX079565	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-22	HS0685 HS0685 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06851.PET.fastq	SRR292240	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR292240/SRR292240.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30CGAAAXX_3.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390727	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR390727/SRR390727.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0685_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0685	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685	RNA	EFO	SRS212580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685 HS0685 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0685	SRX079565	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-22	HS0685 HS0685 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06851.PET.fastq	SRR292240	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR292240/SRR292240.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30CGAAAXX_3.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390727	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR390727/SRR390727.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0685_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0685	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685	RNA	EFO	SRS212580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685 HS0685 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0685	SRX079565	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-22	HS0685 HS0685 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06851.PET.fastq	SRR292240	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR292240/SRR292240.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30CGAAAXX_3.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390727	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR390727/SRR390727.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0685_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0685	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685	RNA	EFO	SRS212580	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0685 HS0685 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0685	SRX079565	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-09-22	HS0685 HS0685 run	sequencing assay	EFO	84	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS06851.PET.fastq	SRR292240	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR292240/SRR292240.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30CGAAAXX_3.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390727	@dbgap@:reads/SRP020237/SRS212580/SRX079565/SRR390727/SRR390727.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0685_3.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0747 HS0747 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..fastq	SRR036480	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036480/SRR036480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.exon.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0747 HS0747 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..fastq	SRR036480	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036480/SRR036480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.gene.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0747 HS0747 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..fastq	SRR036480	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036480/SRR036480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.spljxn.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0747 HS0747 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..fastq	SRR036480	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036480/SRR036480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0747_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..1.fastq	SRR036481	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036481/SRR036481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.exon.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..1.fastq	SRR036481	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036481/SRR036481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.gene.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..1.fastq	SRR036481	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036481/SRR036481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.spljxn.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..1.fastq	SRR036481	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036481/SRR036481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0747_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..2.fastq	SRR036482	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036482/SRR036482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.exon.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..2.fastq	SRR036482	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036482/SRR036482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.gene.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..2.fastq	SRR036482	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036482/SRR036482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.spljxn.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0747 HS0747 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..2.fastq	SRR036482	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR036482/SRR036482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0747_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..3.fastq	SRR354110	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354110/SRR354110.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.exon.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..3.fastq	SRR354110	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354110/SRR354110.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.gene.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..3.fastq	SRR354110	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354110/SRR354110.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.spljxn.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..3.fastq	SRR354110	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354110/SRR354110.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0747_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..4.fastq	SRR354111	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354111/SRR354111.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.exon.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..4.fastq	SRR354111	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354111/SRR354111.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.gene.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..4.fastq	SRR354111	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354111/SRR354111.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.spljxn.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..4.fastq	SRR354111	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354111/SRR354111.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0747_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-10	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..5.fastq	SRR354112	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354112/SRR354112.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.exon.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-10	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..5.fastq	SRR354112	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354112/SRR354112.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.gene.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-10	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..5.fastq	SRR354112	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354112/SRR354112.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0747.spljxn.quantification.txt	3
07-31833	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0747	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747	RNA	EFO	SRS405589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0747 HS0747 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	363	HS0747	SRX016929	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-10	HS0747 HS0747 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07471..5.fastq	SRR354112	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR354112/SRR354112.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0747_6_lanes_dupsFlagged.bam	SRR390848	@dbgap@:reads/SRP020237/SRS405589/SRX016929/SRR390848/SRR390848.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0747_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0748 HS0748 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..fastq	SRR037023	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037023/SRR037023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0748 HS0748 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..fastq	SRR037023	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037023/SRR037023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0748 HS0748 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..fastq	SRR037023	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037023/SRR037023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0748 HS0748 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..fastq	SRR037023	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037023/SRR037023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..10.fastq	SRR037024	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037024/SRR037024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..10.fastq	SRR037024	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037024/SRR037024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..10.fastq	SRR037024	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037024/SRR037024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..10.fastq	SRR037024	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037024/SRR037024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..11.fastq	SRR037025	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037025/SRR037025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..11.fastq	SRR037025	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037025/SRR037025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..11.fastq	SRR037025	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037025/SRR037025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..11.fastq	SRR037025	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037025/SRR037025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..12.fastq	SRR037026	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037026/SRR037026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..12.fastq	SRR037026	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037026/SRR037026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..12.fastq	SRR037026	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037026/SRR037026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..12.fastq	SRR037026	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037026/SRR037026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..7.fastq	SRR037027	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037027/SRR037027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..7.fastq	SRR037027	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037027/SRR037027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..7.fastq	SRR037027	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037027/SRR037027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..7.fastq	SRR037027	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037027/SRR037027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..8.fastq	SRR037028	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037028/SRR037028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..8.fastq	SRR037028	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037028/SRR037028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..8.fastq	SRR037028	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037028/SRR037028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..8.fastq	SRR037028	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037028/SRR037028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..9.fastq	SRR037029	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037029/SRR037029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.exon.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..9.fastq	SRR037029	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037029/SRR037029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.gene.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..9.fastq	SRR037029	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037029/SRR037029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0748.spljxn.quantification.txt	3
05-20543	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0748	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748	RNA	EFO	SRS405608	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0748 HS0748 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	380	HS0748	SRX017248	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-22	HS0748 HS0748 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07481..9.fastq	SRR037029	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR037029/SRR037029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0748_7_lanes_dupsFlagged.bam	SRR390830	@dbgap@:reads/SRP020237/SRS405608/SRX017248/SRR390830/SRR390830.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0748_7_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0749 HS0749 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..fastq	SRR036483	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036483/SRR036483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0749 HS0749 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..fastq	SRR036483	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036483/SRR036483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0749 HS0749 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..fastq	SRR036483	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036483/SRR036483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0749 HS0749 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..fastq	SRR036483	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036483/SRR036483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..1.fastq	SRR036484	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036484/SRR036484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..1.fastq	SRR036484	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036484/SRR036484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..1.fastq	SRR036484	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036484/SRR036484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..1.fastq	SRR036484	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036484/SRR036484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..2.fastq	SRR036485	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036485/SRR036485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..2.fastq	SRR036485	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036485/SRR036485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..2.fastq	SRR036485	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036485/SRR036485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..2.fastq	SRR036485	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036485/SRR036485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..3.fastq	SRR036486	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036486/SRR036486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..3.fastq	SRR036486	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036486/SRR036486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..3.fastq	SRR036486	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036486/SRR036486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..3.fastq	SRR036486	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036486/SRR036486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..4.fastq	SRR036487	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036487/SRR036487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..4.fastq	SRR036487	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036487/SRR036487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..4.fastq	SRR036487	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036487/SRR036487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-17	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..4.fastq	SRR036487	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036487/SRR036487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..5.fastq	SRR036488	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036488/SRR036488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..5.fastq	SRR036488	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036488/SRR036488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..5.fastq	SRR036488	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036488/SRR036488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..5.fastq	SRR036488	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036488/SRR036488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..6.fastq	SRR036489	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036489/SRR036489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.exon.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..6.fastq	SRR036489	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036489/SRR036489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.gene.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..6.fastq	SRR036489	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036489/SRR036489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0749.spljxn.quantification.txt	3
05-24666	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0749	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749	RNA	EFO	SRS405590	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0749 HS0749 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	195	HS0749	SRX016931	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-09	HS0749 HS0749 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07491..6.fastq	SRR036489	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR036489/SRR036489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390831	@dbgap@:reads/SRP020237/SRS405590/SRX016931/SRR390831/SRR390831.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0749_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0750 HS0750 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..fastq	SRR036490	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036490/SRR036490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0750 HS0750 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..fastq	SRR036490	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036490/SRR036490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0750 HS0750 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..fastq	SRR036490	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036490/SRR036490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0750 HS0750 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..fastq	SRR036490	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036490/SRR036490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..1.fastq	SRR036491	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036491/SRR036491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..1.fastq	SRR036491	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036491/SRR036491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..1.fastq	SRR036491	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036491/SRR036491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..1.fastq	SRR036491	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036491/SRR036491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..2.fastq	SRR036492	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036492/SRR036492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..2.fastq	SRR036492	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036492/SRR036492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..2.fastq	SRR036492	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036492/SRR036492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..2.fastq	SRR036492	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036492/SRR036492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..3.fastq	SRR036493	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036493/SRR036493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..3.fastq	SRR036493	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036493/SRR036493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..3.fastq	SRR036493	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036493/SRR036493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-02-06	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..3.fastq	SRR036493	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036493/SRR036493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..4.fastq	SRR036494	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036494/SRR036494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..4.fastq	SRR036494	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036494/SRR036494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..4.fastq	SRR036494	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036494/SRR036494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..4.fastq	SRR036494	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036494/SRR036494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..5.fastq	SRR036495	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036495/SRR036495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..5.fastq	SRR036495	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036495/SRR036495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..5.fastq	SRR036495	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036495/SRR036495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..5.fastq	SRR036495	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036495/SRR036495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..6.fastq	SRR036496	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036496/SRR036496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.exon.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..6.fastq	SRR036496	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036496/SRR036496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.gene.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..6.fastq	SRR036496	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036496/SRR036496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0750.spljxn.quantification.txt	3
99-25549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0750	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750	RNA	EFO	SRS405591	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0750 HS0750 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0750	SRX016935	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0750 HS0750 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07501..6.fastq	SRR036496	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR036496/SRR036496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390832	@dbgap@:reads/SRP020237/SRS405591/SRX016935/SRR390832/SRR390832.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0750_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0751 HS0751 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..fastq	SRR036497	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036497/SRR036497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0751 HS0751 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..fastq	SRR036497	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036497/SRR036497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0751 HS0751 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..fastq	SRR036497	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036497/SRR036497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-08	HS0751 HS0751 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..fastq	SRR036497	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036497/SRR036497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..1.fastq	SRR036498	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036498/SRR036498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..1.fastq	SRR036498	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036498/SRR036498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..1.fastq	SRR036498	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036498/SRR036498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..1.fastq	SRR036498	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036498/SRR036498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..2.fastq	SRR036499	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036499/SRR036499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..2.fastq	SRR036499	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036499/SRR036499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..2.fastq	SRR036499	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036499/SRR036499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..2.fastq	SRR036499	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036499/SRR036499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..3.fastq	SRR036500	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036500/SRR036500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..3.fastq	SRR036500	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036500/SRR036500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..3.fastq	SRR036500	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036500/SRR036500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..3.fastq	SRR036500	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036500/SRR036500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..4.fastq	SRR036501	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036501/SRR036501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..4.fastq	SRR036501	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036501/SRR036501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..4.fastq	SRR036501	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036501/SRR036501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..4.fastq	SRR036501	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036501/SRR036501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..5.fastq	SRR036502	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036502/SRR036502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..5.fastq	SRR036502	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036502/SRR036502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..5.fastq	SRR036502	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036502/SRR036502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..5.fastq	SRR036502	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036502/SRR036502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..6.fastq	SRR036503	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036503/SRR036503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.exon.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..6.fastq	SRR036503	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036503/SRR036503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.gene.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..6.fastq	SRR036503	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036503/SRR036503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0751.spljxn.quantification.txt	3
05-19287	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0751	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751	RNA	EFO	SRS405592	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0751 HS0751 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	405	HS0751	SRX016938	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-27	HS0751 HS0751 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS07511..6.fastq	SRR036503	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR036503/SRR036503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390833	@dbgap@:reads/SRP020237/SRS405592/SRX016938/SRR390833/SRR390833.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0751_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0798	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798	RNA	EFO	SRS212581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798 HS0798 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0798	SRX079566	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0798 HS0798 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS07981..fastq	SRR292241	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR292241/SRR292241.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30KWMAAXX_6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390728	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR390728/SRR390728.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0798_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0798	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798	RNA	EFO	SRS212581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798 HS0798 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0798	SRX079566	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0798 HS0798 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS07981..fastq	SRR292241	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR292241/SRR292241.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30KWMAAXX_6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390728	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR390728/SRR390728.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0798_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0798	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798	RNA	EFO	SRS212581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798 HS0798 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0798	SRX079566	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0798 HS0798 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS07981..fastq	SRR292241	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR292241/SRR292241.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30KWMAAXX_6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390728	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR390728/SRR390728.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0798_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0798	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798	RNA	EFO	SRS212581	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0798 HS0798 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS0798	SRX079566	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-11-24	HS0798 HS0798 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS07981..fastq	SRR292241	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR292241/SRR292241.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30KWMAAXX_6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390728	@dbgap@:reads/SRP020237/SRS212581/SRX079566/SRR390728/SRR390728.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0798_6_sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-01	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..fastq	SRR036504	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036504/SRR036504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-01	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..fastq	SRR036504	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036504/SRR036504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-01	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..fastq	SRR036504	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036504/SRR036504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2008-12-01	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..fastq	SRR036504	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036504/SRR036504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..1.fastq	SRR036505	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036505/SRR036505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..1.fastq	SRR036505	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036505/SRR036505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..1.fastq	SRR036505	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036505/SRR036505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..1.fastq	SRR036505	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036505/SRR036505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..2.fastq	SRR036506	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036506/SRR036506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..2.fastq	SRR036506	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036506/SRR036506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..2.fastq	SRR036506	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036506/SRR036506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..2.fastq	SRR036506	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036506/SRR036506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..3.fastq	SRR036507	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036507/SRR036507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..3.fastq	SRR036507	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036507/SRR036507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..3.fastq	SRR036507	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036507/SRR036507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..3.fastq	SRR036507	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036507/SRR036507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..4.fastq	SRR036508	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036508/SRR036508.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..4.fastq	SRR036508	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036508/SRR036508.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..4.fastq	SRR036508	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036508/SRR036508.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..4.fastq	SRR036508	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036508/SRR036508.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..5.fastq	SRR036509	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036509/SRR036509.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..5.fastq	SRR036509	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036509/SRR036509.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..5.fastq	SRR036509	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036509/SRR036509.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..5.fastq	SRR036509	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036509/SRR036509.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..6.fastq	SRR036510	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036510/SRR036510.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.exon.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..6.fastq	SRR036510	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036510/SRR036510.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.gene.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..6.fastq	SRR036510	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036510/SRR036510.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0804.spljxn.quantification.txt	3
06-12968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS0804	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804	RNA	EFO	SRS405593	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0804 HS0804 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	233	HS0804	SRX016940	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-01-12	HS0804 HS0804 run	sequencing assay	EFO	72	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS08041..6.fastq	SRR036510	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR036510/SRR036510.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390834	@dbgap@:reads/SRP020237/SRS405593/SRX016940/SRR390834/SRR390834.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0804_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS0841	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841	RNA	EFO	SRS212582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841 HS0841 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	347	HS0841	SRX079567	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-03	HS0841 HS0841 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08411..fastq	SRR292242	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR292242/SRR292242.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V75AAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390729	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR390729/SRR390729.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0841_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS0841	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841	RNA	EFO	SRS212582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841 HS0841 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	347	HS0841	SRX079567	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-03	HS0841 HS0841 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08411..fastq	SRR292242	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR292242/SRR292242.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V75AAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390729	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR390729/SRR390729.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0841_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS0841	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841	RNA	EFO	SRS212582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841 HS0841 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	347	HS0841	SRX079567	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-03	HS0841 HS0841 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08411..fastq	SRR292242	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR292242/SRR292242.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V75AAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390729	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR390729/SRR390729.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0841_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS0841	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841	RNA	EFO	SRS212582	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0841 HS0841 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	347	HS0841	SRX079567	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-03	HS0841 HS0841 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08411..fastq	SRR292242	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR292242/SRR292242.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V75AAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390729	@dbgap@:reads/SRP020237/SRS212582/SRX079567/SRR390729/SRR390729.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0841_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0842	organism part	EFO		NCIt	"lymph node"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842	RNA	EFO	SRS212583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842 HS0842 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	335	HS0842	SRX079568	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0842 HS0842 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08421..fastq	SRR292243	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR292243/SRR292243.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_4_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390730	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR390730/SRR390730.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0842_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0842	organism part	EFO		NCIt	"lymph node"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842	RNA	EFO	SRS212583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842 HS0842 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	335	HS0842	SRX079568	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0842 HS0842 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08421..fastq	SRR292243	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR292243/SRR292243.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_4_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390730	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR390730/SRR390730.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0842_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0842	organism part	EFO		NCIt	"lymph node"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842	RNA	EFO	SRS212583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842 HS0842 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	335	HS0842	SRX079568	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0842 HS0842 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08421..fastq	SRR292243	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR292243/SRR292243.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_4_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390730	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR390730/SRR390730.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0842_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0842	organism part	EFO		NCIt	"lymph node"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842	RNA	EFO	SRS212583	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0842 HS0842 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	335	HS0842	SRX079568	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0842 HS0842 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS08421..fastq	SRR292243	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR292243/SRR292243.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_4_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390730	@dbgap@:reads/SRP020237/SRS212583/SRX079568/SRR390730/SRR390730.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0842_4_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0900	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900	RNA	EFO	SRS212584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900 HS0900 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	342	HS0900	SRX079569	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0900 HS0900 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09001..fastq	SRR292244	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR292244/SRR292244.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_5_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390731	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR390731/SRR390731.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0900_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0900	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900	RNA	EFO	SRS212584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900 HS0900 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	342	HS0900	SRX079569	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0900 HS0900 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09001..fastq	SRR292244	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR292244/SRR292244.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_5_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390731	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR390731/SRR390731.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0900_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0900	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900	RNA	EFO	SRS212584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900 HS0900 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	342	HS0900	SRX079569	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0900 HS0900 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09001..fastq	SRR292244	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR292244/SRR292244.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_5_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390731	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR390731/SRR390731.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0900_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0900	organism part	EFO		NCIt	"peritoneal cavity fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900	RNA	EFO	SRS212584	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0900 HS0900 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	342	HS0900	SRX079569	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0900 HS0900 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09001..fastq	SRR292244	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR292244/SRR292244.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_5_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390731	@dbgap@:reads/SRP020237/SRS212584/SRX079569/SRR390731/SRR390731.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0900_5_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0901	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901	RNA	EFO	SRS212585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901 HS0901 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	322	HS0901	SRX079570	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0901 HS0901 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09011..fastq	SRR292245	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR292245/SRR292245.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390732	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR390732/SRR390732.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0901_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0901	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901	RNA	EFO	SRS212585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901 HS0901 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	322	HS0901	SRX079570	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0901 HS0901 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09011..fastq	SRR292245	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR292245/SRR292245.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390732	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR390732/SRR390732.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0901_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0901	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901	RNA	EFO	SRS212585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901 HS0901 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	322	HS0901	SRX079570	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0901 HS0901 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09011..fastq	SRR292245	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR292245/SRR292245.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390732	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR390732/SRR390732.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0901_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS0901	organism part	EFO		NCIt	"pleural effusion fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901	RNA	EFO	SRS212585	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0901 HS0901 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	322	HS0901	SRX079570	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-12	HS0901 HS0901 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.9.5	HS09011..fastq	SRR292245	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR292245/SRR292245.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30V9DAAXX_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390732	@dbgap@:reads/SRP020237/SRS212585/SRX079570/SRR390732/SRR390732.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0901_6_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..fastq	SRR036511	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036511/SRR036511.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..fastq	SRR036511	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036511/SRR036511.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..fastq	SRR036511	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036511/SRR036511.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..fastq	SRR036511	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036511/SRR036511.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..10.fastq	SRR036512	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036512/SRR036512.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..10.fastq	SRR036512	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036512/SRR036512.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..10.fastq	SRR036512	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036512/SRR036512.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..10.fastq	SRR036512	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036512/SRR036512.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..11.fastq	SRR036513	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036513/SRR036513.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..11.fastq	SRR036513	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036513/SRR036513.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..11.fastq	SRR036513	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036513/SRR036513.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..11.fastq	SRR036513	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036513/SRR036513.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..12.fastq	SRR036514	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036514/SRR036514.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..12.fastq	SRR036514	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036514/SRR036514.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..12.fastq	SRR036514	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036514/SRR036514.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..12.fastq	SRR036514	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036514/SRR036514.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..7.fastq	SRR036515	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036515/SRR036515.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..7.fastq	SRR036515	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036515/SRR036515.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..7.fastq	SRR036515	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036515/SRR036515.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..7.fastq	SRR036515	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036515/SRR036515.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..8.fastq	SRR036516	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036516/SRR036516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..8.fastq	SRR036516	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036516/SRR036516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..8.fastq	SRR036516	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036516/SRR036516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..8.fastq	SRR036516	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036516/SRR036516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..9.fastq	SRR036517	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036517/SRR036517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.exon.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..9.fastq	SRR036517	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036517/SRR036517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.gene.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..9.fastq	SRR036517	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036517/SRR036517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0926.spljxn.quantification.txt	3
06-11535	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0926	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926	RNA	EFO	SRS405594	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0926 HS0926 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	191	HS0926	SRX016942	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS0926 HS0926 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09261..9.fastq	SRR036517	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR036517/SRR036517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390835	@dbgap@:reads/SRP020237/SRS405594/SRX016942/SRR390835/SRR390835.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0926_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..fastq	SRR036518	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036518/SRR036518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..fastq	SRR036518	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036518/SRR036518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..fastq	SRR036518	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036518/SRR036518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..fastq	SRR036518	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036518/SRR036518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..1.fastq	SRR036519	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036519/SRR036519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..1.fastq	SRR036519	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036519/SRR036519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..1.fastq	SRR036519	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036519/SRR036519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..1.fastq	SRR036519	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036519/SRR036519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..2.fastq	SRR036520	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036520/SRR036520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..2.fastq	SRR036520	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036520/SRR036520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..2.fastq	SRR036520	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036520/SRR036520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..2.fastq	SRR036520	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036520/SRR036520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..3.fastq	SRR036521	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036521/SRR036521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..3.fastq	SRR036521	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036521/SRR036521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..3.fastq	SRR036521	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036521/SRR036521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..3.fastq	SRR036521	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036521/SRR036521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..4.fastq	SRR036522	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036522/SRR036522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..4.fastq	SRR036522	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036522/SRR036522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..4.fastq	SRR036522	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036522/SRR036522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..4.fastq	SRR036522	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036522/SRR036522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..5.fastq	SRR036523	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036523/SRR036523.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..5.fastq	SRR036523	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036523/SRR036523.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..5.fastq	SRR036523	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036523/SRR036523.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..5.fastq	SRR036523	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036523/SRR036523.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..6.fastq	SRR036524	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036524/SRR036524.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.exon.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..6.fastq	SRR036524	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036524/SRR036524.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.gene.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..6.fastq	SRR036524	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036524/SRR036524.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0927.spljxn.quantification.txt	3
06-16316	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0927	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927	RNA	EFO	SRS405595	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0927 HS0927 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	207	HS0927	SRX016944	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-09	HS0927 HS0927 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09271..6.fastq	SRR036524	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR036524/SRR036524.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390836	@dbgap@:reads/SRP020237/SRS405595/SRX016944/SRR390836/SRR390836.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0927_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..fastq	SRR036525	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036525/SRR036525.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..fastq	SRR036525	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036525/SRR036525.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..fastq	SRR036525	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036525/SRR036525.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..fastq	SRR036525	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036525/SRR036525.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..1.fastq	SRR036526	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036526/SRR036526.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..1.fastq	SRR036526	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036526/SRR036526.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..1.fastq	SRR036526	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036526/SRR036526.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..1.fastq	SRR036526	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036526/SRR036526.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..2.fastq	SRR036527	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036527/SRR036527.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..2.fastq	SRR036527	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036527/SRR036527.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..2.fastq	SRR036527	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036527/SRR036527.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..2.fastq	SRR036527	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036527/SRR036527.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..3.fastq	SRR036528	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036528/SRR036528.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..3.fastq	SRR036528	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036528/SRR036528.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..3.fastq	SRR036528	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036528/SRR036528.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..3.fastq	SRR036528	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036528/SRR036528.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..4.fastq	SRR036529	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036529/SRR036529.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..4.fastq	SRR036529	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036529/SRR036529.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..4.fastq	SRR036529	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036529/SRR036529.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..4.fastq	SRR036529	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036529/SRR036529.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..5.fastq	SRR036530	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036530/SRR036530.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..5.fastq	SRR036530	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036530/SRR036530.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..5.fastq	SRR036530	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036530/SRR036530.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..5.fastq	SRR036530	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036530/SRR036530.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..6.fastq	SRR036531	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036531/SRR036531.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.exon.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..6.fastq	SRR036531	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036531/SRR036531.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.gene.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..6.fastq	SRR036531	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036531/SRR036531.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0928.spljxn.quantification.txt	3
06-22057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0928	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928	RNA	EFO	SRS405596	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0928 HS0928 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0928	SRX016946	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0928 HS0928 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09281..6.fastq	SRR036531	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR036531/SRR036531.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390837	@dbgap@:reads/SRP020237/SRS405596/SRX016946/SRR390837/SRR390837.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0928_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..fastq	SRR036532	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036532/SRR036532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..fastq	SRR036532	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036532/SRR036532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..fastq	SRR036532	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036532/SRR036532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..fastq	SRR036532	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036532/SRR036532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..1.fastq	SRR036533	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036533/SRR036533.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..1.fastq	SRR036533	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036533/SRR036533.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..1.fastq	SRR036533	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036533/SRR036533.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..1.fastq	SRR036533	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036533/SRR036533.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..2.fastq	SRR036534	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036534/SRR036534.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..2.fastq	SRR036534	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036534/SRR036534.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..2.fastq	SRR036534	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036534/SRR036534.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..2.fastq	SRR036534	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036534/SRR036534.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..4.fastq	SRR036535	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036535/SRR036535.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..4.fastq	SRR036535	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036535/SRR036535.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..4.fastq	SRR036535	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036535/SRR036535.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..4.fastq	SRR036535	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036535/SRR036535.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..5.fastq	SRR036536	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036536/SRR036536.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..5.fastq	SRR036536	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036536/SRR036536.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..5.fastq	SRR036536	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036536/SRR036536.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..5.fastq	SRR036536	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036536/SRR036536.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..6.fastq	SRR036537	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036537/SRR036537.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..6.fastq	SRR036537	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036537/SRR036537.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..6.fastq	SRR036537	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036537/SRR036537.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-11	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..6.fastq	SRR036537	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036537/SRR036537.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..7.fastq	SRR036538	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036538/SRR036538.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.exon.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..7.fastq	SRR036538	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036538/SRR036538.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.gene.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..7.fastq	SRR036538	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036538/SRR036538.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0929.spljxn.quantification.txt	3
06-23792	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0929	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929	RNA	EFO	SRS405597	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0929 HS0929 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS0929	SRX016948	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0929 HS0929 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09291..7.fastq	SRR036538	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR036538/SRR036538.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390838	@dbgap@:reads/SRP020237/SRS405597/SRX016948/SRR390838/SRR390838.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0929_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..fastq	SRR036539	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036539/SRR036539.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..fastq	SRR036539	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036539/SRR036539.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..fastq	SRR036539	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036539/SRR036539.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-17	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..fastq	SRR036539	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036539/SRR036539.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..10.fastq	SRR036540	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036540/SRR036540.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..10.fastq	SRR036540	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036540/SRR036540.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..10.fastq	SRR036540	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036540/SRR036540.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..10.fastq	SRR036540	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036540/SRR036540.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..11.fastq	SRR036541	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036541/SRR036541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..11.fastq	SRR036541	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036541/SRR036541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..11.fastq	SRR036541	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036541/SRR036541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..11.fastq	SRR036541	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036541/SRR036541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..12.fastq	SRR036542	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036542/SRR036542.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..12.fastq	SRR036542	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036542/SRR036542.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..12.fastq	SRR036542	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036542/SRR036542.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..12.fastq	SRR036542	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036542/SRR036542.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..7.fastq	SRR036543	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036543/SRR036543.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..7.fastq	SRR036543	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036543/SRR036543.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..7.fastq	SRR036543	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036543/SRR036543.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..7.fastq	SRR036543	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036543/SRR036543.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..8.fastq	SRR036544	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036544/SRR036544.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..8.fastq	SRR036544	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036544/SRR036544.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..8.fastq	SRR036544	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036544/SRR036544.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..8.fastq	SRR036544	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036544/SRR036544.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..9.fastq	SRR036545	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036545/SRR036545.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.exon.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..9.fastq	SRR036545	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036545/SRR036545.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.gene.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..9.fastq	SRR036545	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036545/SRR036545.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0930.spljxn.quantification.txt	3
95-32814	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0930	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930	RNA	EFO	SRS405598	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0930 HS0930 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0930	SRX016951	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0930 HS0930 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09301..9.fastq	SRR036545	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR036545/SRR036545.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390839	@dbgap@:reads/SRP020237/SRS405598/SRX016951/SRR390839/SRR390839.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0930_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..fastq	SRR036546	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036546/SRR036546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..fastq	SRR036546	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036546/SRR036546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..fastq	SRR036546	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036546/SRR036546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..fastq	SRR036546	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036546/SRR036546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..1.fastq	SRR036547	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036547/SRR036547.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..1.fastq	SRR036547	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036547/SRR036547.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..1.fastq	SRR036547	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036547/SRR036547.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..1.fastq	SRR036547	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036547/SRR036547.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..2.fastq	SRR036548	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036548/SRR036548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..2.fastq	SRR036548	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036548/SRR036548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..2.fastq	SRR036548	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036548/SRR036548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..2.fastq	SRR036548	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036548/SRR036548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..3.fastq	SRR036549	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036549/SRR036549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..3.fastq	SRR036549	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036549/SRR036549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..3.fastq	SRR036549	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036549/SRR036549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..3.fastq	SRR036549	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036549/SRR036549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..4.fastq	SRR036550	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036550/SRR036550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..4.fastq	SRR036550	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036550/SRR036550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..4.fastq	SRR036550	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036550/SRR036550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..4.fastq	SRR036550	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036550/SRR036550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..5.fastq	SRR036551	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036551/SRR036551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..5.fastq	SRR036551	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036551/SRR036551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..5.fastq	SRR036551	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036551/SRR036551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..5.fastq	SRR036551	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036551/SRR036551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..6.fastq	SRR036552	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036552/SRR036552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.exon.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..6.fastq	SRR036552	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036552/SRR036552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.gene.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..6.fastq	SRR036552	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036552/SRR036552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0931.spljxn.quantification.txt	3
01-26405	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0931	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931	RNA	EFO	SRS405599	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0931 HS0931 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	217	HS0931	SRX016953	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-20	HS0931 HS0931 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09311..6.fastq	SRR036552	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR036552/SRR036552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390840	@dbgap@:reads/SRP020237/SRS405599/SRX016953/SRR390840/SRR390840.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0931_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..fastq	SRR036553	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036553/SRR036553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..fastq	SRR036553	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036553/SRR036553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..fastq	SRR036553	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036553/SRR036553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..fastq	SRR036553	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036553/SRR036553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..1.fastq	SRR036554	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036554/SRR036554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..1.fastq	SRR036554	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036554/SRR036554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..1.fastq	SRR036554	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036554/SRR036554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..1.fastq	SRR036554	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036554/SRR036554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..2.fastq	SRR036555	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036555/SRR036555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..2.fastq	SRR036555	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036555/SRR036555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..2.fastq	SRR036555	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036555/SRR036555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..2.fastq	SRR036555	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036555/SRR036555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..3.fastq	SRR036556	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036556/SRR036556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..3.fastq	SRR036556	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036556/SRR036556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..3.fastq	SRR036556	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036556/SRR036556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..3.fastq	SRR036556	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036556/SRR036556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..4.fastq	SRR036557	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036557/SRR036557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..4.fastq	SRR036557	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036557/SRR036557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..4.fastq	SRR036557	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036557/SRR036557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..4.fastq	SRR036557	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036557/SRR036557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..5.fastq	SRR036558	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036558/SRR036558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..5.fastq	SRR036558	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036558/SRR036558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..5.fastq	SRR036558	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036558/SRR036558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..5.fastq	SRR036558	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036558/SRR036558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..6.fastq	SRR036559	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036559/SRR036559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.exon.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..6.fastq	SRR036559	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036559/SRR036559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.gene.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..6.fastq	SRR036559	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036559/SRR036559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0932.spljxn.quantification.txt	3
03-10363	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0932	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932	RNA	EFO	SRS405600	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0932 HS0932 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	234	HS0932	SRX016955	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-24	HS0932 HS0932 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09321..6.fastq	SRR036559	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR036559/SRR036559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390841	@dbgap@:reads/SRP020237/SRS405600/SRX016955/SRR390841/SRR390841.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0932_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..fastq	SRR036560	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036560/SRR036560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..fastq	SRR036560	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036560/SRR036560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..fastq	SRR036560	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036560/SRR036560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..fastq	SRR036560	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036560/SRR036560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..1.fastq	SRR036561	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036561/SRR036561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..1.fastq	SRR036561	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036561/SRR036561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..1.fastq	SRR036561	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036561/SRR036561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..1.fastq	SRR036561	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036561/SRR036561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..2.fastq	SRR036562	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036562/SRR036562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..2.fastq	SRR036562	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036562/SRR036562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..2.fastq	SRR036562	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036562/SRR036562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..2.fastq	SRR036562	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036562/SRR036562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..3.fastq	SRR036563	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036563/SRR036563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..3.fastq	SRR036563	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036563/SRR036563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..3.fastq	SRR036563	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036563/SRR036563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..3.fastq	SRR036563	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036563/SRR036563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..4.fastq	SRR036564	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036564/SRR036564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..4.fastq	SRR036564	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036564/SRR036564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..4.fastq	SRR036564	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036564/SRR036564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..4.fastq	SRR036564	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036564/SRR036564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..5.fastq	SRR036565	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036565/SRR036565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..5.fastq	SRR036565	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036565/SRR036565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..5.fastq	SRR036565	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036565/SRR036565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..5.fastq	SRR036565	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036565/SRR036565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..6.fastq	SRR036566	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036566/SRR036566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.exon.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..6.fastq	SRR036566	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036566/SRR036566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.gene.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..6.fastq	SRR036566	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036566/SRR036566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0933.spljxn.quantification.txt	3
03-13123	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0933	organism part	EFO	Solid Tumor	NCIt	"INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933	RNA	EFO	SRS405602	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0933 HS0933 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0933	SRX016957	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-16	HS0933 HS0933 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09331..6.fastq	SRR036566	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR036566/SRR036566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390842	@dbgap@:reads/SRP020237/SRS405602/SRX016957/SRR390842/SRR390842.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0933_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..fastq	SRR036567	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036567/SRR036567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..fastq	SRR036567	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036567/SRR036567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..fastq	SRR036567	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036567/SRR036567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..fastq	SRR036567	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036567/SRR036567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..3.fastq	SRR036568	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036568/SRR036568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..3.fastq	SRR036568	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036568/SRR036568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..3.fastq	SRR036568	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036568/SRR036568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..3.fastq	SRR036568	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036568/SRR036568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..4.fastq	SRR036569	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036569/SRR036569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..4.fastq	SRR036569	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036569/SRR036569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..4.fastq	SRR036569	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036569/SRR036569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..4.fastq	SRR036569	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036569/SRR036569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..5.fastq	SRR036570	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036570/SRR036570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..5.fastq	SRR036570	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036570/SRR036570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..5.fastq	SRR036570	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036570/SRR036570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..5.fastq	SRR036570	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036570/SRR036570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..6.fastq	SRR036571	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036571/SRR036571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..6.fastq	SRR036571	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036571/SRR036571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..6.fastq	SRR036571	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036571/SRR036571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..6.fastq	SRR036571	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036571/SRR036571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..7.fastq	SRR036572	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036572/SRR036572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..7.fastq	SRR036572	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036572/SRR036572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..7.fastq	SRR036572	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036572/SRR036572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..7.fastq	SRR036572	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036572/SRR036572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..8.fastq	SRR036573	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036573/SRR036573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.exon.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..8.fastq	SRR036573	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036573/SRR036573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.gene.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..8.fastq	SRR036573	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036573/SRR036573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0934.spljxn.quantification.txt	3
05-24395	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0934	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934	RNA	EFO	SRS405601	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0934 HS0934 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS0934	SRX016959	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS0934 HS0934 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09341..8.fastq	SRR036573	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR036573/SRR036573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390843	@dbgap@:reads/SRP020237/SRS405601/SRX016959/SRR390843/SRR390843.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0934_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..fastq	SRR036574	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036574/SRR036574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..fastq	SRR036574	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036574/SRR036574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..fastq	SRR036574	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036574/SRR036574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-11	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..fastq	SRR036574	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036574/SRR036574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..1.fastq	SRR036575	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036575/SRR036575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..1.fastq	SRR036575	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036575/SRR036575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..1.fastq	SRR036575	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036575/SRR036575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..1.fastq	SRR036575	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036575/SRR036575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..2.fastq	SRR036576	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036576/SRR036576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..2.fastq	SRR036576	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036576/SRR036576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..2.fastq	SRR036576	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036576/SRR036576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..2.fastq	SRR036576	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036576/SRR036576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..3.fastq	SRR036577	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036577/SRR036577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..3.fastq	SRR036577	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036577/SRR036577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..3.fastq	SRR036577	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036577/SRR036577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..3.fastq	SRR036577	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036577/SRR036577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..4.fastq	SRR036578	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036578/SRR036578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..4.fastq	SRR036578	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036578/SRR036578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..4.fastq	SRR036578	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036578/SRR036578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..4.fastq	SRR036578	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036578/SRR036578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..5.fastq	SRR036579	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036579/SRR036579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..5.fastq	SRR036579	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036579/SRR036579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..5.fastq	SRR036579	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036579/SRR036579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	101	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..5.fastq	SRR036579	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036579/SRR036579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..6.fastq	SRR036580	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036580/SRR036580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.exon.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..6.fastq	SRR036580	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036580/SRR036580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.gene.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..6.fastq	SRR036580	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036580/SRR036580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0935.spljxn.quantification.txt	3
08-21175	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0935	organism part	EFO	Solid Tumor	NCIt	"OVARY"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935	RNA	EFO	SRS405603	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0935 HS0935 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	202	HS0935	SRX016962	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS0935 HS0935 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09351..6.fastq	SRR036580	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR036580/SRR036580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390844	@dbgap@:reads/SRP020237/SRS405603/SRX016962/SRR390844/SRR390844.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0935_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR316337	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR316337/SRR316337.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR316337	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR316337/SRR316337.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR316337	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR316337/SRR316337.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR316337	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR316337/SRR316337.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0936-1..1.fastq	SRR1302957	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302957/SRR1302957.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0936-1..1.fastq	SRR1302957	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302957/SRR1302957.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0936-1..1.fastq	SRR1302957	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302957/SRR1302957.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0936-1..1.fastq	SRR1302957	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302957/SRR1302957.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR1302958	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302958/SRR1302958.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR1302958	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302958/SRR1302958.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR1302958	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302958/SRR1302958.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..2.fastq	SRR1302958	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302958/SRR1302958.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..3.fastq	SRR1302959	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302959/SRR1302959.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..3.fastq	SRR1302959	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302959/SRR1302959.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..3.fastq	SRR1302959	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302959/SRR1302959.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..3.fastq	SRR1302959	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302959/SRR1302959.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..4.fastq	SRR1302960	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302960/SRR1302960.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..4.fastq	SRR1302960	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302960/SRR1302960.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..4.fastq	SRR1302960	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302960/SRR1302960.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..4.fastq	SRR1302960	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302960/SRR1302960.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..5.fastq	SRR1302961	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302961/SRR1302961.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..5.fastq	SRR1302961	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302961/SRR1302961.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..5.fastq	SRR1302961	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302961/SRR1302961.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..5.fastq	SRR1302961	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302961/SRR1302961.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..6.fastq	SRR1302962	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302962/SRR1302962.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..6.fastq	SRR1302962	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302962/SRR1302962.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..6.fastq	SRR1302962	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302962/SRR1302962.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..6.fastq	SRR1302962	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302962/SRR1302962.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..7.fastq	SRR1302963	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302963/SRR1302963.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.exon.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..7.fastq	SRR1302963	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302963/SRR1302963.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.gene.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..7.fastq	SRR1302963	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302963/SRR1302963.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0936_7_lanes.spljxn.quantification.txt	3
06-19919	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0936	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936	RNA	EFO	SRS405395	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0936 HS0936 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS0936	SRX085014	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-25	HS0936 HS0936 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0936-1..7.fastq	SRR1302963	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR1302963/SRR1302963.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391281	@dbgap@:reads/SRP020237/SRS405395/SRX085014/SRR391281/SRR391281.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0936_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR316343	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR316343/SRR316343.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR316343	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR316343/SRR316343.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR316343	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR316343/SRR316343.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR316343	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR316343/SRR316343.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..7.fastq	SRR1302921	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302921/SRR1302921.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..7.fastq	SRR1302921	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302921/SRR1302921.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..7.fastq	SRR1302921	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302921/SRR1302921.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..7.fastq	SRR1302921	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302921/SRR1302921.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR1302964	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302964/SRR1302964.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR1302964	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302964/SRR1302964.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR1302964	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302964/SRR1302964.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..1.fastq	SRR1302964	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302964/SRR1302964.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..2.fastq	SRR1302965	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302965/SRR1302965.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..2.fastq	SRR1302965	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302965/SRR1302965.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..2.fastq	SRR1302965	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302965/SRR1302965.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..2.fastq	SRR1302965	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302965/SRR1302965.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..3.fastq	SRR1302966	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302966/SRR1302966.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..3.fastq	SRR1302966	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302966/SRR1302966.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..3.fastq	SRR1302966	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302966/SRR1302966.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..3.fastq	SRR1302966	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302966/SRR1302966.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..4.fastq	SRR1302967	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302967/SRR1302967.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..4.fastq	SRR1302967	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302967/SRR1302967.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..4.fastq	SRR1302967	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302967/SRR1302967.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..4.fastq	SRR1302967	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302967/SRR1302967.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..5.fastq	SRR1302968	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302968/SRR1302968.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..5.fastq	SRR1302968	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302968/SRR1302968.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..5.fastq	SRR1302968	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302968/SRR1302968.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..5.fastq	SRR1302968	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302968/SRR1302968.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..6.fastq	SRR1302969	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302969/SRR1302969.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.exon.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..6.fastq	SRR1302969	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302969/SRR1302969.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.gene.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..6.fastq	SRR1302969	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302969/SRR1302969.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0937_7_lanes.spljxn.quantification.txt	3
05-24561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937	RNA	EFO	SRS405396	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0937 HS0937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	187	HS0937	SRX085015	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-01	HS0937 HS0937 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0937-1..6.fastq	SRR1302969	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR1302969/SRR1302969.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391490	@dbgap@:reads/SRP020237/SRS405396/SRX085015/SRR391490/SRR391490.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0937_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR316349	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR316349/SRR316349.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR316349	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR316349/SRR316349.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR316349	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR316349/SRR316349.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR316349	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR316349/SRR316349.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..2.fastq	SRR1302923	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302923/SRR1302923.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..2.fastq	SRR1302923	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302923/SRR1302923.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..2.fastq	SRR1302923	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302923/SRR1302923.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..2.fastq	SRR1302923	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302923/SRR1302923.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..3.fastq	SRR1302924	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302924/SRR1302924.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..3.fastq	SRR1302924	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302924/SRR1302924.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..3.fastq	SRR1302924	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302924/SRR1302924.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..3.fastq	SRR1302924	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302924/SRR1302924.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR1302970	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302970/SRR1302970.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR1302970	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302970/SRR1302970.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR1302970	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302970/SRR1302970.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..4.fastq	SRR1302970	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302970/SRR1302970.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..5.fastq	SRR1302971	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302971/SRR1302971.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..5.fastq	SRR1302971	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302971/SRR1302971.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..5.fastq	SRR1302971	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302971/SRR1302971.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..5.fastq	SRR1302971	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302971/SRR1302971.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..6.fastq	SRR1302972	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302972/SRR1302972.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..6.fastq	SRR1302972	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302972/SRR1302972.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..6.fastq	SRR1302972	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302972/SRR1302972.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..6.fastq	SRR1302972	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302972/SRR1302972.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..7.fastq	SRR1302973	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302973/SRR1302973.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.exon.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..7.fastq	SRR1302973	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302973/SRR1302973.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.gene.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..7.fastq	SRR1302973	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302973/SRR1302973.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0938_7_lanes.spljxn.quantification.txt	3
06-15922	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938	RNA	EFO	SRS405397	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0938 HS0938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	179	HS0938	SRX085016	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-17	HS0938 HS0938 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0938-1..7.fastq	SRR1302973	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR1302973/SRR1302973.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391491	@dbgap@:reads/SRP020237/SRS405397/SRX085016/SRR391491/SRR391491.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0938_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR316357	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR316357/SRR316357.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR316357	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR316357/SRR316357.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR316357	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR316357/SRR316357.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR316357	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR316357/SRR316357.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-26	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.fastq	SRR1302974	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302974/SRR1302974.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-26	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.fastq	SRR1302974	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302974/SRR1302974.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-26	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.fastq	SRR1302974	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302974/SRR1302974.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-26	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.fastq	SRR1302974	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302974/SRR1302974.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.1.fastq	SRR1302975	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302975/SRR1302975.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.1.fastq	SRR1302975	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302975/SRR1302975.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.1.fastq	SRR1302975	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302975/SRR1302975.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.1.fastq	SRR1302975	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302975/SRR1302975.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.2.fastq	SRR1302976	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302976/SRR1302976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.2.fastq	SRR1302976	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302976/SRR1302976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.2.fastq	SRR1302976	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302976/SRR1302976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.2.fastq	SRR1302976	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302976/SRR1302976.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.3.fastq	SRR1302977	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302977/SRR1302977.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.3.fastq	SRR1302977	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302977/SRR1302977.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.3.fastq	SRR1302977	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302977/SRR1302977.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.3.fastq	SRR1302977	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302977/SRR1302977.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR1302978	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302978/SRR1302978.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR1302978	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302978/SRR1302978.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR1302978	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302978/SRR1302978.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.4.fastq	SRR1302978	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302978/SRR1302978.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.5.fastq	SRR1302979	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302979/SRR1302979.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.5.fastq	SRR1302979	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302979/SRR1302979.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.5.fastq	SRR1302979	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302979/SRR1302979.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.5.fastq	SRR1302979	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302979/SRR1302979.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.6.fastq	SRR1302980	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302980/SRR1302980.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.exon.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.6.fastq	SRR1302980	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302980/SRR1302980.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.gene.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.6.fastq	SRR1302980	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302980/SRR1302980.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0939_7_lanes.spljxn.quantification.txt	3
06-24881	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939	RNA	EFO	SRS405399	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0939 HS0939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS0939	SRX085017	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-02	HS0939 HS0939 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS0939-1.PET.6.fastq	SRR1302980	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR1302980/SRR1302980.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391492	@dbgap@:reads/SRP020237/SRS405399/SRX085017/SRR391492/SRR391492.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0939_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..fastq	SRR036581	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036581/SRR036581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..fastq	SRR036581	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036581/SRR036581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..fastq	SRR036581	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036581/SRR036581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..fastq	SRR036581	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036581/SRR036581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..1.fastq	SRR036582	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036582/SRR036582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..1.fastq	SRR036582	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036582/SRR036582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..1.fastq	SRR036582	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036582/SRR036582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..1.fastq	SRR036582	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036582/SRR036582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..2.fastq	SRR036583	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036583/SRR036583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..2.fastq	SRR036583	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036583/SRR036583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..2.fastq	SRR036583	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036583/SRR036583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..2.fastq	SRR036583	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036583/SRR036583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..3.fastq	SRR036584	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036584/SRR036584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..3.fastq	SRR036584	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036584/SRR036584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..3.fastq	SRR036584	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036584/SRR036584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..3.fastq	SRR036584	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036584/SRR036584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..4.fastq	SRR036585	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036585/SRR036585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..4.fastq	SRR036585	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036585/SRR036585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..4.fastq	SRR036585	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036585/SRR036585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..4.fastq	SRR036585	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036585/SRR036585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..5.fastq	SRR036586	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036586/SRR036586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..5.fastq	SRR036586	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036586/SRR036586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..5.fastq	SRR036586	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036586/SRR036586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..5.fastq	SRR036586	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036586/SRR036586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..6.fastq	SRR036587	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036587/SRR036587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.exon.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..6.fastq	SRR036587	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036587/SRR036587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.gene.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..6.fastq	SRR036587	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036587/SRR036587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0940.spljxn.quantification.txt	3
04-10134	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940	RNA	EFO	SRS405604	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0940 HS0940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	199	HS0940	SRX016964	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS0940 HS0940 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09401..6.fastq	SRR036587	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR036587/SRR036587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390845	@dbgap@:reads/SRP020237/SRS405604/SRX016964/SRR390845/SRR390845.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0940_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..fastq	SRR036588	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036588/SRR036588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.exon.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..fastq	SRR036588	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036588/SRR036588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.gene.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..fastq	SRR036588	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036588/SRR036588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.spljxn.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-03-16	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..fastq	SRR036588	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036588/SRR036588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..1.fastq	SRR036589	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036589/SRR036589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.exon.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..1.fastq	SRR036589	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036589/SRR036589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.gene.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..1.fastq	SRR036589	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036589/SRR036589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.spljxn.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..1.fastq	SRR036589	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036589/SRR036589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..2.fastq	SRR036590	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036590/SRR036590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.exon.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..2.fastq	SRR036590	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036590/SRR036590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.gene.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..2.fastq	SRR036590	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036590/SRR036590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.spljxn.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..2.fastq	SRR036590	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036590/SRR036590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..3.fastq	SRR036591	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036591/SRR036591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.exon.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..3.fastq	SRR036591	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036591/SRR036591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.gene.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..3.fastq	SRR036591	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036591/SRR036591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.spljxn.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS0941 HS0941 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..3.fastq	SRR036591	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR036591/SRR036591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS0941 HS0941 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..4.fastq	SRR354109	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR354109/SRR354109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.exon.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS0941 HS0941 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..4.fastq	SRR354109	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR354109/SRR354109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.gene.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS0941 HS0941 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..4.fastq	SRR354109	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR354109/SRR354109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0941.spljxn.quantification.txt	3
00-26427	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0941	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941	RNA	EFO	SRS405605	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0941 HS0941 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	216	HS0941	SRX016966	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS0941 HS0941 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09411..4.fastq	SRR354109	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR354109/SRR354109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390846	@dbgap@:reads/SRP020237/SRS405605/SRX016966/SRR390846/SRR390846.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0941_5_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..fastq	SRR036592	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036592/SRR036592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..fastq	SRR036592	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036592/SRR036592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..fastq	SRR036592	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036592/SRR036592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..fastq	SRR036592	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036592/SRR036592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..1.fastq	SRR036593	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036593/SRR036593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..1.fastq	SRR036593	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036593/SRR036593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..1.fastq	SRR036593	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036593/SRR036593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..1.fastq	SRR036593	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036593/SRR036593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..2.fastq	SRR036594	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036594/SRR036594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..2.fastq	SRR036594	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036594/SRR036594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..2.fastq	SRR036594	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036594/SRR036594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..2.fastq	SRR036594	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036594/SRR036594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..3.fastq	SRR036595	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036595/SRR036595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..3.fastq	SRR036595	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036595/SRR036595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..3.fastq	SRR036595	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036595/SRR036595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..3.fastq	SRR036595	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036595/SRR036595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..4.fastq	SRR036596	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036596/SRR036596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..4.fastq	SRR036596	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036596/SRR036596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..4.fastq	SRR036596	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036596/SRR036596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..4.fastq	SRR036596	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036596/SRR036596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..5.fastq	SRR036597	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036597/SRR036597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..5.fastq	SRR036597	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036597/SRR036597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..5.fastq	SRR036597	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036597/SRR036597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..5.fastq	SRR036597	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036597/SRR036597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..6.fastq	SRR036598	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036598/SRR036598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.exon.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..6.fastq	SRR036598	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036598/SRR036598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.gene.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..6.fastq	SRR036598	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036598/SRR036598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0942.spljxn.quantification.txt	3
96-20883	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0942	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942	RNA	EFO	SRS405606	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0942 HS0942 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS0942	SRX016968	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-07	HS0942 HS0942 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09421..6.fastq	SRR036598	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR036598/SRR036598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390847	@dbgap@:reads/SRP020237/SRS405606/SRX016968/SRR390847/SRR390847.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0942_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..fastq	SRR036599	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036599/SRR036599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..fastq	SRR036599	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036599/SRR036599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..fastq	SRR036599	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036599/SRR036599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-04-06	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..fastq	SRR036599	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036599/SRR036599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..1.fastq	SRR036600	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036600/SRR036600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..1.fastq	SRR036600	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036600/SRR036600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..1.fastq	SRR036600	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036600/SRR036600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..1.fastq	SRR036600	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036600/SRR036600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..2.fastq	SRR036601	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036601/SRR036601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..2.fastq	SRR036601	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036601/SRR036601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..2.fastq	SRR036601	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036601/SRR036601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..2.fastq	SRR036601	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036601/SRR036601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..3.fastq	SRR036602	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036602/SRR036602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..3.fastq	SRR036602	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036602/SRR036602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..3.fastq	SRR036602	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036602/SRR036602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..3.fastq	SRR036602	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036602/SRR036602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..4.fastq	SRR036603	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036603/SRR036603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..4.fastq	SRR036603	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036603/SRR036603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..4.fastq	SRR036603	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036603/SRR036603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..4.fastq	SRR036603	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036603/SRR036603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..5.fastq	SRR036604	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036604/SRR036604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..5.fastq	SRR036604	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036604/SRR036604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..5.fastq	SRR036604	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036604/SRR036604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..5.fastq	SRR036604	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036604/SRR036604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..6.fastq	SRR036605	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036605/SRR036605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.exon.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..6.fastq	SRR036605	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036605/SRR036605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.gene.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..6.fastq	SRR036605	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036605/SRR036605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0943.spljxn.quantification.txt	3
02-22991	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0943	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943	RNA	EFO	SRS405607	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0943 HS0943 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	232	HS0943	SRX016970	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-14	HS0943 HS0943 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01		HS09431..6.fastq	SRR036605	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR036605/SRR036605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam	SRR390819	@dbgap@:reads/SRP020237/SRS405607/SRX016970/SRR390819/SRR390819.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0943_7_lanes_chaste_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR316361	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR316361/SRR316361.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR316361	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR316361/SRR316361.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR316361	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR316361/SRR316361.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR316361	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR316361/SRR316361.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..1.fastq	SRR1302981	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302981/SRR1302981.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..1.fastq	SRR1302981	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302981/SRR1302981.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..1.fastq	SRR1302981	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302981/SRR1302981.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-01	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..1.fastq	SRR1302981	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302981/SRR1302981.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR1302982	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302982/SRR1302982.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR1302982	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302982/SRR1302982.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR1302982	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302982/SRR1302982.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..2.fastq	SRR1302982	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302982/SRR1302982.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..3.fastq	SRR1302983	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302983/SRR1302983.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..3.fastq	SRR1302983	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302983/SRR1302983.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..3.fastq	SRR1302983	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302983/SRR1302983.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..3.fastq	SRR1302983	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302983/SRR1302983.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..4.fastq	SRR1302984	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302984/SRR1302984.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..4.fastq	SRR1302984	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302984/SRR1302984.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..4.fastq	SRR1302984	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302984/SRR1302984.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..4.fastq	SRR1302984	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302984/SRR1302984.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..5.fastq	SRR1302985	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302985/SRR1302985.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..5.fastq	SRR1302985	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302985/SRR1302985.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..5.fastq	SRR1302985	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302985/SRR1302985.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..5.fastq	SRR1302985	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302985/SRR1302985.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..6.fastq	SRR1302986	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302986/SRR1302986.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..6.fastq	SRR1302986	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302986/SRR1302986.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..6.fastq	SRR1302986	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302986/SRR1302986.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..6.fastq	SRR1302986	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302986/SRR1302986.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..7.fastq	SRR1302987	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302987/SRR1302987.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.exon.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..7.fastq	SRR1302987	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302987/SRR1302987.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.gene.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..7.fastq	SRR1302987	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302987/SRR1302987.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS0944_7_lanes.spljxn.quantification.txt	3
05-17793	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS0944	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944	RNA	EFO	SRS405398	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS0944 HS0944 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS0944	SRX085018	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS0944 HS0944 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS0944-1..7.fastq	SRR1302987	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR1302987/SRR1302987.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391493	@dbgap@:reads/SRP020237/SRS405398/SRX085018/SRR391493/SRR391493.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS0944_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR316369	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR316369/SRR316369.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR316369	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR316369/SRR316369.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR316369	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR316369/SRR316369.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR316369	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR316369/SRR316369.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.fastq	SRR1302988	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302988/SRR1302988.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.fastq	SRR1302988	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302988/SRR1302988.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.fastq	SRR1302988	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302988/SRR1302988.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.fastq	SRR1302988	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302988/SRR1302988.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.1.fastq	SRR1302989	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302989/SRR1302989.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.1.fastq	SRR1302989	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302989/SRR1302989.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.1.fastq	SRR1302989	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302989/SRR1302989.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.1.fastq	SRR1302989	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302989/SRR1302989.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR1302990	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302990/SRR1302990.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR1302990	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302990/SRR1302990.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR1302990	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302990/SRR1302990.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.2.fastq	SRR1302990	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302990/SRR1302990.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.3.fastq	SRR1302991	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302991/SRR1302991.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.3.fastq	SRR1302991	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302991/SRR1302991.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.3.fastq	SRR1302991	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302991/SRR1302991.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.3.fastq	SRR1302991	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302991/SRR1302991.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.4.fastq	SRR1302992	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302992/SRR1302992.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.4.fastq	SRR1302992	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302992/SRR1302992.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.4.fastq	SRR1302992	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302992/SRR1302992.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.4.fastq	SRR1302992	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302992/SRR1302992.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.5.fastq	SRR1302993	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302993/SRR1302993.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.5.fastq	SRR1302993	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302993/SRR1302993.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.5.fastq	SRR1302993	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302993/SRR1302993.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.5.fastq	SRR1302993	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302993/SRR1302993.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.6.fastq	SRR1302994	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302994/SRR1302994.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.exon.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.6.fastq	SRR1302994	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302994/SRR1302994.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.gene.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.6.fastq	SRR1302994	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302994/SRR1302994.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1131_7_lanes.spljxn.quantification.txt	3
03-30438	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1131	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131	RNA	EFO	SRS405401	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1131 HS1131 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	192	HS1131	SRX085019	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1131 HS1131 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1131-1.PET.6.fastq	SRR1302994	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR1302994/SRR1302994.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391494	@dbgap@:reads/SRP020237/SRS405401/SRX085019/SRR391494/SRR391494.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1131_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR316377	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR316377/SRR316377.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR316377	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR316377/SRR316377.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR316377	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR316377/SRR316377.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR316377	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR316377/SRR316377.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1132-1.PET.fastq	SRR1302995	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302995/SRR1302995.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1132-1.PET.fastq	SRR1302995	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302995/SRR1302995.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1132-1.PET.fastq	SRR1302995	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302995/SRR1302995.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1132-1.PET.fastq	SRR1302995	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302995/SRR1302995.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.1.fastq	SRR1302996	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302996/SRR1302996.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.1.fastq	SRR1302996	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302996/SRR1302996.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.1.fastq	SRR1302996	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302996/SRR1302996.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.1.fastq	SRR1302996	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302996/SRR1302996.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.2.fastq	SRR1302997	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302997/SRR1302997.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.2.fastq	SRR1302997	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302997/SRR1302997.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.2.fastq	SRR1302997	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302997/SRR1302997.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.2.fastq	SRR1302997	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302997/SRR1302997.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR1302998	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302998/SRR1302998.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR1302998	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302998/SRR1302998.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR1302998	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302998/SRR1302998.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.3.fastq	SRR1302998	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302998/SRR1302998.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.4.fastq	SRR1302999	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302999/SRR1302999.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.4.fastq	SRR1302999	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302999/SRR1302999.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.4.fastq	SRR1302999	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302999/SRR1302999.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.4.fastq	SRR1302999	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1302999/SRR1302999.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.5.fastq	SRR1303000	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303000/SRR1303000.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.5.fastq	SRR1303000	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303000/SRR1303000.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.5.fastq	SRR1303000	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303000/SRR1303000.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.5.fastq	SRR1303000	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303000/SRR1303000.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.6.fastq	SRR1303001	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303001/SRR1303001.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.exon.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.6.fastq	SRR1303001	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303001/SRR1303001.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.gene.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.6.fastq	SRR1303001	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303001/SRR1303001.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1132_7_lanes.spljxn.quantification.txt	3
94-26795	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1132	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132	RNA	EFO	SRS405400	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1132 HS1132 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1132	SRX085020	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-29	HS1132 HS1132 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1132-1.PET.6.fastq	SRR1303001	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR1303001/SRR1303001.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391495	@dbgap@:reads/SRP020237/SRS405400/SRX085020/SRR391495/SRR391495.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1132_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR316385	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR316385/SRR316385.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR316385	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR316385/SRR316385.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR316385	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR316385/SRR316385.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR316385	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR316385/SRR316385.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.fastq	SRR1303002	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303002/SRR1303002.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.fastq	SRR1303002	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303002/SRR1303002.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.fastq	SRR1303002	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303002/SRR1303002.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-05-27	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.fastq	SRR1303002	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303002/SRR1303002.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.1.fastq	SRR1303003	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303003/SRR1303003.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.1.fastq	SRR1303003	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303003/SRR1303003.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.1.fastq	SRR1303003	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303003/SRR1303003.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.1.fastq	SRR1303003	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303003/SRR1303003.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.2.fastq	SRR1303004	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303004/SRR1303004.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.2.fastq	SRR1303004	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303004/SRR1303004.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.2.fastq	SRR1303004	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303004/SRR1303004.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.2.fastq	SRR1303004	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303004/SRR1303004.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.3.fastq	SRR1303005	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303005/SRR1303005.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.3.fastq	SRR1303005	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303005/SRR1303005.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.3.fastq	SRR1303005	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303005/SRR1303005.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.3.fastq	SRR1303005	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303005/SRR1303005.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR1303006	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303006/SRR1303006.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR1303006	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303006/SRR1303006.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR1303006	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303006/SRR1303006.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.4.fastq	SRR1303006	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303006/SRR1303006.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.5.fastq	SRR1303007	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303007/SRR1303007.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.5.fastq	SRR1303007	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303007/SRR1303007.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.5.fastq	SRR1303007	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303007/SRR1303007.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.5.fastq	SRR1303007	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303007/SRR1303007.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.6.fastq	SRR1303008	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303008/SRR1303008.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.exon.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.6.fastq	SRR1303008	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303008/SRR1303008.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.gene.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.6.fastq	SRR1303008	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303008/SRR1303008.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1133_7_lanes.spljxn.quantification.txt	3
05-23110	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1133	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133	RNA	EFO	SRS405402	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1133 HS1133 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	220	HS1133	SRX085021	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1133 HS1133 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1133-1.PET.6.fastq	SRR1303008	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR1303008/SRR1303008.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391283	@dbgap@:reads/SRP020237/SRS405402/SRX085021/SRR391283/SRR391283.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1133_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR316388	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR316388/SRR316388.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.exon.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR316388	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR316388/SRR316388.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.gene.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR316388	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR316388/SRR316388.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.spljxn.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR316388	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR316388/SRR316388.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR1303009	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303009/SRR1303009.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.exon.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR1303009	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303009/SRR1303009.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.gene.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR1303009	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303009/SRR1303009.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.spljxn.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..fastq	SRR1303009	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303009/SRR1303009.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..1.fastq	SRR1303010	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303010/SRR1303010.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.exon.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..1.fastq	SRR1303010	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303010/SRR1303010.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.gene.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..1.fastq	SRR1303010	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303010/SRR1303010.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.spljxn.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..1.fastq	SRR1303010	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303010/SRR1303010.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..2.fastq	SRR1303011	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303011/SRR1303011.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.exon.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..2.fastq	SRR1303011	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303011/SRR1303011.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.gene.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..2.fastq	SRR1303011	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303011/SRR1303011.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.spljxn.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1134 HS1134 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1134-1..2.fastq	SRR1303011	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303011/SRR1303011.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS1134 HS1134 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1134-1..3.fastq	SRR1303012	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303012/SRR1303012.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.exon.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS1134 HS1134 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1134-1..3.fastq	SRR1303012	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303012/SRR1303012.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.gene.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS1134 HS1134 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1134-1..3.fastq	SRR1303012	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303012/SRR1303012.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1134_4_lanes.spljxn.quantification.txt	3
06-24915	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1134	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134	RNA	EFO	SRS405403	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1134 HS1134 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1134	SRX085022	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-13	HS1134 HS1134 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1134-1..3.fastq	SRR1303012	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR1303012/SRR1303012.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391284	@dbgap@:reads/SRP020237/SRS405403/SRX085022/SRR391284/SRR391284.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1134_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR316394	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR316394/SRR316394.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR316394	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR316394/SRR316394.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR316394	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR316394/SRR316394.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR316394	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR316394/SRR316394.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1135-1.PET.fastq	SRR1303013	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303013/SRR1303013.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1135-1.PET.fastq	SRR1303013	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303013/SRR1303013.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1135-1.PET.fastq	SRR1303013	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303013/SRR1303013.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-17	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1135-1.PET.fastq	SRR1303013	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303013/SRR1303013.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.1.fastq	SRR1303014	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303014/SRR1303014.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.1.fastq	SRR1303014	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303014/SRR1303014.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.1.fastq	SRR1303014	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303014/SRR1303014.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.1.fastq	SRR1303014	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303014/SRR1303014.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR1303015	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303015/SRR1303015.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR1303015	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303015/SRR1303015.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR1303015	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303015/SRR1303015.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.2.fastq	SRR1303015	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303015/SRR1303015.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.3.fastq	SRR1303016	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303016/SRR1303016.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.3.fastq	SRR1303016	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303016/SRR1303016.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.3.fastq	SRR1303016	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303016/SRR1303016.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.3.fastq	SRR1303016	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303016/SRR1303016.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.4.fastq	SRR1303017	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303017/SRR1303017.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.4.fastq	SRR1303017	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303017/SRR1303017.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.4.fastq	SRR1303017	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303017/SRR1303017.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.4.fastq	SRR1303017	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303017/SRR1303017.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.5.fastq	SRR1303018	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303018/SRR1303018.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.5.fastq	SRR1303018	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303018/SRR1303018.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.5.fastq	SRR1303018	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303018/SRR1303018.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.5.fastq	SRR1303018	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303018/SRR1303018.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.6.fastq	SRR1303019	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303019/SRR1303019.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.exon.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.6.fastq	SRR1303019	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303019/SRR1303019.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.gene.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.6.fastq	SRR1303019	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303019/SRR1303019.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1135_7_lanes.spljxn.quantification.txt	3
07-37968	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1135	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135	RNA	EFO	SRS405404	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1135 HS1135 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	213	HS1135	SRX085023	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1135 HS1135 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1135-1.PET.6.fastq	SRR1303019	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR1303019/SRR1303019.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391496	@dbgap@:reads/SRP020237/SRS405404/SRX085023/SRR391496/SRR391496.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1135_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR316399	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR316399/SRR316399.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR316399	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR316399/SRR316399.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR316399	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR316399/SRR316399.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR316399	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR316399/SRR316399.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR1303020	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303020/SRR1303020.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR1303020	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303020/SRR1303020.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR1303020	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303020/SRR1303020.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-09	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1136-1.PET.fastq	SRR1303020	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303020/SRR1303020.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.1.fastq	SRR1303021	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303021/SRR1303021.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.1.fastq	SRR1303021	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303021/SRR1303021.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.1.fastq	SRR1303021	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303021/SRR1303021.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.1.fastq	SRR1303021	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303021/SRR1303021.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.2.fastq	SRR1303022	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303022/SRR1303022.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.2.fastq	SRR1303022	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303022/SRR1303022.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.2.fastq	SRR1303022	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303022/SRR1303022.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.2.fastq	SRR1303022	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303022/SRR1303022.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.3.fastq	SRR1303023	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303023/SRR1303023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.3.fastq	SRR1303023	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303023/SRR1303023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.3.fastq	SRR1303023	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303023/SRR1303023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.3.fastq	SRR1303023	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303023/SRR1303023.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.4.fastq	SRR1303024	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303024/SRR1303024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.4.fastq	SRR1303024	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303024/SRR1303024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.4.fastq	SRR1303024	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303024/SRR1303024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.4.fastq	SRR1303024	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303024/SRR1303024.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.5.fastq	SRR1303025	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303025/SRR1303025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.5.fastq	SRR1303025	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303025/SRR1303025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.5.fastq	SRR1303025	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303025/SRR1303025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.5.fastq	SRR1303025	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303025/SRR1303025.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.6.fastq	SRR1303026	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303026/SRR1303026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.exon.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.6.fastq	SRR1303026	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303026/SRR1303026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.gene.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.6.fastq	SRR1303026	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303026/SRR1303026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1136_7_lanes.spljxn.quantification.txt	3
08-15460	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136	RNA	EFO	SRS405405	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1136 HS1136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	231	HS1136	SRX085024	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1136 HS1136 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1136-1.PET.6.fastq	SRR1303026	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR1303026/SRR1303026.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391285	@dbgap@:reads/SRP020237/SRS405405/SRX085024/SRR391285/SRR391285.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1136_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR316409	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR316409/SRR316409.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR316409	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR316409/SRR316409.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR316409	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR316409/SRR316409.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR316409	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR316409/SRR316409.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..fastq	SRR1303027	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303027/SRR1303027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..fastq	SRR1303027	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303027/SRR1303027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..fastq	SRR1303027	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303027/SRR1303027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..fastq	SRR1303027	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303027/SRR1303027.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..1.fastq	SRR1303028	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303028/SRR1303028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..1.fastq	SRR1303028	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303028/SRR1303028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..1.fastq	SRR1303028	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303028/SRR1303028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..1.fastq	SRR1303028	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303028/SRR1303028.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..2.fastq	SRR1303029	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303029/SRR1303029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..2.fastq	SRR1303029	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303029/SRR1303029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..2.fastq	SRR1303029	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303029/SRR1303029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..2.fastq	SRR1303029	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303029/SRR1303029.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR1303030	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303030/SRR1303030.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR1303030	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303030/SRR1303030.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR1303030	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303030/SRR1303030.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..3.fastq	SRR1303030	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303030/SRR1303030.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..4.fastq	SRR1303031	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303031/SRR1303031.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..4.fastq	SRR1303031	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303031/SRR1303031.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..4.fastq	SRR1303031	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303031/SRR1303031.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..4.fastq	SRR1303031	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303031/SRR1303031.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..5.fastq	SRR1303032	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303032/SRR1303032.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..5.fastq	SRR1303032	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303032/SRR1303032.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..5.fastq	SRR1303032	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303032/SRR1303032.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..5.fastq	SRR1303032	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303032/SRR1303032.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..6.fastq	SRR1303033	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303033/SRR1303033.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.exon.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..6.fastq	SRR1303033	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303033/SRR1303033.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.gene.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..6.fastq	SRR1303033	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303033/SRR1303033.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1137_7_lanes.spljxn.quantification.txt	3
01-19969	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1137	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137	RNA	EFO	SRS405406	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1137 HS1137 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1137	SRX085025	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1137 HS1137 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1137-1..6.fastq	SRR1303033	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR1303033/SRR1303033.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391497	@dbgap@:reads/SRP020237/SRS405406/SRX085025/SRR391497/SRR391497.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1137_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR316415	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR316415/SRR316415.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR316415	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR316415/SRR316415.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR316415	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR316415/SRR316415.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR316415	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR316415/SRR316415.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.fastq	SRR1303034	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303034/SRR1303034.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.fastq	SRR1303034	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303034/SRR1303034.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.fastq	SRR1303034	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303034/SRR1303034.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.fastq	SRR1303034	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303034/SRR1303034.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.10.fastq	SRR1303035	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303035/SRR1303035.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.10.fastq	SRR1303035	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303035/SRR1303035.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.10.fastq	SRR1303035	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303035/SRR1303035.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.10.fastq	SRR1303035	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303035/SRR1303035.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR1303036	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303036/SRR1303036.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR1303036	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303036/SRR1303036.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR1303036	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303036/SRR1303036.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.11.fastq	SRR1303036	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303036/SRR1303036.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.12.fastq	SRR1303037	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303037/SRR1303037.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.12.fastq	SRR1303037	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303037/SRR1303037.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.12.fastq	SRR1303037	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303037/SRR1303037.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.12.fastq	SRR1303037	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303037/SRR1303037.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.7.fastq	SRR1303038	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303038/SRR1303038.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.7.fastq	SRR1303038	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303038/SRR1303038.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.7.fastq	SRR1303038	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303038/SRR1303038.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.7.fastq	SRR1303038	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303038/SRR1303038.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.8.fastq	SRR1303039	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303039/SRR1303039.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.8.fastq	SRR1303039	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303039/SRR1303039.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.8.fastq	SRR1303039	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303039/SRR1303039.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.8.fastq	SRR1303039	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303039/SRR1303039.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.9.fastq	SRR1303040	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303040/SRR1303040.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.exon.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.9.fastq	SRR1303040	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303040/SRR1303040.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.gene.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.9.fastq	SRR1303040	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303040/SRR1303040.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1138_7_lanes.spljxn.quantification.txt	3
01-26579	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1138	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138	RNA	EFO	SRS405407	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1138 HS1138 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	284	HS1138	SRX085026	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1138 HS1138 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1138-1.PET.9.fastq	SRR1303040	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR1303040/SRR1303040.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391498	@dbgap@:reads/SRP020237/SRS405407/SRX085026/SRR391498/SRR391498.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1138_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1163	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163	RNA	EFO	SRS212586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163 HS1163 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS1163	SRX079571	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1163 HS1163 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11631.PET.fastq	SRR292246	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR292246/SRR292246.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_2_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390733	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR390733/SRR390733.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1163_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1163	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163	RNA	EFO	SRS212586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163 HS1163 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS1163	SRX079571	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1163 HS1163 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11631.PET.fastq	SRR292246	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR292246/SRR292246.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_2_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390733	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR390733/SRR390733.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1163_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1163	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163	RNA	EFO	SRS212586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163 HS1163 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS1163	SRX079571	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1163 HS1163 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11631.PET.fastq	SRR292246	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR292246/SRR292246.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_2_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390733	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR390733/SRR390733.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1163_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1163	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163	RNA	EFO	SRS212586	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1163 HS1163 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS1163	SRX079571	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1163 HS1163 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11631.PET.fastq	SRR292246	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR292246/SRR292246.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_2_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390733	@dbgap@:reads/SRP020237/SRS212586/SRX079571/SRR390733/SRR390733.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1163_2_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR316425	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR316425/SRR316425.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR316425	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR316425/SRR316425.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR316425	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR316425/SRR316425.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR316425	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR316425/SRR316425.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.fastq	SRR1303041	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303041/SRR1303041.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.fastq	SRR1303041	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303041/SRR1303041.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.fastq	SRR1303041	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303041/SRR1303041.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-24	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.fastq	SRR1303041	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303041/SRR1303041.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.1.fastq	SRR1303042	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303042/SRR1303042.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.1.fastq	SRR1303042	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303042/SRR1303042.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.1.fastq	SRR1303042	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303042/SRR1303042.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.1.fastq	SRR1303042	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303042/SRR1303042.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.2.fastq	SRR1303043	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303043/SRR1303043.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.2.fastq	SRR1303043	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303043/SRR1303043.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.2.fastq	SRR1303043	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303043/SRR1303043.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.2.fastq	SRR1303043	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303043/SRR1303043.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.3.fastq	SRR1303044	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303044/SRR1303044.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.3.fastq	SRR1303044	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303044/SRR1303044.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.3.fastq	SRR1303044	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303044/SRR1303044.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.3.fastq	SRR1303044	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303044/SRR1303044.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.4.fastq	SRR1303045	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303045/SRR1303045.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.4.fastq	SRR1303045	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303045/SRR1303045.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.4.fastq	SRR1303045	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303045/SRR1303045.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.4.fastq	SRR1303045	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303045/SRR1303045.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR1303046	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303046/SRR1303046.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR1303046	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303046/SRR1303046.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR1303046	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303046/SRR1303046.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.5.fastq	SRR1303046	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303046/SRR1303046.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.6.fastq	SRR1303047	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303047/SRR1303047.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.exon.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.6.fastq	SRR1303047	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303047/SRR1303047.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.gene.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.6.fastq	SRR1303047	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303047/SRR1303047.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1164_7_lanes.spljxn.quantification.txt	3
01-18667	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1164	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164	RNA	EFO	SRS405408	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1164 HS1164 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	251	HS1164	SRX085027	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1164 HS1164 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1164-1.PET.6.fastq	SRR1303047	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR1303047/SRR1303047.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391499	@dbgap@:reads/SRP020237/SRS405408/SRX085027/SRR391499/SRR391499.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1164_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR316430	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR316430/SRR316430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR316430	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR316430/SRR316430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR316430	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR316430/SRR316430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR316430	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR316430/SRR316430.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..fastq	SRR1303048	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303048/SRR1303048.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..fastq	SRR1303048	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303048/SRR1303048.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..fastq	SRR1303048	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303048/SRR1303048.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-23	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..fastq	SRR1303048	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303048/SRR1303048.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1181-1..1.fastq	SRR1303049	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303049/SRR1303049.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1181-1..1.fastq	SRR1303049	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303049/SRR1303049.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1181-1..1.fastq	SRR1303049	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303049/SRR1303049.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1181-1..1.fastq	SRR1303049	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303049/SRR1303049.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..2.fastq	SRR1303050	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303050/SRR1303050.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..2.fastq	SRR1303050	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303050/SRR1303050.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..2.fastq	SRR1303050	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303050/SRR1303050.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..2.fastq	SRR1303050	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303050/SRR1303050.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR1303051	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303051/SRR1303051.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR1303051	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303051/SRR1303051.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR1303051	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303051/SRR1303051.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..3.fastq	SRR1303051	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303051/SRR1303051.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..4.fastq	SRR1303052	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303052/SRR1303052.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..4.fastq	SRR1303052	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303052/SRR1303052.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..4.fastq	SRR1303052	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303052/SRR1303052.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..4.fastq	SRR1303052	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303052/SRR1303052.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..5.fastq	SRR1303053	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303053/SRR1303053.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..5.fastq	SRR1303053	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303053/SRR1303053.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..5.fastq	SRR1303053	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303053/SRR1303053.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..5.fastq	SRR1303053	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303053/SRR1303053.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..6.fastq	SRR1303054	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303054/SRR1303054.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.exon.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..6.fastq	SRR1303054	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303054/SRR1303054.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.gene.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..6.fastq	SRR1303054	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303054/SRR1303054.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1181_7_lanes.spljxn.quantification.txt	3
05-24401	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1181	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181	RNA	EFO	SRS405409	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1181 HS1181 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	264	HS1181	SRX085028	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-22	HS1181 HS1181 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1181-1..6.fastq	SRR1303054	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR1303054/SRR1303054.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391500	@dbgap@:reads/SRP020237/SRS405409/SRX085028/SRR391500/SRR391500.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1181_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1182	organism part	EFO		NCIt	"peripheral blood"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182	RNA	EFO	SRS212587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182 HS1182 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1182	SRX079572	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1182 HS1182 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11821.PET.fastq	SRR292247	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR292247/SRR292247.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_3_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390734	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR390734/SRR390734.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1182_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1182	organism part	EFO		NCIt	"peripheral blood"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182	RNA	EFO	SRS212587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182 HS1182 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1182	SRX079572	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1182 HS1182 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11821.PET.fastq	SRR292247	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR292247/SRR292247.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_3_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390734	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR390734/SRR390734.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1182_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1182	organism part	EFO		NCIt	"peripheral blood"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182	RNA	EFO	SRS212587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182 HS1182 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1182	SRX079572	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1182 HS1182 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11821.PET.fastq	SRR292247	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR292247/SRR292247.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_3_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390734	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR390734/SRR390734.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1182_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS1182	organism part	EFO		NCIt	"peripheral blood"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182	RNA	EFO	SRS212587	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1182 HS1182 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1182	SRX079572	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1182 HS1182 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11821.PET.fastq	SRR292247	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR292247/SRR292247.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	30TR6AAXX_3_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390734	@dbgap@:reads/SRP020237/SRS212587/SRX079572/SRR390734/SRR390734.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1182_3_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS1183	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183	RNA	EFO	SRS212588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183 HS1183 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	375	HS1183	SRX079573	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-06	HS1183 HS1183 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11831.PET.fastq	SRR292248	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR292248/SRR292248.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	31434AAXX_7_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390735	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR390735/SRR390735.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1183_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS1183	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183	RNA	EFO	SRS212588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183 HS1183 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	375	HS1183	SRX079573	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-06	HS1183 HS1183 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11831.PET.fastq	SRR292248	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR292248/SRR292248.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	31434AAXX_7_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390735	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR390735/SRR390735.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1183_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS1183	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183	RNA	EFO	SRS212588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183 HS1183 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	375	HS1183	SRX079573	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-06	HS1183 HS1183 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11831.PET.fastq	SRR292248	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR292248/SRR292248.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	31434AAXX_7_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390735	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR390735/SRR390735.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1183_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt		NCIt	HS1183	organism part	EFO		NCIt	"bone marrow"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183	RNA	EFO	SRS212588	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1183 HS1183 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	375	HS1183	SRX079573	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-06	HS1183 HS1183 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS11831.PET.fastq	SRR292248	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR292248/SRR292248.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	31434AAXX_7_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam	SRR390735	@dbgap@:reads/SRP020237/SRS212588/SRX079573/SRR390735/SRR390735.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1183_7_f1b6.sorted_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR316435	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR316435/SRR316435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.exon.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR316435	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR316435/SRR316435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.gene.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR316435	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR316435/SRR316435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.spljxn.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR316435	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR316435/SRR316435.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1184-1.PET.fastq	SRR1303055	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303055/SRR1303055.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.exon.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1184-1.PET.fastq	SRR1303055	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303055/SRR1303055.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.gene.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1184-1.PET.fastq	SRR1303055	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303055/SRR1303055.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.spljxn.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1184-1.PET.fastq	SRR1303055	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303055/SRR1303055.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR1303056	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303056/SRR1303056.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.exon.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR1303056	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303056/SRR1303056.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.gene.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR1303056	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303056/SRR1303056.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.spljxn.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.1.fastq	SRR1303056	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303056/SRR1303056.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.2.fastq	SRR1303057	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303057/SRR1303057.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.exon.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.2.fastq	SRR1303057	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303057/SRR1303057.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.gene.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.2.fastq	SRR1303057	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303057/SRR1303057.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.spljxn.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.2.fastq	SRR1303057	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303057/SRR1303057.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.3.fastq	SRR1303058	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303058/SRR1303058.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.exon.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.3.fastq	SRR1303058	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303058/SRR1303058.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.gene.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.3.fastq	SRR1303058	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303058/SRR1303058.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1184_4_lanes.spljxn.quantification.txt	3
05-12472	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1184	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184	RNA	EFO	SRS405522	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1184 HS1184 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1184	SRX085029	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1184 HS1184 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1184-1.PET.3.fastq	SRR1303058	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR1303058/SRR1303058.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391501	@dbgap@:reads/SRP020237/SRS405522/SRX085029/SRR391501/SRR391501.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1184_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR316439	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR316439/SRR316439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.exon.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR316439	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR316439/SRR316439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.gene.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR316439	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR316439/SRR316439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.spljxn.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR316439	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR316439/SRR316439.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1185-1.PET.fastq	SRR1303059	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303059/SRR1303059.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.exon.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1185-1.PET.fastq	SRR1303059	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303059/SRR1303059.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.gene.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1185-1.PET.fastq	SRR1303059	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303059/SRR1303059.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.spljxn.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1185-1.PET.fastq	SRR1303059	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303059/SRR1303059.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR1303060	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303060/SRR1303060.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.exon.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR1303060	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303060/SRR1303060.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.gene.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR1303060	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303060/SRR1303060.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.spljxn.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.1.fastq	SRR1303060	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303060/SRR1303060.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.2.fastq	SRR1303061	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303061/SRR1303061.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.exon.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.2.fastq	SRR1303061	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303061/SRR1303061.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.gene.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.2.fastq	SRR1303061	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303061/SRR1303061.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.spljxn.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.2.fastq	SRR1303061	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303061/SRR1303061.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.3.fastq	SRR1303062	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303062/SRR1303062.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.exon.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.3.fastq	SRR1303062	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303062/SRR1303062.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.gene.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.3.fastq	SRR1303062	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303062/SRR1303062.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1185_4_lanes.spljxn.quantification.txt	3
05-14720	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1185	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185	RNA	EFO	SRS405523	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1185 HS1185 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1185	SRX085030	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1185 HS1185 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1185-1.PET.3.fastq	SRR1303062	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR1303062/SRR1303062.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391502	@dbgap@:reads/SRP020237/SRS405523/SRX085030/SRR391502/SRR391502.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1185_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1186-1.PET.fastq	SRR316442	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316442/SRR316442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.exon.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1186-1.PET.fastq	SRR316442	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316442/SRR316442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.gene.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1186-1.PET.fastq	SRR316442	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316442/SRR316442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.spljxn.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1186-1.PET.fastq	SRR316442	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316442/SRR316442.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.1.fastq	SRR316443	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316443/SRR316443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.exon.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.1.fastq	SRR316443	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316443/SRR316443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.gene.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.1.fastq	SRR316443	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316443/SRR316443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.spljxn.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.1.fastq	SRR316443	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316443/SRR316443.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.2.fastq	SRR316444	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316444/SRR316444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.exon.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.2.fastq	SRR316444	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316444/SRR316444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.gene.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.2.fastq	SRR316444	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316444/SRR316444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.spljxn.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.2.fastq	SRR316444	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316444/SRR316444.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.3.fastq	SRR316445	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316445/SRR316445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.exon.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.3.fastq	SRR316445	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316445/SRR316445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.gene.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.3.fastq	SRR316445	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316445/SRR316445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1186_4_lanes.spljxn.quantification.txt	3
05-14545	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1186	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186	RNA	EFO	SRS405524	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1186 HS1186 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	222	HS1186	SRX085031	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1186 HS1186 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1186-1.PET.3.fastq	SRR316445	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR316445/SRR316445.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391503	@dbgap@:reads/SRP020237/SRS405524/SRX085031/SRR391503/SRR391503.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1186_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1199-1.PET.fastq	SRR316446	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316446/SRR316446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.exon.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1199-1.PET.fastq	SRR316446	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316446/SRR316446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.gene.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1199-1.PET.fastq	SRR316446	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316446/SRR316446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.spljxn.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-03	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1199-1.PET.fastq	SRR316446	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316446/SRR316446.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.1.fastq	SRR316447	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316447/SRR316447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.exon.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.1.fastq	SRR316447	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316447/SRR316447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.gene.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.1.fastq	SRR316447	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316447/SRR316447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.spljxn.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.1.fastq	SRR316447	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316447/SRR316447.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.2.fastq	SRR316448	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316448/SRR316448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.exon.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.2.fastq	SRR316448	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316448/SRR316448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.gene.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.2.fastq	SRR316448	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316448/SRR316448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.spljxn.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.2.fastq	SRR316448	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316448/SRR316448.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.3.fastq	SRR316449	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316449/SRR316449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.exon.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.3.fastq	SRR316449	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316449/SRR316449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.gene.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.3.fastq	SRR316449	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316449/SRR316449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1199_4_lanes.spljxn.quantification.txt	3
05-19843	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1199	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199	RNA	EFO	SRS405525	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1199 HS1199 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS1199	SRX085032	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-07	HS1199 HS1199 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1199-1.PET.3.fastq	SRR316449	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR316449/SRR316449.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391504	@dbgap@:reads/SRP020237/SRS405525/SRX085032/SRR391504/SRR391504.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1199_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-22	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.1.fastq	SRR316450	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316450/SRR316450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.exon.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-22	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.1.fastq	SRR316450	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316450/SRR316450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.gene.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-22	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.1.fastq	SRR316450	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316450/SRR316450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.spljxn.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-22	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.1.fastq	SRR316450	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316450/SRR316450.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.2.fastq	SRR316451	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316451/SRR316451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.exon.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.2.fastq	SRR316451	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316451/SRR316451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.gene.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.2.fastq	SRR316451	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316451/SRR316451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.spljxn.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.2.fastq	SRR316451	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316451/SRR316451.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.3.fastq	SRR316452	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316452/SRR316452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.exon.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.3.fastq	SRR316452	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316452/SRR316452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.gene.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.3.fastq	SRR316452	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316452/SRR316452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.spljxn.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.3.fastq	SRR316452	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316452/SRR316452.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.4.fastq	SRR316453	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316453/SRR316453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.exon.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.4.fastq	SRR316453	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316453/SRR316453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.gene.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.4.fastq	SRR316453	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316453/SRR316453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1200_4_lanes.spljxn.quantification.txt	3
03-10481	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1200	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200	RNA	EFO	SRS405526	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1200 HS1200 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	265	HS1200	SRX085033	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1200 HS1200 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1200-1.PET.4.fastq	SRR316453	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR316453/SRR316453.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391505	@dbgap@:reads/SRP020237/SRS405526/SRX085033/SRR391505/SRR391505.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1200_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-19	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1201-1.PET.fastq	SRR316454	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316454/SRR316454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.exon.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-19	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1201-1.PET.fastq	SRR316454	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316454/SRR316454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.gene.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-19	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1201-1.PET.fastq	SRR316454	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316454/SRR316454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.spljxn.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-19	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1201-1.PET.fastq	SRR316454	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316454/SRR316454.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.1.fastq	SRR316455	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316455/SRR316455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.exon.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.1.fastq	SRR316455	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316455/SRR316455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.gene.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.1.fastq	SRR316455	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316455/SRR316455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.spljxn.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.1.fastq	SRR316455	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316455/SRR316455.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.2.fastq	SRR316456	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316456/SRR316456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.exon.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.2.fastq	SRR316456	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316456/SRR316456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.gene.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.2.fastq	SRR316456	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316456/SRR316456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.spljxn.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.2.fastq	SRR316456	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316456/SRR316456.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.3.fastq	SRR316457	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316457/SRR316457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.exon.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.3.fastq	SRR316457	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316457/SRR316457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.gene.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.3.fastq	SRR316457	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316457/SRR316457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1201_4_lanes.spljxn.quantification.txt	3
04-28117	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1201	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201	RNA	EFO	SRS405527	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1201 HS1201 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	221	HS1201	SRX085034	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1201 HS1201 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1201-1.PET.3.fastq	SRR316457	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR316457/SRR316457.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391506	@dbgap@:reads/SRP020237/SRS405527/SRX085034/SRR391506/SRR391506.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1201_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1202-1..fastq	SRR316458	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316458/SRR316458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1202-1..fastq	SRR316458	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316458/SRR316458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1202-1..fastq	SRR316458	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316458/SRR316458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1202-1..fastq	SRR316458	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316458/SRR316458.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..1.fastq	SRR316459	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316459/SRR316459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..1.fastq	SRR316459	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316459/SRR316459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..1.fastq	SRR316459	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316459/SRR316459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..1.fastq	SRR316459	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316459/SRR316459.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..2.fastq	SRR316460	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316460/SRR316460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..2.fastq	SRR316460	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316460/SRR316460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..2.fastq	SRR316460	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316460/SRR316460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..2.fastq	SRR316460	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316460/SRR316460.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..3.fastq	SRR316461	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316461/SRR316461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..3.fastq	SRR316461	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316461/SRR316461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..3.fastq	SRR316461	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316461/SRR316461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..3.fastq	SRR316461	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316461/SRR316461.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..4.fastq	SRR316462	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316462/SRR316462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..4.fastq	SRR316462	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316462/SRR316462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..4.fastq	SRR316462	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316462/SRR316462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..4.fastq	SRR316462	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316462/SRR316462.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..5.fastq	SRR316463	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316463/SRR316463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..5.fastq	SRR316463	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316463/SRR316463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..5.fastq	SRR316463	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316463/SRR316463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..5.fastq	SRR316463	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316463/SRR316463.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..6.fastq	SRR316464	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316464/SRR316464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..6.fastq	SRR316464	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316464/SRR316464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..6.fastq	SRR316464	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316464/SRR316464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..6.fastq	SRR316464	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316464/SRR316464.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..7.fastq	SRR316465	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316465/SRR316465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.exon.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..7.fastq	SRR316465	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316465/SRR316465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.gene.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..7.fastq	SRR316465	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316465/SRR316465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1202_8_lanes.spljxn.quantification.txt	3
07-21038	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1202	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202	RNA	EFO	SRS405528	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1202 HS1202 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	208	HS1202	SRX085035	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-13	HS1202 HS1202 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1202-1..7.fastq	SRR316465	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR316465/SRR316465.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391507	@dbgap@:reads/SRP020237/SRS405528/SRX085035/SRR391507/SRR391507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1202_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1203-1.PET.fastq	SRR316466	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316466/SRR316466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.exon.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1203-1.PET.fastq	SRR316466	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316466/SRR316466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.gene.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1203-1.PET.fastq	SRR316466	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316466/SRR316466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.spljxn.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1203-1.PET.fastq	SRR316466	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316466/SRR316466.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.1.fastq	SRR316467	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316467/SRR316467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.exon.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.1.fastq	SRR316467	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316467/SRR316467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.gene.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.1.fastq	SRR316467	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316467/SRR316467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.spljxn.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.1.fastq	SRR316467	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316467/SRR316467.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.2.fastq	SRR316468	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316468/SRR316468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.exon.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.2.fastq	SRR316468	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316468/SRR316468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.gene.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.2.fastq	SRR316468	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316468/SRR316468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.spljxn.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.2.fastq	SRR316468	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316468/SRR316468.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.3.fastq	SRR316469	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316469/SRR316469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.exon.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.3.fastq	SRR316469	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316469/SRR316469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.gene.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.3.fastq	SRR316469	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316469/SRR316469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1203_4_lanes.spljxn.quantification.txt	3
08-10448	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1203	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203	RNA	EFO	SRS405529	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1203 HS1203 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS1203	SRX085036	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1203 HS1203 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1203-1.PET.3.fastq	SRR316469	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR316469/SRR316469.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391508	@dbgap@:reads/SRP020237/SRS405529/SRX085036/SRR391508/SRR391508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1203_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..fastq	SRR316470	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316470/SRR316470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.exon.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..fastq	SRR316470	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316470/SRR316470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.gene.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..fastq	SRR316470	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316470/SRR316470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.spljxn.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-26	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..fastq	SRR316470	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316470/SRR316470.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..1.fastq	SRR316471	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316471/SRR316471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.exon.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..1.fastq	SRR316471	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316471/SRR316471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.gene.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..1.fastq	SRR316471	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316471/SRR316471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.spljxn.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..1.fastq	SRR316471	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316471/SRR316471.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..2.fastq	SRR316472	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316472/SRR316472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.exon.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..2.fastq	SRR316472	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316472/SRR316472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.gene.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..2.fastq	SRR316472	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316472/SRR316472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.spljxn.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..2.fastq	SRR316472	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316472/SRR316472.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..3.fastq	SRR316473	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316473/SRR316473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.exon.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..3.fastq	SRR316473	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316473/SRR316473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.gene.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..3.fastq	SRR316473	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316473/SRR316473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1204_4_lanes.spljxn.quantification.txt	3
06-28477	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Follicular Lymphoma	NCIt	HS1204	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204	RNA	EFO	SRS405530	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1204 HS1204 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1204	SRX085037	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1204 HS1204 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1204-1..3.fastq	SRR316473	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR316473/SRR316473.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391509	@dbgap@:reads/SRP020237/SRS405530/SRX085037/SRR391509/SRR391509.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1204_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.fastq	SRR316474	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316474/SRR316474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.exon.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.fastq	SRR316474	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316474/SRR316474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.gene.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.fastq	SRR316474	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316474/SRR316474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.spljxn.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-06-30	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.fastq	SRR316474	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316474/SRR316474.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.1.fastq	SRR316475	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316475/SRR316475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.exon.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.1.fastq	SRR316475	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316475/SRR316475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.gene.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.1.fastq	SRR316475	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316475/SRR316475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.spljxn.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.1.fastq	SRR316475	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316475/SRR316475.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.2.fastq	SRR316476	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316476/SRR316476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.exon.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.2.fastq	SRR316476	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316476/SRR316476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.gene.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.2.fastq	SRR316476	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316476/SRR316476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.spljxn.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-24	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1205-1.PET.2.fastq	SRR316476	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316476/SRR316476.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-31	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.3.fastq	SRR316477	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316477/SRR316477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.exon.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-31	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.3.fastq	SRR316477	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316477/SRR316477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.gene.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-31	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.3.fastq	SRR316477	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316477/SRR316477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1205_4_lanes.spljxn.quantification.txt	3
01-16433	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1205	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205	RNA	EFO	SRS405531	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1205 HS1205 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA		HS1205	SRX085038	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-31	HS1205 HS1205 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1205-1.PET.3.fastq	SRR316477	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR316477/SRR316477.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391510	@dbgap@:reads/SRP020237/SRS405531/SRX085038/SRR391510/SRR391510.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1205_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..fastq	SRR316478	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316478/SRR316478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..fastq	SRR316478	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316478/SRR316478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..fastq	SRR316478	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316478/SRR316478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-07-03	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..fastq	SRR316478	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316478/SRR316478.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..1.fastq	SRR316479	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316479/SRR316479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..1.fastq	SRR316479	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316479/SRR316479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..1.fastq	SRR316479	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316479/SRR316479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..1.fastq	SRR316479	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316479/SRR316479.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..2.fastq	SRR316480	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316480/SRR316480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..2.fastq	SRR316480	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316480/SRR316480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..2.fastq	SRR316480	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316480/SRR316480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-21	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1350-1..2.fastq	SRR316480	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316480/SRR316480.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..3.fastq	SRR316481	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316481/SRR316481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..3.fastq	SRR316481	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316481/SRR316481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..3.fastq	SRR316481	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316481/SRR316481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..3.fastq	SRR316481	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316481/SRR316481.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..4.fastq	SRR316482	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316482/SRR316482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..4.fastq	SRR316482	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316482/SRR316482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..4.fastq	SRR316482	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316482/SRR316482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..4.fastq	SRR316482	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316482/SRR316482.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..5.fastq	SRR316483	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316483/SRR316483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..5.fastq	SRR316483	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316483/SRR316483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..5.fastq	SRR316483	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316483/SRR316483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..5.fastq	SRR316483	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316483/SRR316483.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..6.fastq	SRR316484	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316484/SRR316484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.exon.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..6.fastq	SRR316484	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316484/SRR316484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.gene.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..6.fastq	SRR316484	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316484/SRR316484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1350_7_lanes.spljxn.quantification.txt	3
06-24718	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1350	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350	RNA	EFO	SRS405410	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1350 HS1350 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS1350	SRX085039	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1350 HS1350 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1350-1..6.fastq	SRR316484	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR316484/SRR316484.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR391511	@dbgap@:reads/SRP020237/SRS405410/SRX085039/SRR391511/SRR391511.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1350_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..fastq	SRR316485	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316485/SRR316485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.exon.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..fastq	SRR316485	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316485/SRR316485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.gene.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..fastq	SRR316485	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316485/SRR316485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.spljxn.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-04	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..fastq	SRR316485	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316485/SRR316485.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..1.fastq	SRR316486	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316486/SRR316486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.exon.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..1.fastq	SRR316486	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316486/SRR316486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.gene.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..1.fastq	SRR316486	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316486/SRR316486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.spljxn.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-05	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..1.fastq	SRR316486	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316486/SRR316486.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-12	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..2.fastq	SRR316487	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316487/SRR316487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.exon.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-12	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..2.fastq	SRR316487	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316487/SRR316487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.gene.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-12	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..2.fastq	SRR316487	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316487/SRR316487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.spljxn.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-01-12	HS1352 HS1352 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1352-1..2.fastq	SRR316487	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316487/SRR316487.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS1352 HS1352 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1352-1..3.fastq	SRR316488	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316488/SRR316488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.exon.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS1352 HS1352 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1352-1..3.fastq	SRR316488	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316488/SRR316488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.gene.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS1352 HS1352 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1352-1..3.fastq	SRR316488	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316488/SRR316488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1352_4_lanes.spljxn.quantification.txt	3
06-10398	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1352	organism part	EFO	Solid Tumor	NCIt	"ENT SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352	RNA	EFO	SRS405411	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1352 HS1352 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS1352	SRX085040	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS1352 HS1352 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1352-1..3.fastq	SRR316488	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR316488/SRR316488.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390855	@dbgap@:reads/SRP020237/SRS405411/SRX085040/SRR390855/SRR390855.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1352_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..fastq	SRR316489	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316489/SRR316489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.exon.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..fastq	SRR316489	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316489/SRR316489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.gene.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..fastq	SRR316489	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316489/SRR316489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.spljxn.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..fastq	SRR316489	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316489/SRR316489.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..1.fastq	SRR316490	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316490/SRR316490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.exon.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..1.fastq	SRR316490	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316490/SRR316490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.gene.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..1.fastq	SRR316490	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316490/SRR316490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.spljxn.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..1.fastq	SRR316490	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316490/SRR316490.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..2.fastq	SRR316491	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316491/SRR316491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.exon.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..2.fastq	SRR316491	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316491/SRR316491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.gene.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..2.fastq	SRR316491	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316491/SRR316491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.spljxn.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1356 HS1356 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1356-1..2.fastq	SRR316491	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316491/SRR316491.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1356 HS1356 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1356-1..4.fastq	SRR316492	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316492/SRR316492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.exon.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1356 HS1356 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1356-1..4.fastq	SRR316492	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316492/SRR316492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.gene.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1356 HS1356 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1356-1..4.fastq	SRR316492	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316492/SRR316492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1356_4_lanes.spljxn.quantification.txt	3
02-22023	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1356	organism part	EFO	Solid Tumor	NCIt	"SOFT TISSUE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356	RNA	EFO	SRS405412	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1356 HS1356 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1356	SRX085041	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1356 HS1356 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1356-1..4.fastq	SRR316492	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR316492/SRR316492.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390856	@dbgap@:reads/SRP020237/SRS405412/SRX085041/SRR390856/SRR390856.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1356_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..fastq	SRR316493	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316493/SRR316493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..fastq	SRR316493	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316493/SRR316493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..fastq	SRR316493	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316493/SRR316493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..fastq	SRR316493	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316493/SRR316493.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..1.fastq	SRR316494	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316494/SRR316494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..1.fastq	SRR316494	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316494/SRR316494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..1.fastq	SRR316494	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316494/SRR316494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..1.fastq	SRR316494	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316494/SRR316494.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..2.fastq	SRR316495	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316495/SRR316495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..2.fastq	SRR316495	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316495/SRR316495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..2.fastq	SRR316495	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316495/SRR316495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..2.fastq	SRR316495	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316495/SRR316495.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..3.fastq	SRR316496	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316496/SRR316496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..3.fastq	SRR316496	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316496/SRR316496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..3.fastq	SRR316496	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316496/SRR316496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..3.fastq	SRR316496	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316496/SRR316496.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..4.fastq	SRR316497	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316497/SRR316497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..4.fastq	SRR316497	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316497/SRR316497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..4.fastq	SRR316497	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316497/SRR316497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..4.fastq	SRR316497	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316497/SRR316497.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..5.fastq	SRR316498	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316498/SRR316498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..5.fastq	SRR316498	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316498/SRR316498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..5.fastq	SRR316498	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316498/SRR316498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..5.fastq	SRR316498	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316498/SRR316498.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..6.fastq	SRR316499	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316499/SRR316499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.exon.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..6.fastq	SRR316499	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316499/SRR316499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.gene.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..6.fastq	SRR316499	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316499/SRR316499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1358_7_lanes.spljxn.quantification.txt	3
05-24904	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1358	organism part	EFO	Solid Tumor	NCIt	"THYROID"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358	RNA	EFO	SRS405413	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1358 HS1358 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	307	HS1358	SRX085042	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-10	HS1358 HS1358 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1358-1..6.fastq	SRR316499	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR316499/SRR316499.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390857	@dbgap@:reads/SRP020237/SRS405413/SRX085042/SRR390857/SRR390857.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1358_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1360-1..fastq	SRR316500	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316500/SRR316500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.exon.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1360-1..fastq	SRR316500	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316500/SRR316500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.gene.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1360-1..fastq	SRR316500	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316500/SRR316500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.spljxn.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1360-1..fastq	SRR316500	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316500/SRR316500.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..1.fastq	SRR316501	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316501/SRR316501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.exon.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..1.fastq	SRR316501	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316501/SRR316501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.gene.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..1.fastq	SRR316501	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316501/SRR316501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.spljxn.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..1.fastq	SRR316501	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316501/SRR316501.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..2.fastq	SRR316502	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316502/SRR316502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.exon.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..2.fastq	SRR316502	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316502/SRR316502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.gene.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..2.fastq	SRR316502	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316502/SRR316502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.spljxn.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-11	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..2.fastq	SRR316502	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316502/SRR316502.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..3.fastq	SRR316503	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316503/SRR316503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.exon.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..3.fastq	SRR316503	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316503/SRR316503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.gene.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..3.fastq	SRR316503	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316503/SRR316503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1360_4_lanes.spljxn.quantification.txt	3
92-33015	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1360	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360	RNA	EFO	SRS405532	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1360 HS1360 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	275	HS1360	SRX085043	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1360 HS1360 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1360-1..3.fastq	SRR316503	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR316503/SRR316503.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390858	@dbgap@:reads/SRP020237/SRS405532/SRX085043/SRR390858/SRR390858.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1360_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1361-1..fastq	SRR316504	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316504/SRR316504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.exon.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1361-1..fastq	SRR316504	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316504/SRR316504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.gene.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1361-1..fastq	SRR316504	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316504/SRR316504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.spljxn.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-13	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1361-1..fastq	SRR316504	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316504/SRR316504.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..1.fastq	SRR316505	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316505/SRR316505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.exon.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..1.fastq	SRR316505	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316505/SRR316505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.gene.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..1.fastq	SRR316505	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316505/SRR316505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.spljxn.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..1.fastq	SRR316505	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316505/SRR316505.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..2.fastq	SRR316506	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316506/SRR316506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.exon.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..2.fastq	SRR316506	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316506/SRR316506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.gene.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..2.fastq	SRR316506	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316506/SRR316506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.spljxn.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..2.fastq	SRR316506	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316506/SRR316506.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..3.fastq	SRR316507	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316507/SRR316507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.exon.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..3.fastq	SRR316507	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316507/SRR316507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.gene.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..3.fastq	SRR316507	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316507/SRR316507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1361_4_lanes.spljxn.quantification.txt	3
03-28399	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Follicular Lymphoma	NCIt	HS1361	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361	RNA	EFO	SRS405533	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1361 HS1361 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	272	HS1361	SRX085044	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1361 HS1361 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1361-1..3.fastq	SRR316507	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR316507/SRR316507.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390859	@dbgap@:reads/SRP020237/SRS405533/SRX085044/SRR390859/SRR390859.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1361_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR316513	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR316513/SRR316513.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR316513	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR316513/SRR316513.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR316513	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR316513/SRR316513.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR316513	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR316513/SRR316513.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	91	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR554507	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR554507/SRR554507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	91	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR554507	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR554507/SRR554507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	91	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR554507	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR554507/SRR554507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	91	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR554507	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR554507/SRR554507.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1452 HS1452 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..fastq	SRR1303063	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303063/SRR1303063.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1452 HS1452 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..fastq	SRR1303063	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303063/SRR1303063.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1452 HS1452 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..fastq	SRR1303063	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303063/SRR1303063.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1452 HS1452 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..fastq	SRR1303063	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303063/SRR1303063.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-01	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..1.fastq	SRR1303064	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303064/SRR1303064.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-01	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..1.fastq	SRR1303064	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303064/SRR1303064.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-01	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..1.fastq	SRR1303064	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303064/SRR1303064.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-01	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..1.fastq	SRR1303064	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303064/SRR1303064.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..2.fastq	SRR1303065	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303065/SRR1303065.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..2.fastq	SRR1303065	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303065/SRR1303065.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..2.fastq	SRR1303065	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303065/SRR1303065.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..2.fastq	SRR1303065	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303065/SRR1303065.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..3.fastq	SRR1303066	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303066/SRR1303066.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..3.fastq	SRR1303066	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303066/SRR1303066.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..3.fastq	SRR1303066	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303066/SRR1303066.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1452-1..3.fastq	SRR1303066	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303066/SRR1303066.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..4.fastq	SRR1303067	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303067/SRR1303067.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..4.fastq	SRR1303067	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303067/SRR1303067.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..4.fastq	SRR1303067	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303067/SRR1303067.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..4.fastq	SRR1303067	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303067/SRR1303067.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR1303068	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303068/SRR1303068.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR1303068	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303068/SRR1303068.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR1303068	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303068/SRR1303068.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..5.fastq	SRR1303068	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303068/SRR1303068.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..6.fastq	SRR1303069	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303069/SRR1303069.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..6.fastq	SRR1303069	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303069/SRR1303069.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..6.fastq	SRR1303069	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303069/SRR1303069.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..6.fastq	SRR1303069	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303069/SRR1303069.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..7.fastq	SRR1303070	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303070/SRR1303070.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..7.fastq	SRR1303070	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303070/SRR1303070.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..7.fastq	SRR1303070	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303070/SRR1303070.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-26	HS1452 HS1452 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1452-1..7.fastq	SRR1303070	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303070/SRR1303070.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303110	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303110/SRR1303110.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.exon.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303110	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303110/SRR1303110.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.gene.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303110	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303110/SRR1303110.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1452_8_lanes.spljxn.quantification.txt	3
92-56188	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1452	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452	RNA	EFO	SRS405415	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1452 HS1452 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	271	HS1452	SRX085045	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1452 HS1452 run	sequencing assay	EFO	100	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1452_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303110	@dbgap@:reads/SRP020237/SRS405415/SRX085045/SRR1303110/SRR1303110.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1452_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..fastq	SRR316516	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316516/SRR316516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..fastq	SRR316516	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316516/SRR316516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..fastq	SRR316516	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316516/SRR316516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..fastq	SRR316516	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316516/SRR316516.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..1.fastq	SRR316517	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316517/SRR316517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..1.fastq	SRR316517	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316517/SRR316517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..1.fastq	SRR316517	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316517/SRR316517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..1.fastq	SRR316517	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316517/SRR316517.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..2.fastq	SRR316518	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316518/SRR316518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..2.fastq	SRR316518	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316518/SRR316518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..2.fastq	SRR316518	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316518/SRR316518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..2.fastq	SRR316518	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316518/SRR316518.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..3.fastq	SRR316519	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316519/SRR316519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..3.fastq	SRR316519	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316519/SRR316519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..3.fastq	SRR316519	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316519/SRR316519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..3.fastq	SRR316519	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316519/SRR316519.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..4.fastq	SRR316520	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316520/SRR316520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..4.fastq	SRR316520	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316520/SRR316520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..4.fastq	SRR316520	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316520/SRR316520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..4.fastq	SRR316520	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316520/SRR316520.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..5.fastq	SRR316521	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316521/SRR316521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..5.fastq	SRR316521	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316521/SRR316521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..5.fastq	SRR316521	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316521/SRR316521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..5.fastq	SRR316521	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316521/SRR316521.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..6.fastq	SRR316522	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316522/SRR316522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.exon.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..6.fastq	SRR316522	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316522/SRR316522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.gene.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..6.fastq	SRR316522	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316522/SRR316522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1454_7_lanes.spljxn.quantification.txt	3
03-30549	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1454	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454	RNA	EFO	SRS405414	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1454 HS1454 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1454	SRX085046	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-29	HS1454 HS1454 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1454-1..6.fastq	SRR316522	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR316522/SRR316522.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390861	@dbgap@:reads/SRP020237/SRS405414/SRX085046/SRR390861/SRR390861.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1454_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR316523	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR316523/SRR316523.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR316523	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR316523/SRR316523.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR316523	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR316523/SRR316523.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR316523	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR316523/SRR316523.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	104	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged_dupsFlagged.bam	SRR554508	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR554508/SRR554508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	104	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged_dupsFlagged.bam	SRR554508	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR554508/SRR554508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	104	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged_dupsFlagged.bam	SRR554508	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR554508/SRR554508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	104	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged_dupsFlagged.bam	SRR554508	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR554508/SRR554508.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR1303071	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303071/SRR1303071.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR1303071	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303071/SRR1303071.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR1303071	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303071/SRR1303071.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-08-20	HS1456 HS1456 run	sequencing assay	EFO	51	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1456-1..fastq	SRR1303071	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303071/SRR1303071.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..1.fastq	SRR1303072	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303072/SRR1303072.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..1.fastq	SRR1303072	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303072/SRR1303072.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..1.fastq	SRR1303072	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303072/SRR1303072.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..1.fastq	SRR1303072	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303072/SRR1303072.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..2.fastq	SRR1303073	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303073/SRR1303073.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..2.fastq	SRR1303073	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303073/SRR1303073.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..2.fastq	SRR1303073	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303073/SRR1303073.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-14	HS1456 HS1456 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..2.fastq	SRR1303073	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303073/SRR1303073.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..3.fastq	SRR1303074	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303074/SRR1303074.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..3.fastq	SRR1303074	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303074/SRR1303074.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..3.fastq	SRR1303074	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303074/SRR1303074.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..3.fastq	SRR1303074	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303074/SRR1303074.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..4.fastq	SRR1303075	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303075/SRR1303075.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..4.fastq	SRR1303075	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303075/SRR1303075.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..4.fastq	SRR1303075	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303075/SRR1303075.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..4.fastq	SRR1303075	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303075/SRR1303075.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..5.fastq	SRR1303076	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303076/SRR1303076.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..5.fastq	SRR1303076	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303076/SRR1303076.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..5.fastq	SRR1303076	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303076/SRR1303076.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..5.fastq	SRR1303076	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303076/SRR1303076.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..6.fastq	SRR1303077	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303077/SRR1303077.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..6.fastq	SRR1303077	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303077/SRR1303077.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..6.fastq	SRR1303077	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303077/SRR1303077.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-28	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..6.fastq	SRR1303077	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303077/SRR1303077.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..7.fastq	SRR1303078	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303078/SRR1303078.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..7.fastq	SRR1303078	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303078/SRR1303078.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..7.fastq	SRR1303078	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303078/SRR1303078.sra	1							bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1456 HS1456 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1456-1..7.fastq	SRR1303078	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303078/SRR1303078.sra	1							bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	114	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303111	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303111/SRR1303111.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.exon.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	114	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303111	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303111/SRR1303111.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.gene.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	114	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303111	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303111/SRR1303111.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1456_8_lanes.spljxn.quantification.txt	3
03-31974	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1456	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456	RNA	EFO	SRS405416	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1456 HS1456 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	235	HS1456	SRX085047	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA		HS1456 HS1456 run	sequencing assay	EFO	114	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01						bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1456_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR1303111	@dbgap@:reads/SRP020237/SRS405416/SRX085047/SRR1303111/SRR1303111.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1456_8_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR316532	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR316532/SRR316532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR316532	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR316532/SRR316532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR316532	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR316532/SRR316532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR316532	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR316532/SRR316532.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..fastq	SRR1303079	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303079/SRR1303079.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..fastq	SRR1303079	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303079/SRR1303079.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..fastq	SRR1303079	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303079/SRR1303079.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..fastq	SRR1303079	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303079/SRR1303079.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR1303080	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303080/SRR1303080.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR1303080	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303080/SRR1303080.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR1303080	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303080/SRR1303080.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..1.fastq	SRR1303080	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303080/SRR1303080.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..2.fastq	SRR1303081	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303081/SRR1303081.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..2.fastq	SRR1303081	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303081/SRR1303081.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..2.fastq	SRR1303081	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303081/SRR1303081.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1458 HS1458 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1458-1..2.fastq	SRR1303081	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303081/SRR1303081.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..4.fastq	SRR1303082	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303082/SRR1303082.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..4.fastq	SRR1303082	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303082/SRR1303082.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..4.fastq	SRR1303082	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303082/SRR1303082.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..4.fastq	SRR1303082	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303082/SRR1303082.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..5.fastq	SRR1303083	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303083/SRR1303083.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..5.fastq	SRR1303083	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303083/SRR1303083.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..5.fastq	SRR1303083	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303083/SRR1303083.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..5.fastq	SRR1303083	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303083/SRR1303083.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-12	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..6.fastq	SRR1303084	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303084/SRR1303084.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.exon.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-12	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..6.fastq	SRR1303084	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303084/SRR1303084.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.gene.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-12	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..6.fastq	SRR1303084	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303084/SRR1303084.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1458_6_lanes.spljxn.quantification.txt	3
81-52884	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1458	organism part	EFO	Solid Tumor	NCIt	"BREAST"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458	RNA	EFO	SRS405417	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1458 HS1458 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	286	HS1458	SRX085048	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-12	HS1458 HS1458 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1458-1..6.fastq	SRR1303084	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR1303084/SRR1303084.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1458_6_lanes_dupsFlagged.bam	SRR390863	@dbgap@:reads/SRP020237/SRS405417/SRX085048/SRR390863/SRR390863.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1458_6_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR316541	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR316541/SRR316541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR316541	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR316541/SRR316541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR316541	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR316541/SRR316541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR316541	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR316541/SRR316541.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1460-2..fastq	SRR1303085	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303085/SRR1303085.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1460-2..fastq	SRR1303085	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303085/SRR1303085.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1460-2..fastq	SRR1303085	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303085/SRR1303085.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-04	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.4.0	HS1460-2..fastq	SRR1303085	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303085/SRR1303085.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..1.fastq	SRR1303086	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303086/SRR1303086.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..1.fastq	SRR1303086	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303086/SRR1303086.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..1.fastq	SRR1303086	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303086/SRR1303086.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..1.fastq	SRR1303086	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303086/SRR1303086.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..2.fastq	SRR1303087	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303087/SRR1303087.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..2.fastq	SRR1303087	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303087/SRR1303087.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..2.fastq	SRR1303087	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303087/SRR1303087.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..2.fastq	SRR1303087	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303087/SRR1303087.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..3.fastq	SRR1303088	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303088/SRR1303088.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..3.fastq	SRR1303088	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303088/SRR1303088.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..3.fastq	SRR1303088	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303088/SRR1303088.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..3.fastq	SRR1303088	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303088/SRR1303088.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR1303089	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303089/SRR1303089.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR1303089	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303089/SRR1303089.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR1303089	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303089/SRR1303089.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..4.fastq	SRR1303089	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303089/SRR1303089.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..5.fastq	SRR1303090	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303090/SRR1303090.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..5.fastq	SRR1303090	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303090/SRR1303090.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..5.fastq	SRR1303090	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303090/SRR1303090.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..5.fastq	SRR1303090	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303090/SRR1303090.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..6.fastq	SRR1303091	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303091/SRR1303091.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.exon.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..6.fastq	SRR1303091	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303091/SRR1303091.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.gene.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..6.fastq	SRR1303091	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303091/SRR1303091.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1460_7_lanes.spljxn.quantification.txt	3
05-24006	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1460	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460	RNA	EFO	SRS405418	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1460 HS1460 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	227	HS1460	SRX085049	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-05	HS1460 HS1460 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1460-2..6.fastq	SRR1303091	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR1303091/SRR1303091.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390864	@dbgap@:reads/SRP020237/SRS405418/SRX085049/SRR390864/SRR390864.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1460_7_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR316546	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR316546/SRR316546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.exon.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR316546	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR316546/SRR316546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.gene.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR316546	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR316546/SRR316546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.spljxn.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR316546	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR316546/SRR316546.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..fastq	SRR1303092	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303092/SRR1303092.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.exon.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..fastq	SRR1303092	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303092/SRR1303092.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.gene.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..fastq	SRR1303092	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303092/SRR1303092.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.spljxn.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-09-25	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..fastq	SRR1303092	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303092/SRR1303092.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..1.fastq	SRR1303093	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303093/SRR1303093.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.exon.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..1.fastq	SRR1303093	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303093/SRR1303093.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.gene.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..1.fastq	SRR1303093	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303093/SRR1303093.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.spljxn.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..1.fastq	SRR1303093	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303093/SRR1303093.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR1303094	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303094/SRR1303094.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.exon.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR1303094	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303094/SRR1303094.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.gene.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR1303094	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303094/SRR1303094.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.spljxn.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1462 HS1462 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1462-1..2.fastq	SRR1303094	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303094/SRR1303094.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1462 HS1462 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1462-1..4.fastq	SRR1303095	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303095/SRR1303095.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.exon.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1462 HS1462 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1462-1..4.fastq	SRR1303095	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303095/SRR1303095.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.gene.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1462 HS1462 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1462-1..4.fastq	SRR1303095	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303095/SRR1303095.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1462_4_lanes.spljxn.quantification.txt	3
05-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1462	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462	RNA	EFO	SRS405419	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1462 HS1462 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS1462	SRX085050	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS1462 HS1462 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1462-1..4.fastq	SRR1303095	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR1303095/SRR1303095.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390865	@dbgap@:reads/SRP020237/SRS405419/SRX085050/SRR390865/SRR390865.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1462_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..fastq	SRR316548	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316548/SRR316548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.exon.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..fastq	SRR316548	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316548/SRR316548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.gene.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..fastq	SRR316548	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316548/SRR316548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.spljxn.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..fastq	SRR316548	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316548/SRR316548.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..1.fastq	SRR316549	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316549/SRR316549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.exon.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..1.fastq	SRR316549	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316549/SRR316549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.gene.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..1.fastq	SRR316549	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316549/SRR316549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.spljxn.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..1.fastq	SRR316549	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316549/SRR316549.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..2.fastq	SRR316550	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316550/SRR316550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.exon.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..2.fastq	SRR316550	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316550/SRR316550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.gene.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..2.fastq	SRR316550	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316550/SRR316550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.spljxn.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1555 HS1555 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1555-1..2.fastq	SRR316550	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316550/SRR316550.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1555 HS1555 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1555-1..4.fastq	SRR316551	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316551/SRR316551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.exon.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1555 HS1555 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1555-1..4.fastq	SRR316551	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316551/SRR316551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.gene.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1555 HS1555 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1555-1..4.fastq	SRR316551	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316551/SRR316551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1555_4_lanes.spljxn.quantification.txt	3
05-11328	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1555	organism part	EFO	Solid Tumor	NCIt	"TONSIL"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555	RNA	EFO	SRS405420	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1555 HS1555 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1555	SRX085051	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1555 HS1555 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1555-1..4.fastq	SRR316551	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR316551/SRR316551.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390866	@dbgap@:reads/SRP020237/SRS405420/SRX085051/SRR390866/SRR390866.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1555_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..fastq	SRR316552	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316552/SRR316552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.exon.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..fastq	SRR316552	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316552/SRR316552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.gene.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..fastq	SRR316552	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316552/SRR316552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.spljxn.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..fastq	SRR316552	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316552/SRR316552.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..1.fastq	SRR316553	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316553/SRR316553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.exon.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..1.fastq	SRR316553	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316553/SRR316553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.gene.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..1.fastq	SRR316553	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316553/SRR316553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.spljxn.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..1.fastq	SRR316553	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316553/SRR316553.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..2.fastq	SRR316554	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316554/SRR316554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.exon.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..2.fastq	SRR316554	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316554/SRR316554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.gene.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..2.fastq	SRR316554	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316554/SRR316554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.spljxn.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1556 HS1556 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1556-1..2.fastq	SRR316554	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316554/SRR316554.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1556 HS1556 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1556-1..3.fastq	SRR316555	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316555/SRR316555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.exon.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1556 HS1556 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1556-1..3.fastq	SRR316555	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316555/SRR316555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.gene.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1556 HS1556 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1556-1..3.fastq	SRR316555	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316555/SRR316555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1556_4_lanes.spljxn.quantification.txt	3
06-30145	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1556	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556	RNA	EFO	SRS405421	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1556 HS1556 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	257	HS1556	SRX085052	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1556 HS1556 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1556-1..3.fastq	SRR316555	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR316555/SRR316555.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390867	@dbgap@:reads/SRP020237/SRS405421/SRX085052/SRR390867/SRR390867.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1556_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..fastq	SRR316556	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316556/SRR316556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.exon.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..fastq	SRR316556	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316556/SRR316556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.gene.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..fastq	SRR316556	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316556/SRR316556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.spljxn.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..fastq	SRR316556	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316556/SRR316556.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..1.fastq	SRR316557	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316557/SRR316557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.exon.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..1.fastq	SRR316557	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316557/SRR316557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.gene.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..1.fastq	SRR316557	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316557/SRR316557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.spljxn.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..1.fastq	SRR316557	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316557/SRR316557.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..2.fastq	SRR316558	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316558/SRR316558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.exon.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..2.fastq	SRR316558	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316558/SRR316558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.gene.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..2.fastq	SRR316558	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316558/SRR316558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.spljxn.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1557 HS1557 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1557-1..2.fastq	SRR316558	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316558/SRR316558.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1557 HS1557 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1557-1..3.fastq	SRR316559	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316559/SRR316559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.exon.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1557 HS1557 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1557-1..3.fastq	SRR316559	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316559/SRR316559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.gene.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1557 HS1557 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1557-1..3.fastq	SRR316559	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316559/SRR316559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1557_4_lanes.spljxn.quantification.txt	3
02-13818	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1557	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557	RNA	EFO	SRS405422	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1557 HS1557 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS1557	SRX085053	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1557 HS1557 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1557-1..3.fastq	SRR316559	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR316559/SRR316559.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390868	@dbgap@:reads/SRP020237/SRS405422/SRX085053/SRR390868/SRR390868.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1557_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..fastq	SRR316560	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316560/SRR316560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.exon.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..fastq	SRR316560	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316560/SRR316560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.gene.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..fastq	SRR316560	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316560/SRR316560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.spljxn.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-10-27	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..fastq	SRR316560	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316560/SRR316560.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..1.fastq	SRR316561	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316561/SRR316561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.exon.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..1.fastq	SRR316561	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316561/SRR316561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.gene.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..1.fastq	SRR316561	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316561/SRR316561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.spljxn.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..1.fastq	SRR316561	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316561/SRR316561.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..2.fastq	SRR316562	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316562/SRR316562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.exon.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..2.fastq	SRR316562	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316562/SRR316562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.gene.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..2.fastq	SRR316562	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316562/SRR316562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.spljxn.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-16	HS1558 HS1558 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1558-1..2.fastq	SRR316562	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316562/SRR316562.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1558 HS1558 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1558-1..3.fastq	SRR316563	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316563/SRR316563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.exon.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1558 HS1558 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1558-1..3.fastq	SRR316563	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316563/SRR316563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.gene.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1558 HS1558 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1558-1..3.fastq	SRR316563	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316563/SRR316563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1558_4_lanes.spljxn.quantification.txt	3
01-25197	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1558	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558	RNA	EFO	SRS405423	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1558 HS1558 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	249	HS1558	SRX085054	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1558 HS1558 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1558-1..3.fastq	SRR316563	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR316563/SRR316563.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390869	@dbgap@:reads/SRP020237/SRS405423/SRX085054/SRR390869/SRR390869.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1558_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1559-1..fastq	SRR316564	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316564/SRR316564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.exon.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1559-1..fastq	SRR316564	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316564/SRR316564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.gene.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1559-1..fastq	SRR316564	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316564/SRR316564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.spljxn.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-11-02	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.3.2	HS1559-1..fastq	SRR316564	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316564/SRR316564.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..3.fastq	SRR316565	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316565/SRR316565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.exon.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..3.fastq	SRR316565	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316565/SRR316565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.gene.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..3.fastq	SRR316565	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316565/SRR316565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.spljxn.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..3.fastq	SRR316565	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316565/SRR316565.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..4.fastq	SRR316566	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316566/SRR316566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.exon.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..4.fastq	SRR316566	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316566/SRR316566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.gene.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..4.fastq	SRR316566	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316566/SRR316566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.spljxn.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2009-12-07	HS1559 HS1559 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1559-1..4.fastq	SRR316566	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316566/SRR316566.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1559 HS1559 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1559-1..5.fastq	SRR316567	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316567/SRR316567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.exon.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1559 HS1559 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1559-1..5.fastq	SRR316567	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316567/SRR316567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.gene.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1559 HS1559 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1559-1..5.fastq	SRR316567	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316567/SRR316567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1559_4_lanes.spljxn.quantification.txt	3
02-20170	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1559	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559	RNA	EFO	SRS405424	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1559 HS1559 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1559	SRX085055	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS1559 HS1559 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1559-1..5.fastq	SRR316567	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR316567/SRR316567.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390870	@dbgap@:reads/SRP020237/SRS405424/SRX085055/SRR390870/SRR390870.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1559_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..1.fastq	SRR316568	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316568/SRR316568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.exon.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..1.fastq	SRR316568	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316568/SRR316568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.gene.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..1.fastq	SRR316568	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316568/SRR316568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.spljxn.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..1.fastq	SRR316568	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316568/SRR316568.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..2.fastq	SRR316569	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316569/SRR316569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.exon.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..2.fastq	SRR316569	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316569/SRR316569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.gene.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..2.fastq	SRR316569	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316569/SRR316569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.spljxn.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..2.fastq	SRR316569	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316569/SRR316569.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..3.fastq	SRR316570	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316570/SRR316570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.exon.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..3.fastq	SRR316570	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316570/SRR316570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.gene.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..3.fastq	SRR316570	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316570/SRR316570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1974_3_lanes.spljxn.quantification.txt	3
97-14402	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1974	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974	RNA	EFO	SRS405425	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1974 HS1974 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	244	HS1974	SRX085056	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS1974 HS1974 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1974-1..3.fastq	SRR316570	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR316570/SRR316570.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390871	@dbgap@:reads/SRP020237/SRS405425/SRX085056/SRR390871/SRR390871.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1974_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..1.fastq	SRR316571	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316571/SRR316571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.exon.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..1.fastq	SRR316571	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316571/SRR316571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.gene.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..1.fastq	SRR316571	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316571/SRR316571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.spljxn.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..1.fastq	SRR316571	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316571/SRR316571.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..2.fastq	SRR316572	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316572/SRR316572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.exon.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..2.fastq	SRR316572	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316572/SRR316572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.gene.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..2.fastq	SRR316572	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316572/SRR316572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.spljxn.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..2.fastq	SRR316572	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316572/SRR316572.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..3.fastq	SRR316573	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316573/SRR316573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.exon.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..3.fastq	SRR316573	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316573/SRR316573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.gene.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..3.fastq	SRR316573	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316573/SRR316573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1975_3_lanes.spljxn.quantification.txt	3
06-16716	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1975	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975	RNA	EFO	SRS405426	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1975 HS1975 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	214	HS1975	SRX085057	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1975 HS1975 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1975-1..3.fastq	SRR316573	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR316573/SRR316573.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390872	@dbgap@:reads/SRP020237/SRS405426/SRX085057/SRR390872/SRR390872.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1975_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..1.fastq	SRR316574	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316574/SRR316574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.exon.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..1.fastq	SRR316574	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316574/SRR316574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.gene.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..1.fastq	SRR316574	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316574/SRR316574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.spljxn.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..1.fastq	SRR316574	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316574/SRR316574.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..2.fastq	SRR316575	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316575/SRR316575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.exon.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..2.fastq	SRR316575	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316575/SRR316575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.gene.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..2.fastq	SRR316575	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316575/SRR316575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.spljxn.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..2.fastq	SRR316575	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316575/SRR316575.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..3.fastq	SRR316576	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316576/SRR316576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.exon.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..3.fastq	SRR316576	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316576/SRR316576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.gene.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..3.fastq	SRR316576	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316576/SRR316576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1976_3_lanes.spljxn.quantification.txt	3
06-23057	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1976	organism part	EFO	Solid Tumor	NCIt	"PROSTATE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976	RNA	EFO	SRS405427	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1976 HS1976 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	239	HS1976	SRX085058	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1976 HS1976 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1976-1..3.fastq	SRR316576	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR316576/SRR316576.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390873	@dbgap@:reads/SRP020237/SRS405427/SRX085058/SRR390873/SRR390873.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1976_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..1.fastq	SRR316577	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316577/SRR316577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.exon.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..1.fastq	SRR316577	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316577/SRR316577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.gene.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..1.fastq	SRR316577	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316577/SRR316577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.spljxn.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..1.fastq	SRR316577	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316577/SRR316577.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..2.fastq	SRR316578	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316578/SRR316578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.exon.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..2.fastq	SRR316578	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316578/SRR316578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.gene.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..2.fastq	SRR316578	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316578/SRR316578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.spljxn.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..2.fastq	SRR316578	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316578/SRR316578.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..3.fastq	SRR316579	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316579/SRR316579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.exon.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..3.fastq	SRR316579	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316579/SRR316579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.gene.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..3.fastq	SRR316579	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316579/SRR316579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1977_3_lanes.spljxn.quantification.txt	3
02-24725	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1977	organism part	EFO	Solid Tumor	NCIt	"SMALL INTESTINE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977	RNA	EFO	SRS405428	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1977 HS1977 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS1977	SRX085059	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1977 HS1977 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1977-1..3.fastq	SRR316579	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR316579/SRR316579.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390874	@dbgap@:reads/SRP020237/SRS405428/SRX085059/SRR390874/SRR390874.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1977_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..1.fastq	SRR316580	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316580/SRR316580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.exon.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..1.fastq	SRR316580	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316580/SRR316580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.gene.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..1.fastq	SRR316580	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316580/SRR316580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.spljxn.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..1.fastq	SRR316580	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316580/SRR316580.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..2.fastq	SRR316581	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316581/SRR316581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.exon.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..2.fastq	SRR316581	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316581/SRR316581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.gene.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..2.fastq	SRR316581	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316581/SRR316581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.spljxn.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..2.fastq	SRR316581	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316581/SRR316581.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..3.fastq	SRR316582	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316582/SRR316582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.exon.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..3.fastq	SRR316582	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316582/SRR316582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.gene.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..3.fastq	SRR316582	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316582/SRR316582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1978_3_lanes.spljxn.quantification.txt	3
09-12737	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1978	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978	RNA	EFO	SRS405429	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1978 HS1978 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS1978	SRX085060	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS1978 HS1978 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1978-1..3.fastq	SRR316582	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR316582/SRR316582.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390875	@dbgap@:reads/SRP020237/SRS405429/SRX085060/SRR390875/SRR390875.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1978_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1979 HS1979 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1979-1..fastq	SRR316583	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316583/SRR316583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.exon.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1979 HS1979 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1979-1..fastq	SRR316583	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316583/SRR316583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.gene.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1979 HS1979 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1979-1..fastq	SRR316583	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316583/SRR316583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.spljxn.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1979 HS1979 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1979-1..fastq	SRR316583	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316583/SRR316583.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1979_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..1.fastq	SRR316584	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316584/SRR316584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.exon.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..1.fastq	SRR316584	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316584/SRR316584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.gene.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..1.fastq	SRR316584	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316584/SRR316584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.spljxn.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..1.fastq	SRR316584	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316584/SRR316584.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1979_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..2.fastq	SRR316585	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316585/SRR316585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.exon.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..2.fastq	SRR316585	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316585/SRR316585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.gene.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..2.fastq	SRR316585	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316585/SRR316585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.spljxn.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..2.fastq	SRR316585	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316585/SRR316585.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1979_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..3.fastq	SRR316586	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316586/SRR316586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.exon.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..3.fastq	SRR316586	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316586/SRR316586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.gene.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..3.fastq	SRR316586	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316586/SRR316586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1979_4_lanes.spljxn.quantification.txt	3
01-12047	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1979	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979	RNA	EFO	SRS405430	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1979 HS1979 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	247	HS1979	SRX085061	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-18	HS1979 HS1979 run	sequencing assay	EFO	159	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1979-1..3.fastq	SRR316586	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR316586/SRR316586.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1979_4_lanes_dupsFlagged.bam	SRR390876	@dbgap@:reads/SRP020237/SRS405430/SRX085061/SRR390876/SRR390876.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1979_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1980-1..fastq	SRR316587	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316587/SRR316587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.exon.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1980-1..fastq	SRR316587	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316587/SRR316587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.gene.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1980-1..fastq	SRR316587	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316587/SRR316587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.spljxn.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1980-1..fastq	SRR316587	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316587/SRR316587.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..1.fastq	SRR316588	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316588/SRR316588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.exon.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..1.fastq	SRR316588	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316588/SRR316588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.gene.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..1.fastq	SRR316588	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316588/SRR316588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.spljxn.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..1.fastq	SRR316588	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316588/SRR316588.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..2.fastq	SRR316589	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316589/SRR316589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.exon.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..2.fastq	SRR316589	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316589/SRR316589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.gene.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..2.fastq	SRR316589	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316589/SRR316589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.spljxn.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..2.fastq	SRR316589	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316589/SRR316589.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..3.fastq	SRR316590	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316590/SRR316590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.exon.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..3.fastq	SRR316590	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316590/SRR316590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.gene.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..3.fastq	SRR316590	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316590/SRR316590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1980_4_lanes.spljxn.quantification.txt	3
01-21689	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1980	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980	RNA	EFO	SRS405431	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1980 HS1980 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	228	HS1980	SRX085062	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1980 HS1980 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1980-1..3.fastq	SRR316590	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR316590/SRR316590.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390877	@dbgap@:reads/SRP020237/SRS405431/SRX085062/SRR390877/SRR390877.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1980_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1981-1..fastq	SRR316591	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316591/SRR316591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.exon.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1981-1..fastq	SRR316591	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316591/SRR316591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.gene.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1981-1..fastq	SRR316591	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316591/SRR316591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.spljxn.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1981-1..fastq	SRR316591	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316591/SRR316591.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..1.fastq	SRR316592	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316592/SRR316592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.exon.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..1.fastq	SRR316592	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316592/SRR316592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.gene.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..1.fastq	SRR316592	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316592/SRR316592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.spljxn.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..1.fastq	SRR316592	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316592/SRR316592.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..2.fastq	SRR316593	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316593/SRR316593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.exon.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..2.fastq	SRR316593	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316593/SRR316593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.gene.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..2.fastq	SRR316593	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316593/SRR316593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.spljxn.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..2.fastq	SRR316593	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316593/SRR316593.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..3.fastq	SRR316594	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316594/SRR316594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.exon.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..3.fastq	SRR316594	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316594/SRR316594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.gene.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..3.fastq	SRR316594	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316594/SRR316594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1981_4_lanes.spljxn.quantification.txt	3
08-15393	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1981	organism part	EFO	Solid Tumor	NCIt	"BONE MARROW"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981	RNA	EFO	SRS405432	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1981 HS1981 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	259	HS1981	SRX085063	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS1981 HS1981 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1981-1..3.fastq	SRR316594	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR316594/SRR316594.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390878	@dbgap@:reads/SRP020237/SRS405432/SRX085063/SRR390878/SRR390878.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1981_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1982-1..fastq	SRR316595	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316595/SRR316595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.exon.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1982-1..fastq	SRR316595	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316595/SRR316595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.gene.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1982-1..fastq	SRR316595	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316595/SRR316595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.spljxn.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1982-1..fastq	SRR316595	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316595/SRR316595.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..1.fastq	SRR316596	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316596/SRR316596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.exon.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..1.fastq	SRR316596	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316596/SRR316596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.gene.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..1.fastq	SRR316596	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316596/SRR316596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.spljxn.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..1.fastq	SRR316596	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316596/SRR316596.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..2.fastq	SRR316597	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316597/SRR316597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.exon.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..2.fastq	SRR316597	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316597/SRR316597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.gene.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..2.fastq	SRR316597	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316597/SRR316597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.spljxn.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..2.fastq	SRR316597	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316597/SRR316597.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..3.fastq	SRR316598	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316598/SRR316598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.exon.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..3.fastq	SRR316598	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316598/SRR316598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.gene.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..3.fastq	SRR316598	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316598/SRR316598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1982_4_lanes.spljxn.quantification.txt	3
08-15577	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1982	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982	RNA	EFO	SRS405433	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1982 HS1982 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS1982	SRX085064	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS1982 HS1982 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS1982-1..3.fastq	SRR316598	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR316598/SRR316598.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390879	@dbgap@:reads/SRP020237/SRS405433/SRX085064/SRR390879/SRR390879.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1982_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1983-1..fastq	SRR316599	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316599/SRR316599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.exon.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1983-1..fastq	SRR316599	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316599/SRR316599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.gene.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1983-1..fastq	SRR316599	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316599/SRR316599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.spljxn.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1983-1..fastq	SRR316599	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316599/SRR316599.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..1.fastq	SRR316600	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316600/SRR316600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.exon.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..1.fastq	SRR316600	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316600/SRR316600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.gene.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..1.fastq	SRR316600	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316600/SRR316600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.spljxn.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..1.fastq	SRR316600	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316600/SRR316600.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..2.fastq	SRR316601	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316601/SRR316601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.exon.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..2.fastq	SRR316601	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316601/SRR316601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.gene.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..2.fastq	SRR316601	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316601/SRR316601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.spljxn.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..2.fastq	SRR316601	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316601/SRR316601.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..3.fastq	SRR316602	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316602/SRR316602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.exon.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..3.fastq	SRR316602	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316602/SRR316602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.gene.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..3.fastq	SRR316602	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316602/SRR316602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1983_4_lanes.spljxn.quantification.txt	3
03-26817	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1983	organism part	EFO	Solid Tumor	NCIt	"SKIN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983	RNA	EFO	SRS405434	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1983 HS1983 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	262	HS1983	SRX085065	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1983 HS1983 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1983-1..3.fastq	SRR316602	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR316602/SRR316602.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390880	@dbgap@:reads/SRP020237/SRS405434/SRX085065/SRR390880/SRR390880.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1983_4_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1984-1..fastq	SRR316603	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316603/SRR316603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.exon.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1984-1..fastq	SRR316603	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316603/SRR316603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.gene.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1984-1..fastq	SRR316603	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316603/SRR316603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.spljxn.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-02-17	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.5.35.0	HS1984-1..fastq	SRR316603	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316603/SRR316603.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1984_4_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..1.fastq	SRR316604	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316604/SRR316604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.exon.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..1.fastq	SRR316604	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316604/SRR316604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.gene.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..1.fastq	SRR316604	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316604/SRR316604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.spljxn.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..1.fastq	SRR316604	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316604/SRR316604.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1984_4_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..2.fastq	SRR316605	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316605/SRR316605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.exon.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..2.fastq	SRR316605	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316605/SRR316605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.gene.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..2.fastq	SRR316605	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316605/SRR316605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.spljxn.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..2.fastq	SRR316605	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316605/SRR316605.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1984_4_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..3.fastq	SRR316606	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316606/SRR316606.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.exon.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..3.fastq	SRR316606	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316606/SRR316606.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.gene.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..3.fastq	SRR316606	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316606/SRR316606.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS1984_4_lanes.spljxn.quantification.txt	3
85-63855	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS1984	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984	RNA	EFO	SRS405435	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS1984 HS1984 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	224	HS1984	SRX085066	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-15	HS1984 HS1984 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS1984-1..3.fastq	SRR316606	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR316606/SRR316606.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS1984_4_lanes_dupsFlagged.bam	SRR390881	@dbgap@:reads/SRP020237/SRS405435/SRX085066/SRR390881/SRR390881.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS1984_4_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS2047	organism part	EFO		NCIt	"cerebrospinal fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047	RNA	EFO	SRS212589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047 HS2047 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS2047	SRX079574	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-29	HS2047 HS2047 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0;Illumina RTA 1.6.0	HS20471..fastq	SRR292249	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR292249/SRR292249.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	70093AAXX_8_withJunctionsOnGenome_dupsFlagged.bam	SRR390726	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR390726/SRR390726.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2047_1_lanes.exon.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS2047	organism part	EFO		NCIt	"cerebrospinal fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047	RNA	EFO	SRS212589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047 HS2047 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS2047	SRX079574	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-29	HS2047 HS2047 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0;Illumina RTA 1.6.0	HS20471..fastq	SRR292249	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR292249/SRR292249.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	70093AAXX_8_withJunctionsOnGenome_dupsFlagged.bam	SRR390726	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR390726/SRR390726.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2047_1_lanes.gene.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS2047	organism part	EFO		NCIt	"cerebrospinal fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047	RNA	EFO	SRS212589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047 HS2047 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS2047	SRX079574	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-29	HS2047 HS2047 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0;Illumina RTA 1.6.0	HS20471..fastq	SRR292249	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR292249/SRR292249.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	70093AAXX_8_withJunctionsOnGenome_dupsFlagged.bam	SRR390726	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR390726/SRR390726.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2047_1_lanes.spljxn.quantification.txt	3
	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt		NCIt	HS2047	organism part	EFO		NCIt	"cerebrospinal fluid"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047	RNA	EFO	SRS212589	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2047 HS2047 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS2047	SRX079574	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-03-29	HS2047 HS2047 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0;Illumina RTA 1.6.0	HS20471..fastq	SRR292249	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR292249/SRR292249.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	70093AAXX_8_withJunctionsOnGenome_dupsFlagged.bam	SRR390726	@dbgap@:reads/SRP020237/SRS212589/SRX079574/SRR390726/SRR390726.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2047_8_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2048-1..fastq	SRR316607	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316607/SRR316607.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.exon.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2048-1..fastq	SRR316607	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316607/SRR316607.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.gene.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2048-1..fastq	SRR316607	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316607/SRR316607.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.spljxn.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2048-1..fastq	SRR316607	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316607/SRR316607.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2048_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..1.fastq	SRR316608	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316608/SRR316608.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.exon.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..1.fastq	SRR316608	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316608/SRR316608.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.gene.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..1.fastq	SRR316608	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316608/SRR316608.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.spljxn.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..1.fastq	SRR316608	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316608/SRR316608.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2048_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..2.fastq	SRR316609	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316609/SRR316609.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.exon.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..2.fastq	SRR316609	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316609/SRR316609.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.gene.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..2.fastq	SRR316609	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316609/SRR316609.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2048_3_lanes.spljxn.quantification.txt	3
05-12939	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2048	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048	RNA	EFO	SRS405436	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2048 HS2048 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	223	HS2048	SRX085067	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2048 HS2048 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2048-1..2.fastq	SRR316609	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR316609/SRR316609.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2048_3_lanes_dupsFlagged.bam	SRR390882	@dbgap@:reads/SRP020237/SRS405436/SRX085067/SRR390882/SRR390882.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2048_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2049-1..fastq	SRR316610	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316610/SRR316610.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.exon.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2049-1..fastq	SRR316610	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316610/SRR316610.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.gene.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2049-1..fastq	SRR316610	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316610/SRR316610.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.spljxn.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-16	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.32.0	HS2049-1..fastq	SRR316610	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316610/SRR316610.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2049_3_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..1.fastq	SRR316611	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316611/SRR316611.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.exon.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..1.fastq	SRR316611	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316611/SRR316611.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.gene.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..1.fastq	SRR316611	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316611/SRR316611.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.spljxn.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..1.fastq	SRR316611	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316611/SRR316611.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2049_3_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..2.fastq	SRR316612	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316612/SRR316612.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.exon.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..2.fastq	SRR316612	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316612/SRR316612.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.gene.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..2.fastq	SRR316612	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316612/SRR316612.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2049_3_lanes.spljxn.quantification.txt	3
07-32561	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2049	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049	RNA	EFO	SRS405437	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2049 HS2049 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS2049	SRX085068	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2049 HS2049 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2049-1..2.fastq	SRR316612	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR316612/SRR316612.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2049_3_lanes_dupsFlagged.bam	SRR390883	@dbgap@:reads/SRP020237/SRS405437/SRX085068/SRR390883/SRR390883.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2049_3_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-26	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..fastq	SRR316613	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316613/SRR316613.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.exon.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-26	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..fastq	SRR316613	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316613/SRR316613.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.gene.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-26	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..fastq	SRR316613	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316613/SRR316613.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.spljxn.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-26	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..fastq	SRR316613	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316613/SRR316613.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..1.fastq	SRR316614	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316614/SRR316614.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.exon.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..1.fastq	SRR316614	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316614/SRR316614.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.gene.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..1.fastq	SRR316614	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316614/SRR316614.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.spljxn.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..1.fastq	SRR316614	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316614/SRR316614.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..2.fastq	SRR316615	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316615/SRR316615.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.exon.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..2.fastq	SRR316615	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316615/SRR316615.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.gene.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..2.fastq	SRR316615	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316615/SRR316615.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2050_3_lanes.spljxn.quantification.txt	3
99-27137	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2050	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050	RNA	EFO	SRS405438	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2050 HS2050 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	201	HS2050	SRX085069	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2050 HS2050 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2050-1..2.fastq	SRR316615	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR316615/SRR316615.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390884	@dbgap@:reads/SRP020237/SRS405438/SRX085069/SRR390884/SRR390884.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2050_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..fastq	SRR316616	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316616/SRR316616.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.exon.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..fastq	SRR316616	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316616/SRR316616.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.gene.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..fastq	SRR316616	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316616/SRR316616.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.spljxn.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..fastq	SRR316616	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316616/SRR316616.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..1.fastq	SRR316617	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316617/SRR316617.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.exon.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..1.fastq	SRR316617	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316617/SRR316617.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.gene.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..1.fastq	SRR316617	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316617/SRR316617.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.spljxn.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..1.fastq	SRR316617	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316617/SRR316617.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..2.fastq	SRR316618	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316618/SRR316618.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.exon.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..2.fastq	SRR316618	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316618/SRR316618.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.gene.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..2.fastq	SRR316618	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316618/SRR316618.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2051_3_lanes.spljxn.quantification.txt	3
09-33003	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2051	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051	RNA	EFO	SRS405439	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2051 HS2051 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	182	HS2051	SRX085070	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2051 HS2051 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2051-1..2.fastq	SRR316618	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR316618/SRR316618.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390885	@dbgap@:reads/SRP020237/SRS405439/SRX085070/SRR390885/SRR390885.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2051_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..fastq	SRR316619	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316619/SRR316619.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.exon.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..fastq	SRR316619	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316619/SRR316619.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.gene.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..fastq	SRR316619	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316619/SRR316619.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.spljxn.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..fastq	SRR316619	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316619/SRR316619.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..1.fastq	SRR316620	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316620/SRR316620.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.exon.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..1.fastq	SRR316620	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316620/SRR316620.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.gene.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..1.fastq	SRR316620	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316620/SRR316620.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.spljxn.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..1.fastq	SRR316620	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316620/SRR316620.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..2.fastq	SRR316621	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316621/SRR316621.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.exon.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..2.fastq	SRR316621	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316621/SRR316621.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.gene.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..2.fastq	SRR316621	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316621/SRR316621.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2053_3_lanes.spljxn.quantification.txt	3
82-57570	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2053	organism part	EFO	Solid Tumor	NCIt	"STOMACH"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053	RNA	EFO	SRS405440	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2053 HS2053 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	205	HS2053	SRX085071	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2053 HS2053 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2053-1..2.fastq	SRR316621	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR316621/SRR316621.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390886	@dbgap@:reads/SRP020237/SRS405440/SRX085071/SRR390886/SRR390886.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2053_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..fastq	SRR316622	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316622/SRR316622.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.exon.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..fastq	SRR316622	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316622/SRR316622.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.gene.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..fastq	SRR316622	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316622/SRR316622.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.spljxn.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..fastq	SRR316622	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316622/SRR316622.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2054_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..1.fastq	SRR316623	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316623/SRR316623.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.exon.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..1.fastq	SRR316623	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316623/SRR316623.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.gene.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..1.fastq	SRR316623	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316623/SRR316623.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.spljxn.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-28	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..1.fastq	SRR316623	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316623/SRR316623.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2054_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-14	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..3.fastq	SRR316624	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316624/SRR316624.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.exon.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-14	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..3.fastq	SRR316624	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316624/SRR316624.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.gene.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-14	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..3.fastq	SRR316624	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316624/SRR316624.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2054_3_lanes.spljxn.quantification.txt	3
05-12224	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2054	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054	RNA	EFO	SRS405441	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2054 HS2054 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2054	SRX085072	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-14	HS2054 HS2054 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2054-1..3.fastq	SRR316624	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR316624/SRR316624.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2054_3_lanes_dupsFlagged.bam	SRR390887	@dbgap@:reads/SRP020237/SRS405441/SRX085072/SRR390887/SRR390887.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2054_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..fastq	SRR316625	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316625/SRR316625.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.exon.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..fastq	SRR316625	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316625/SRR316625.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.gene.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..fastq	SRR316625	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316625/SRR316625.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.spljxn.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..fastq	SRR316625	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316625/SRR316625.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..1.fastq	SRR316626	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316626/SRR316626.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.exon.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..1.fastq	SRR316626	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316626/SRR316626.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.gene.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..1.fastq	SRR316626	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316626/SRR316626.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.spljxn.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..1.fastq	SRR316626	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316626/SRR316626.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..2.fastq	SRR316627	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316627/SRR316627.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.exon.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..2.fastq	SRR316627	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316627/SRR316627.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.gene.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..2.fastq	SRR316627	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316627/SRR316627.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2055_3_lanes.spljxn.quantification.txt	3
07-30109	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2055	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055	RNA	EFO	SRS405442	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2055 HS2055 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2055	SRX085073	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2055 HS2055 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2055-1..2.fastq	SRR316627	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR316627/SRR316627.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390888	@dbgap@:reads/SRP020237/SRS405442/SRX085073/SRR390888/SRR390888.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2055_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..fastq	SRR316628	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316628/SRR316628.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.exon.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..fastq	SRR316628	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316628/SRR316628.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.gene.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..fastq	SRR316628	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316628/SRR316628.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.spljxn.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..fastq	SRR316628	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316628/SRR316628.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..1.fastq	SRR316629	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316629/SRR316629.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.exon.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..1.fastq	SRR316629	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316629/SRR316629.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.gene.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..1.fastq	SRR316629	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316629/SRR316629.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.spljxn.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..1.fastq	SRR316629	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316629/SRR316629.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..2.fastq	SRR316630	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316630/SRR316630.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.exon.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..2.fastq	SRR316630	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316630/SRR316630.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.gene.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..2.fastq	SRR316630	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316630/SRR316630.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2056_3_lanes.spljxn.quantification.txt	3
SPEC-1120	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2056	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056	RNA	EFO	SRS405443	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2056 HS2056 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2056	SRX085074	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2056 HS2056 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2056-1..2.fastq	SRR316630	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR316630/SRR316630.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390889	@dbgap@:reads/SRP020237/SRS405443/SRX085074/SRR390889/SRR390889.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2056_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..fastq	SRR316631	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316631/SRR316631.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.exon.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..fastq	SRR316631	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316631/SRR316631.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.gene.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..fastq	SRR316631	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316631/SRR316631.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.spljxn.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-03	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..fastq	SRR316631	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316631/SRR316631.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..1.fastq	SRR316632	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316632/SRR316632.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.exon.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..1.fastq	SRR316632	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316632/SRR316632.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.gene.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..1.fastq	SRR316632	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316632/SRR316632.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.spljxn.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..1.fastq	SRR316632	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316632/SRR316632.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..2.fastq	SRR316633	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316633/SRR316633.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.exon.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..2.fastq	SRR316633	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316633/SRR316633.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.gene.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..2.fastq	SRR316633	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316633/SRR316633.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2058_3_lanes.spljxn.quantification.txt	3
SPEC-1185	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2058	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058	RNA	EFO	SRS405444	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2058 HS2058 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2058	SRX085075	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-21	HS2058 HS2058 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2058-1..2.fastq	SRR316633	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR316633/SRR316633.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390890	@dbgap@:reads/SRP020237/SRS405444/SRX085075/SRR390890/SRR390890.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2058_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..fastq	SRR316634	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316634/SRR316634.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.exon.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..fastq	SRR316634	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316634/SRR316634.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.gene.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..fastq	SRR316634	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316634/SRR316634.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.spljxn.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-04-23	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..fastq	SRR316634	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316634/SRR316634.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..1.fastq	SRR316635	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316635/SRR316635.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.exon.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..1.fastq	SRR316635	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316635/SRR316635.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.gene.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..1.fastq	SRR316635	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316635/SRR316635.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.spljxn.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..1.fastq	SRR316635	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316635/SRR316635.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..2.fastq	SRR316636	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316636/SRR316636.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.exon.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..2.fastq	SRR316636	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316636/SRR316636.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.gene.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..2.fastq	SRR316636	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316636/SRR316636.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2059_3_lanes.spljxn.quantification.txt	3
SPEC-1187	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2059	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059	RNA	EFO	SRS405445	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2059 HS2059 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	225	HS2059	SRX085076	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-20	HS2059 HS2059 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2059-1..2.fastq	SRR316636	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR316636/SRR316636.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390891	@dbgap@:reads/SRP020237/SRS405445/SRX085076/SRR390891/SRR390891.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2059_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..2.fastq	SRR316637	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316637/SRR316637.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.exon.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..2.fastq	SRR316637	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316637/SRR316637.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.gene.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..2.fastq	SRR316637	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316637/SRR316637.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.spljxn.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-18	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..2.fastq	SRR316637	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316637/SRR316637.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..3.fastq	SRR316638	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316638/SRR316638.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.exon.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..3.fastq	SRR316638	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316638/SRR316638.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.gene.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..3.fastq	SRR316638	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316638/SRR316638.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.spljxn.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..3.fastq	SRR316638	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316638/SRR316638.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..4.fastq	SRR316639	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316639/SRR316639.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.exon.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..4.fastq	SRR316639	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316639/SRR316639.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.gene.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..4.fastq	SRR316639	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316639/SRR316639.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2060_3_lanes.spljxn.quantification.txt	3
SPEC-1203	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2060	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060	RNA	EFO	SRS405446	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2060 HS2060 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	237	HS2060	SRX085077	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2060 HS2060 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2060-1..4.fastq	SRR316639	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR316639/SRR316639.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390892	@dbgap@:reads/SRP020237/SRS405446/SRX085077/SRR390892/SRR390892.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2060_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..1.fastq	SRR316640	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316640/SRR316640.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.exon.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..1.fastq	SRR316640	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316640/SRR316640.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.gene.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..1.fastq	SRR316640	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316640/SRR316640.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.spljxn.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..1.fastq	SRR316640	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316640/SRR316640.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2248_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..2.fastq	SRR316641	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316641/SRR316641.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.exon.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..2.fastq	SRR316641	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316641/SRR316641.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.gene.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..2.fastq	SRR316641	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316641/SRR316641.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.spljxn.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..2.fastq	SRR316641	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316641/SRR316641.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2248_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..3.fastq	SRR316642	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316642/SRR316642.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.exon.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..3.fastq	SRR316642	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316642/SRR316642.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.gene.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..3.fastq	SRR316642	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316642/SRR316642.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2248_3_lanes.spljxn.quantification.txt	3
09-41082	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2248	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248	RNA	EFO	SRS405447	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2248 HS2248 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	219	HS2248	SRX085078	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-22	HS2248 HS2248 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2248-1..3.fastq	SRR316642	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR316642/SRR316642.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2248_3_lanes_dupsFlagged.bam	SRR390893	@dbgap@:reads/SRP020237/SRS405447/SRX085078/SRR390893/SRR390893.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2248_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..fastq	SRR316643	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316643/SRR316643.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.exon.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..fastq	SRR316643	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316643/SRR316643.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.gene.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..fastq	SRR316643	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316643/SRR316643.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.spljxn.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..fastq	SRR316643	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316643/SRR316643.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..1.fastq	SRR316644	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316644/SRR316644.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.exon.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..1.fastq	SRR316644	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316644/SRR316644.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.gene.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..1.fastq	SRR316644	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316644/SRR316644.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.spljxn.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..1.fastq	SRR316644	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316644/SRR316644.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..2.fastq	SRR316645	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316645/SRR316645.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.exon.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..2.fastq	SRR316645	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316645/SRR316645.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.gene.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..2.fastq	SRR316645	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316645/SRR316645.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2249_3_lanes.spljxn.quantification.txt	3
00-15694	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2249	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249	RNA	EFO	SRS405448	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2249 HS2249 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2249	SRX085079	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2249 HS2249 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2249-1..2.fastq	SRR316645	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR316645/SRR316645.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390894	@dbgap@:reads/SRP020237/SRS405448/SRX085079/SRR390894/SRR390894.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2249_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..fastq	SRR316646	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316646/SRR316646.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.exon.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..fastq	SRR316646	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316646/SRR316646.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.gene.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..fastq	SRR316646	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316646/SRR316646.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.spljxn.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..fastq	SRR316646	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316646/SRR316646.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..1.fastq	SRR316647	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316647/SRR316647.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.exon.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..1.fastq	SRR316647	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316647/SRR316647.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.gene.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..1.fastq	SRR316647	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316647/SRR316647.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.spljxn.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..1.fastq	SRR316647	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316647/SRR316647.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..2.fastq	SRR316648	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316648/SRR316648.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.exon.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..2.fastq	SRR316648	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316648/SRR316648.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.gene.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..2.fastq	SRR316648	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316648/SRR316648.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2250_3_lanes.spljxn.quantification.txt	3
07-25012	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2250	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250	RNA	EFO	SRS405449	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2250 HS2250 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	246	HS2250	SRX085080	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-07	HS2250 HS2250 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2250-1..2.fastq	SRR316648	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR316648/SRR316648.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390895	@dbgap@:reads/SRP020237/SRS405449/SRX085080/SRR390895/SRR390895.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2250_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..fastq	SRR316649	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316649/SRR316649.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.exon.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..fastq	SRR316649	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316649/SRR316649.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.gene.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..fastq	SRR316649	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316649/SRR316649.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.spljxn.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-05-10	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..fastq	SRR316649	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316649/SRR316649.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..1.fastq	SRR316650	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316650/SRR316650.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.exon.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..1.fastq	SRR316650	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316650/SRR316650.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.gene.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..1.fastq	SRR316650	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316650/SRR316650.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.spljxn.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..1.fastq	SRR316650	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316650/SRR316650.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..2.fastq	SRR316651	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316651/SRR316651.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.exon.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..2.fastq	SRR316651	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316651/SRR316651.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.gene.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..2.fastq	SRR316651	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316651/SRR316651.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2251_3_lanes.spljxn.quantification.txt	3
06-33777	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2251	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251	RNA	EFO	SRS405450	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2251 HS2251 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	218	HS2251	SRX085081	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2251 HS2251 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2251-1..2.fastq	SRR316651	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR316651/SRR316651.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam	SRR390896	@dbgap@:reads/SRP020237/SRS405450/SRX085081/SRR390896/SRR390896.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2251_3_lanes_withJunctionsOnGenome_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..1.fastq	SRR316652	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316652/SRR316652.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.exon.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..1.fastq	SRR316652	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316652/SRR316652.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.gene.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..1.fastq	SRR316652	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316652/SRR316652.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.spljxn.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-01	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..1.fastq	SRR316652	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316652/SRR316652.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2252_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..2.fastq	SRR316653	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316653/SRR316653.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.exon.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..2.fastq	SRR316653	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316653/SRR316653.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.gene.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..2.fastq	SRR316653	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316653/SRR316653.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.spljxn.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..2.fastq	SRR316653	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316653/SRR316653.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2252_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..3.fastq	SRR316654	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316654/SRR316654.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.exon.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..3.fastq	SRR316654	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316654/SRR316654.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.gene.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..3.fastq	SRR316654	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316654/SRR316654.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2252_3_lanes.spljxn.quantification.txt	3
08-25894	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2252	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252	RNA	EFO	SRS405451	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2252 HS2252 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	226	HS2252	SRX085082	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-06-26	HS2252 HS2252 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2252-1..3.fastq	SRR316654	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR316654/SRR316654.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2252_3_lanes_dupsFlagged.bam	SRR390897	@dbgap@:reads/SRP020237/SRS405451/SRX085082/SRR390897/SRR390897.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2252_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..fastq	SRR316655	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316655/SRR316655.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2604_2_lanes.exon.quantification.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..fastq	SRR316655	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316655/SRR316655.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2604_2_lanes.gene.quantification.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..fastq	SRR316655	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316655/SRR316655.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2604_2_lanes.spljxn.quantification.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..fastq	SRR316655	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316655/SRR316655.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2604_2_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..1.fastq	SRR316656	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316656/SRR316656.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2604_2_lanes.exon.quantification.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..1.fastq	SRR316656	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316656/SRR316656.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2604_2_lanes.gene.quantification.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..1.fastq	SRR316656	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316656/SRR316656.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2604_2_lanes.spljxn.quantification.txt	3
05-15797	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2604	organism part	EFO	Solid Tumor	NCIt	"SPLEEN"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604	RNA	EFO	SRS405452	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2604 HS2604 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	280	HS2604	SRX085083	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2604 HS2604 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2604-1..1.fastq	SRR316656	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR316656/SRR316656.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2604_2_lanes_dupsFlagged.bam	SRR390898	@dbgap@:reads/SRP020237/SRS405452/SRX085083/SRR390898/SRR390898.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2604_2_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..fastq	SRR316657	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316657/SRR316657.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.exon.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..fastq	SRR316657	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316657/SRR316657.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.gene.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..fastq	SRR316657	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316657/SRR316657.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.spljxn.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-15	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..fastq	SRR316657	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316657/SRR316657.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2605_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..1.fastq	SRR316658	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316658/SRR316658.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.exon.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..1.fastq	SRR316658	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316658/SRR316658.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.gene.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..1.fastq	SRR316658	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316658/SRR316658.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.spljxn.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-07	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..1.fastq	SRR316658	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316658/SRR316658.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2605_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..2.fastq	SRR316659	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316659/SRR316659.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.exon.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..2.fastq	SRR316659	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316659/SRR316659.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.gene.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..2.fastq	SRR316659	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316659/SRR316659.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2605_3_lanes.spljxn.quantification.txt	3
06-15256	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2605	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605	RNA	EFO	SRS405453	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2605 HS2605 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2605	SRX085084	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2605 HS2605 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2605-1..2.fastq	SRR316659	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR316659/SRR316659.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2605_3_lanes_dupsFlagged.bam	SRR390899	@dbgap@:reads/SRP020237/SRS405453/SRX085084/SRR390899/SRR390899.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2605_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..fastq	SRR316660	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316660/SRR316660.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.exon.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..fastq	SRR316660	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316660/SRR316660.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.gene.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..fastq	SRR316660	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316660/SRR316660.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.spljxn.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..fastq	SRR316660	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316660/SRR316660.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2606_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..1.fastq	SRR316661	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316661/SRR316661.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.exon.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..1.fastq	SRR316661	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316661/SRR316661.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.gene.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..1.fastq	SRR316661	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316661/SRR316661.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.spljxn.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..1.fastq	SRR316661	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316661/SRR316661.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2606_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..2.fastq	SRR316662	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316662/SRR316662.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.exon.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..2.fastq	SRR316662	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316662/SRR316662.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.gene.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..2.fastq	SRR316662	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316662/SRR316662.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2606_3_lanes.spljxn.quantification.txt	3
08-11596	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2606	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606	RNA	EFO	SRS405454	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2606 HS2606 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2606	SRX085085	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2606 HS2606 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2606-1..2.fastq	SRR316662	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR316662/SRR316662.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2606_3_lanes_dupsFlagged.bam	SRR390900	@dbgap@:reads/SRP020237/SRS405454/SRX085085/SRR390900/SRR390900.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2606_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..fastq	SRR316663	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316663/SRR316663.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.exon.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..fastq	SRR316663	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316663/SRR316663.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.gene.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..fastq	SRR316663	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316663/SRR316663.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.spljxn.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-07-13	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..fastq	SRR316663	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316663/SRR316663.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2607_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..1.fastq	SRR316664	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316664/SRR316664.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.exon.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..1.fastq	SRR316664	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316664/SRR316664.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.gene.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..1.fastq	SRR316664	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316664/SRR316664.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.spljxn.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-08-05	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..1.fastq	SRR316664	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316664/SRR316664.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2607_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..2.fastq	SRR316665	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316665/SRR316665.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.exon.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..2.fastq	SRR316665	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316665/SRR316665.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.gene.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..2.fastq	SRR316665	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316665/SRR316665.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2607_3_lanes.spljxn.quantification.txt	3
06-25674	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2607	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607	RNA	EFO	SRS405455	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2607 HS2607 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	250	HS2607	SRX085086	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-09-09	HS2607 HS2607 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.6.47.1	HS2607-1..2.fastq	SRR316665	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR316665/SRR316665.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2607_3_lanes_dupsFlagged.bam	SRR390901	@dbgap@:reads/SRP020237/SRS405455/SRX085086/SRR390901/SRR390901.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2607_3_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2937-1..fastq	SRR316666	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316666/SRR316666.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2937_2_lanes.exon.quantification.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2937-1..fastq	SRR316666	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316666/SRR316666.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2937_2_lanes.gene.quantification.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2937-1..fastq	SRR316666	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316666/SRR316666.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2937_2_lanes.spljxn.quantification.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2937-1..fastq	SRR316666	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316666/SRR316666.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2937_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2937-1..1.fastq	SRR316667	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316667/SRR316667.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2937_2_lanes.exon.quantification.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2937-1..1.fastq	SRR316667	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316667/SRR316667.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2937_2_lanes.gene.quantification.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2937-1..1.fastq	SRR316667	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316667/SRR316667.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2937_2_lanes.spljxn.quantification.txt	3
06-34043	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2937	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937	RNA	EFO	SRS405456	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2937 HS2937 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2937	SRX085087	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2937 HS2937 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2937-1..1.fastq	SRR316667	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR316667/SRR316667.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2937_2_lanes_dupsFlagged.bam	SRR390902	@dbgap@:reads/SRP020237/SRS405456/SRX085087/SRR390902/SRR390902.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2937_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2938-1..fastq	SRR316668	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316668/SRR316668.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2938_2_lanes.exon.quantification.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2938-1..fastq	SRR316668	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316668/SRR316668.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2938_2_lanes.gene.quantification.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2938-1..fastq	SRR316668	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316668/SRR316668.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2938_2_lanes.spljxn.quantification.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2938-1..fastq	SRR316668	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316668/SRR316668.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2938_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2938-1..1.fastq	SRR316669	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316669/SRR316669.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2938_2_lanes.exon.quantification.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2938-1..1.fastq	SRR316669	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316669/SRR316669.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2938_2_lanes.gene.quantification.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2938-1..1.fastq	SRR316669	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316669/SRR316669.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2938_2_lanes.spljxn.quantification.txt	3
04-20644	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2938	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938	RNA	EFO	SRS405457	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2938 HS2938 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	260	HS2938	SRX085088	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2938 HS2938 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2938-1..1.fastq	SRR316669	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR316669/SRR316669.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2938_2_lanes_dupsFlagged.bam	SRR390903	@dbgap@:reads/SRP020237/SRS405457/SRX085088/SRR390903/SRR390903.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2938_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR316670	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR316670/SRR316670.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.exon.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR316670	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR316670/SRR316670.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.gene.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR316670	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR316670/SRR316670.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.spljxn.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR316670	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR316670/SRR316670.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2939_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR1303096	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303096/SRR1303096.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.exon.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR1303096	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303096/SRR1303096.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.gene.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR1303096	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303096/SRR1303096.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.spljxn.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2939-1..fastq	SRR1303096	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303096/SRR1303096.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2939_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2939-1..1.fastq	SRR1303097	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303097/SRR1303097.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.exon.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2939-1..1.fastq	SRR1303097	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303097/SRR1303097.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.gene.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2939-1..1.fastq	SRR1303097	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303097/SRR1303097.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2939_2_lanes.spljxn.quantification.txt	3
04-36422	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2939	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939	RNA	EFO	SRS405458	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2939 HS2939 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	240	HS2939	SRX085089	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2939 HS2939 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2939-1..1.fastq	SRR1303097	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR1303097/SRR1303097.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2939_2_lanes_dupsFlagged.bam	SRR390904	@dbgap@:reads/SRP020237/SRS405458/SRX085089/SRR390904/SRR390904.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2939_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR316672	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR316672/SRR316672.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.exon.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR316672	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR316672/SRR316672.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.gene.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR316672	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR316672/SRR316672.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.spljxn.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR316672	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR316672/SRR316672.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2940_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR1303098	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303098/SRR1303098.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.exon.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR1303098	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303098/SRR1303098.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.gene.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR1303098	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303098/SRR1303098.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.spljxn.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-01	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS2940-1..fastq	SRR1303098	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303098/SRR1303098.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2940_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2940-1..1.fastq	SRR1303099	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303099/SRR1303099.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.exon.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2940-1..1.fastq	SRR1303099	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303099/SRR1303099.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.gene.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2940-1..1.fastq	SRR1303099	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303099/SRR1303099.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS2940_2_lanes.spljxn.quantification.txt	3
06-18547	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	female	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS2940	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940	RNA	EFO	SRS405459	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS2940 HS2940 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	245	HS2940	SRX085090	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS2940 HS2940 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS2940-1..1.fastq	SRR1303099	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR1303099/SRR1303099.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS2940_2_lanes_dupsFlagged.bam	SRR390905	@dbgap@:reads/SRP020237/SRS405459/SRX085090/SRR390905/SRR390905.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS2940_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR316675	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR316675/SRR316675.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.exon.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR316675	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR316675/SRR316675.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.gene.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR316675	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR316675/SRR316675.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.spljxn.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR316675	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR316675/SRR316675.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3014_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-22	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..fastq	SRR1303100	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303100/SRR1303100.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.exon.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-22	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..fastq	SRR1303100	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303100/SRR1303100.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.gene.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-22	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..fastq	SRR1303100	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303100/SRR1303100.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.spljxn.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-22	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..fastq	SRR1303100	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303100/SRR1303100.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3014_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR1303101	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303101/SRR1303101.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.exon.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR1303101	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303101/SRR1303101.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.gene.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR1303101	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303101/SRR1303101.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.spljxn.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..1.fastq	SRR1303101	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303101/SRR1303101.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3014_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..2.fastq	SRR1303102	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303102/SRR1303102.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.exon.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..2.fastq	SRR1303102	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303102/SRR1303102.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.gene.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..2.fastq	SRR1303102	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303102/SRR1303102.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.spljxn.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..2.fastq	SRR1303102	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303102/SRR1303102.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3014_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..3.fastq	SRR1303103	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303103/SRR1303103.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.exon.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..3.fastq	SRR1303103	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303103/SRR1303103.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.gene.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..3.fastq	SRR1303103	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303103/SRR1303103.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3014_4_lanes.spljxn.quantification.txt	3
07-17613	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3014	organism part	EFO	Solid Tumor	NCIt	"TESTICLE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014	RNA	EFO	SRS405460	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3014 HS3014 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	238	HS3014	SRX085091	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-17	HS3014 HS3014 run	sequencing assay	EFO	102	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.8.70.0	HS3014-1..3.fastq	SRR1303103	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR1303103/SRR1303103.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3014_4_lanes_dupsFlagged.bam	SRR390906	@dbgap@:reads/SRP020237/SRS405460/SRX085091/SRR390906/SRR390906.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3014_4_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR316679	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR316679/SRR316679.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.exon.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR316679	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR316679/SRR316679.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.gene.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR316679	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR316679/SRR316679.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.spljxn.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR316679	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR316679/SRR316679.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3105_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-15	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..fastq	SRR1303104	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303104/SRR1303104.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.exon.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-15	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..fastq	SRR1303104	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303104/SRR1303104.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.gene.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-15	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..fastq	SRR1303104	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303104/SRR1303104.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.spljxn.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-11-15	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..fastq	SRR1303104	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303104/SRR1303104.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3105_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR1303105	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303105/SRR1303105.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.exon.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR1303105	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303105/SRR1303105.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.gene.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR1303105	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303105/SRR1303105.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3105_2_lanes.spljxn.quantification.txt	3
06-14634	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3105	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105	RNA	EFO	SRS405461	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3105 HS3105 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	255	HS3105	SRX085092	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-09	HS3105 HS3105 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3105-1..1.fastq	SRR1303105	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR1303105/SRR1303105.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3105_2_lanes_dupsFlagged.bam	SRR390907	@dbgap@:reads/SRP020237/SRS405461/SRX085092/SRR390907/SRR390907.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3105_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR316681	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR316681/SRR316681.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.exon.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR316681	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR316681/SRR316681.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.gene.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR316681	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR316681/SRR316681.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.spljxn.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR316681	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR316681/SRR316681.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3120_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..fastq	SRR1303106	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303106/SRR1303106.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.exon.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..fastq	SRR1303106	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303106/SRR1303106.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.gene.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..fastq	SRR1303106	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303106/SRR1303106.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.spljxn.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..fastq	SRR1303106	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303106/SRR1303106.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3120_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR1303107	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303107/SRR1303107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.exon.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR1303107	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303107/SRR1303107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.gene.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR1303107	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303107/SRR1303107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3120_2_lanes.spljxn.quantification.txt	3
04-29264	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3120	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120	RNA	EFO	SRS405462	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3120 HS3120 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	215	HS3120	SRX085093	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-06	HS3120 HS3120 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3120-1..1.fastq	SRR1303107	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR1303107/SRR1303107.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3120_2_lanes_dupsFlagged.bam	SRR390908	@dbgap@:reads/SRP020237/SRS405462/SRX085093/SRR390908/SRR390908.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3120_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR316683	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR316683/SRR316683.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.exon.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR316683	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR316683/SRR316683.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.gene.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR316683	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR316683/SRR316683.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.spljxn.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR316683	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR316683/SRR316683.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3129_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..fastq	SRR1303108	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303108/SRR1303108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.exon.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..fastq	SRR1303108	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303108/SRR1303108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.gene.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..fastq	SRR1303108	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303108/SRR1303108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.spljxn.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..fastq	SRR1303108	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303108/SRR1303108.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3129_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR1303109	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303109/SRR1303109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.exon.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR1303109	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303109/SRR1303109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.gene.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR1303109	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303109/SRR1303109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3129_2_lanes.spljxn.quantification.txt	3
06-23907	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3129	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129	RNA	EFO	SRS405463	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3129 HS3129 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	236	HS3129	SRX085094	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-GAIIx:01	BCCA	2010-12-13	HS3129 HS3129 run	sequencing assay	EFO	152	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Bustard 1.8.0	HS3129-1..1.fastq	SRR1303109	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR1303109/SRR1303109.sra	1	bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3129_2_lanes_dupsFlagged.bam	SRR390909	@dbgap@:reads/SRP020237/SRS405463/SRX085094/SRR390909/SRR390909.sra	2	NCBI36_BCCAGSC_variant	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3129_2_lanes_dupsFlagged.bam.varFilter.0.1.12a.Scored.ge1.anno1.maf.txt	3
07-30628	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136	RNA	EFO	SRS405464	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136 HS3136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS3136	SRX101101	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-HiSeq2000:01	BCCA	2011-06-23	HS3136 HS3136 run	sequencing assay	EFO	147	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.9.35.0					bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3136_2_lanes_dupsFlagged.bam	SRR353116	@dbgap@:reads/SRP020237/SRS405464/SRX101101/SRR353116/SRR353116.sra	2	NCBI36	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3136_2_lanes.exon.quantification.txt	3
07-30628	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136	RNA	EFO	SRS405464	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136 HS3136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS3136	SRX101101	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-HiSeq2000:01	BCCA	2011-06-23	HS3136 HS3136 run	sequencing assay	EFO	147	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.9.35.0					bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3136_2_lanes_dupsFlagged.bam	SRR353116	@dbgap@:reads/SRP020237/SRS405464/SRX101101/SRR353116/SRR353116.sra	2	NCBI36	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3136_2_lanes.gene.quantification.txt	3
07-30628	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136	RNA	EFO	SRS405464	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136 HS3136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS3136	SRX101101	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-HiSeq2000:01	BCCA	2011-06-23	HS3136 HS3136 run	sequencing assay	EFO	147	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.9.35.0					bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3136_2_lanes_dupsFlagged.bam	SRR353116	@dbgap@:reads/SRP020237/SRS405464/SRX101101/SRR353116/SRR353116.sra	2	NCBI36	bcgsc.ca:Protocol:mRNAseq-Expression:01	HS3136_2_lanes.spljxn.quantification.txt	3
07-30628	Children's Oncology Group	whole organism	EFO	Homo sapiens	NCBITaxon	male	NCIt	Diffuse Large B-Cell Lymphoma	NCIt	HS3136	organism part	EFO	Solid Tumor	NCIt	"LYMPH NODE"	bcgsc.ca:Protocol:RNA-Extraction:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136	RNA	EFO	SRS405464	bcgsc.ca:Protocol:mRNAseq-LibraryPrep-Illumina:01	BC Cancer Agency Michael Smith Genome Sciences Centre	HS3136 HS3136 library	PAIRED	TRANSCRIPTOMIC	RNA-Seq	cDNA	210	HS3136	SRX101101	"PolyA+ RNA was purified using the MACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), from 5-10ug of DNaseI-treated total RNA as per the manufacturer's instructions. Double-stranded cDNA was synthesized from the purified polyA+RNA using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Invitrogen) at a concentration of 5uM. The cDNA was fragmented by sonication and a paired-end sequencing library prepared following the Illumina paired-end library preparation protocol (Illumina, Hayward, CA, USA)."	bcgsc.ca:Protocol:mRNAseq-Sequence-Illumina-HiSeq2000:01	BCCA	2011-06-23	HS3136 HS3136 run	sequencing assay	EFO	147	bcgsc.ca:Protocol:mRNAseq-BaseCall-Illumina:01	Illumina RTA 1.9.35.0					bcgsc.ca:Protocol:mRNAseq-ReadAlign:01	HS3136_2_lanes_dupsFlagged.bam	SRR353116	@dbgap@:reads/SRP020237/SRS405464/SRX101101/SRR353116/SRR353116.sra	2	NCBI36	bcgsc.ca:Protocol:mRNAseq-VariantCall:01	HS3136_2_lanes_dupsFlagged.bam.varFilter.Scored.ge1.anno1.maf.txt	3
